[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"fda-warning-letters-search:[\"ev3 Inc\",\"\",\"\",\"\",\"\",1]":3,"fda-latest-sync-dates":397},{"warningLetters":4,"total":396},[5,32,51,73,94,115,137,155,172,192,210,227,249,272,287,307,324,340,355,375],{"id":6,"raw":7,"subject":12,"body_html":14,"body_text":15,"firm_name":16,"letter_id":17,"created_at":18,"fei_number":19,"letter_url":20,"updated_at":21,"action_type":22,"case_status":23,"posted_date":24,"marcs_cms_no":25,"product_type":26,"closeout_date":19,"issuing_office":11,"recipient_name":27,"body_fetched_at":28,"delivery_method":29,"recipient_title":19,"reference_number":30,"action_taken_date":31,"medical_device_id":19,"response_letter_date":19},847,[8,9,10,11,12,13,13,13],"\u003Ctime datetime=\"2025-06-03T04:00:00Z\">06\u002F03\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-05-14T04:00:00Z\">05\u002F14\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fevi-labs-llc-705846-05142025\">Evi Labs LLC\u003C\u002Fa>","Center for Drug Evaluation and Research (CDER)","CGMP\u002FFinished Pharmaceuticals\u002FAdulterated","","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>320-25-74\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Luis E. Echeverria\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President \u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Evi Labs LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>9110 NW 106th Street\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Medley\u003C\u002Fspan>, \u003Cspan>FL\u003C\u002Fspan> \u003Cspan>33178\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>Warning Letter\u003C\u002Fstrong> 320-25-74\u003C\u002Fp>\u003Cp>May 14, 2025\u003C\u002Fp>\u003Cp>Dear Mr. Echeverria:\u003C\u002Fp>\u003Cp>The United States Food and Drug Administration (FDA) inspected your drug manufacturing facility, Evi Labs LLC, FEI 3014581785, at 9110 NW 106th Street, Medley, Florida, from January 9 to 15, 2025.\u003C\u002Fp>\u003Cp>This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\u003C\u002Fp>\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\u003Cp>We reviewed your January 30, 2025 response to our Form FDA 483 in detail. Your response is inadequate because you failed to provide supportive documentation for evaluation or adequate evidence of corrective actions taken to bring your operations into compliance with CGMP.\u003C\u002Fp>\u003Cp>During our inspection, our investigators observed specific violations including, but not limited to, the following.\u003C\u002Fp>\u003Cp>\u003Cstrong>1. Your firm failed to have, for each batch of drug product, appropriate laboratory determination of satisfactory conformance to final specifications for the drug product, including the identity and strength of each active ingredient, prior to release (21 CFR 211.165(a)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>You manufacture over-the-counter (OTC) drug products, including topical drug products containing the active ingredient aluminum chlorohydrate. You released batches of drug products for distribution without conducting adequate strength and identity testing.\u003C\u002Fp>\u003Cp>In your response, you provide test results from retained samples of Zermat brand antiperspirant deodorants. However, your response is inadequate because some results did not meet your established specifications. For example, test results for lot 291023 of Zermat Kiwi Perfumado, topical roll-on antiperspirant, showed a concentration of aluminum chlorohydrate that far exceeded the product labeled amount. Furthermore, under the OTC antiperspirant monograph (M019), aluminum chlorohydrate is permitted in concentrations up to 25%. However, the potency for lot 291023 was found to be above 25% for aluminum chlorohydrate. A topical roll-on antiperspirant drug product with a concentration above 25% for aluminum chlorohydrate is not permitted under M019. You did not include an investigation into these failing results nor provide an action plan to address violative drug product in interstate commerce within expiry.\u003C\u002Fp>\u003Cp>Testing is essential to ensure that the drug products you manufacture conform to all pre-determined quality attributes appropriate for their intended use and to ensure active ingredients meet specifications based on label claim. Because you lacked adequate testing of each batch of your drug products, you do not know whether they conform to all appropriate finished product specifications and are suitable for release to consumers.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A list of chemical specifications, including test methods, used to analyze each lot of your drug products before a lot disposition decision.\u003C\u002Fli>\u003Cli>An action plan and timelines for conducting full chemical testing of retain samples to determine the quality of all batches of drug product distributed to the United States that are within expiry as of the date of this letter.\u003C\u002Fli>\u003Cli>A summary of all results obtained from testing retain samples from each batch. If such testing reveals substandard quality drug products, take rapid corrective actions, such as notifying customers and product recalls.\u003C\u002Fli>\u003Cli>A comprehensive independent assessment of your laboratory practices, procedures, methods, equipment, documentation, and analyst competencies. Based on this review, provide a detailed plan to remediate and evaluate the effectiveness of your laboratory system.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>2. Your firm failed to establish laboratory controls that include scientifically sound and appropriate specifications, standards, sampling plans, and test procedures designed to assure that components, drug product containers, closures, in-process materials, labeling, and drug products conform to appropriate standards of identity, strength, quality, and purity (21 CFR 211.160(b)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your firm failed to establish adequate microbiological specifications for your OTC drug products including \u003Cstrong>(b)(4)\u003C\u002Fstrong> oral suspension and topical antiperspirant deodorants. For example, your microbiological specifications were set at \u003Cstrong>(b)(4)\u003C\u002Fstrong> times greater than the United States Pharmacopoeia (USP) guidance for each of the dosage forms. This resulted in your approval and release of antiperspirant drug products which had exceeded the microbiological quality for your products intended use.\u003C\u002Fp>\u003Cp>In your response, you state that you have implemented microbiological limits specifications that align with USP guidance and commit to obtaining speciation for any further recovered micro-organisms. However, you have not committed to perform retrospective testing and assessing impact on previously distributed product that may not have met your newly established specifications.\u003C\u002Fp>\u003Cp>Adequate microbial specifications and testing methods to detect objectionable microorganisms in the presence of each drug product must be established to ensure that they are suitable for use by consumers.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A list of microbial specifications, including test methods, used to analyze each lot of your drug products before a lot disposition decision.\u003C\u002Fli>\u003Cli>An action plan and timelines for conducting microbiological testing of retain samples to determine the quality of all batches of drug product distributed to the United States that are within expiry as of the date of this letter.\u003C\u002Fli>\u003Cli>A summary of all results obtained from testing retain samples from each batch. If such testing reveals substandard quality drug products, take rapid corrective actions, such as notifying customers and product recalls.\u003C\u002Fli>\u003Cli>Clarification on whether you intend to continue production for each of your OTC drug products.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>3. Your firm failed to establish adequate written procedures for production and process control designed to assure that the drug products you manufacture have the identity, strength, quality, and purity they purport or are represented to possess, and your firm’s quality control unit did not review and approve those procedures, including any changes (21 CFR 211.100(a)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cem>Inadequate Water System\u003C\u002Fem>\u003C\u002Fp>\u003Cp>Your firm uses water as a component to manufacture your OTC drug products, including aqueous drugs labeled for use in \u003Cstrong>(b)(4)\u003C\u002Fstrong>. You failed to adequately validate your water production process to ensure it was consistently producing water of appropriate quality for its intended use, including the manufacture of oral and topical drug products. Additionally, your \u003Cstrong>(b)(4)\u003C\u002Fstrong> water system was not adequately designed or maintained, which could foster the development of biofilms. For example, your water system included a dead leg, was not continuously circulating, and was not subjected to validated sanitization processes. Furthermore, you failed to demonstrate that your water system was adequately monitored to ensure it consistently produced water that met appropriate chemical and microbial attributes.\u003C\u002Fp>\u003Cp>In your response, you commit to hiring a consultant to re-design your water system. However, your response is inadequate because you have not committed to perform routine monitoring and to perform a retrospective impact assessment for products manufactured with water which failed to meet compendial standards and appropriate microbial quality.\u003C\u002Fp>\u003Cp>\u003Cstrong>(b)(4)\u003C\u002Fstrong> water must be suitable for its intended use and routinely tested to ensure ongoing conformance with appropriate chemical and microbiological attributes. Routine monitoring of microbial counts and identity of contamination in the system is integral to ensuring oversight of the ongoing state of control and suitability of water for use in pharmaceutical manufacturing operations.\u003C\u002Fp>\u003Cp>\u003Cem>Inadequate Process Validation\u003C\u002Fem>\u003C\u002Fp>\u003Cp>You have not validated the processes used to manufacture your OTC drug products.&nbsp;\u003C\u002Fp>\u003Cp>Furthermore, you failed to ensure adequate documentation and control over critical processing steps subject to variation (e.g., blend times, speeds, and temperatures) and proper qualification of equipment including scales used for your weight-based manufacturing processes.\u003C\u002Fp>\u003Cp>In your response, you commit to writing validation procedures and providing critical process parameters. However, your response is inadequate because there is no assurance of completed process validation for each product, and you did not include critical attributes of a blended process dependent on variations in temperature. You also commit to calibrating your scales; however, you failed to provide supporting documentation. In addition, you did not consider a retrospective assessment of potential impact to your product distributed to the United States within expiry.\u003C\u002Fp>\u003Cp>Process validation evaluates the soundness of design and state of control of a process throughout its lifecycle. Each significant stage of a manufacturing process must be designed appropriately and assure the quality of raw material inputs, in-process materials, and finished drugs.\u003C\u002Fp>\u003Cp>Process qualification studies include intensive monitoring and testing throughout each significant process stage to characterize intra-batch variation and evaluates batches to determine whether an initial state of control has been established.\u003C\u002Fp>\u003Cp>Successful process qualification studies are necessary before commercial distribution. Thereafter, ongoing vigilant oversight of process performance and product quality is necessary to ensure you maintain a stable manufacturing operation throughout the product lifecycle. See FDA’s guidance for industry, \u003Cem>Process Validation: General Principles and Practices, for general principles and approaches\u003C\u002Fem> that the FDA considers appropriate elements of process validation at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71021\u002Fdownload.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A comprehensive, independent assessment of your water system design, control, and maintenance.\u003C\u002Fli>\u003Cli>A thorough remediation plan to install and operate a suitable water system. Include a robust ongoing control, maintenance, and monitoring program to ensure the remediated system design consistently produces water adhering to \u003Cstrong>(b)(4)\u003C\u002Fstrong> Water, \u003Cstrong>(b)(4)\u003C\u002Fstrong> monograph specifications and appropriate microbial limits.\u003C\u002Fli>\u003Cli>A detailed risk assessment addressing the potential effects of the observed water system failures on the quality of all drug product lots currently in U.S. distribution or within expiry. Specify actions that you will take in response to the risk assessment, such as customer notifications and product recalls.\u003C\u002Fli>\u003Cli>A detailed summary of your validation program for ensuring a state of control throughout the product lifecycle, along with associated procedures. Describe your program for process performance qualification (PPQ), and ongoing monitoring of both intra-batch and inter-batch variation to ensure a continuing state of control.\u003C\u002Fli>\u003Cli>A timeline for performing PPQ or each of your marketed drug products.\u003C\u002Fli>\u003Cli>Process performance protocol(s), and written procedures for qualification of equipment and facilities.\u003C\u002Fli>\u003Cli>A detailed program for designing, validating, maintaining, controlling and monitoring each of your manufacturing processes that includes vigilant monitoring of intra-batch and inter-batch variation to ensure an ongoing state of control. Also, include your program for qualification of your equipment and facility.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>4. Your firm failed to establish an adequate quality control unit with the responsibility and authority to approve or reject all components, drug product containers, closures, in-process materials, packaging materials, labeling, and drug products and the authority to review production records to assure that no errors have occurred or, if errors have occurred, that they have been fully investigated (21 CFR 211.22(a)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The records and information you provided demonstrate that your quality unit (QU) did not effectively exercise its responsibilities to oversee the quality of your drug manufacturing operations. Specifically, your QU failed to:\u003C\u002Fp>\u003Cul>\u003Cli>Ensure the quality of active pharmaceutical ingredients used in \u003Cstrong>(b)(4)\u003C\u002Fstrong> oral suspension drug product (21 CFR 211.84).\u003C\u002Fli>\u003Cli>Ensure thorough investigations into unexplained discrepancies or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).\u003C\u002Fli>\u003Cli>Ensure appropriate controls over computer or related systems to assure that only authorized personnel institute changes in master production and control records, or other records (21 CFR 211.68(b)).\u003C\u002Fli>\u003Cli>Ensure establishment of a written testing program designed to assess the stability characteristics of drug products and to use results of stability testing to determine appropriate storage conditions and expiration dates (21 CFR 211.166(a)).\u003C\u002Fli>\u003C\u002Ful>\u003Cp>Furthermore, your quality unit failed to reject topical drug products for distribution which either failed microbial limits testing or had not been subjected to finished product testing for potency.\u003C\u002Fp>\u003Cp>In your response, you acknowledge that you lack stability data for your \u003Cstrong>(b)(4)\u003C\u002Fstrong> oral suspension drug product and committed to placing samples on stability. Your response is inadequate because you did not commit to retrospective testing of retained samples to support product currently in interstate commerce. Additionally, stability data provided for your topical antiperspirant drug products did not reflect your actual operations (e.g., facility, equipment, and manufacturing processes), and your proposed stability protocol did not include stability indicating methods as well as assessment for impurities or microbial quality. Furthermore, you do not commit to reviewing original data for each batch produced prior to product approval and release.\u003C\u002Fp>\u003Cp>Significant findings in this letter demonstrate that your firm does not operate an effective quality system in accordance with CGMP. In addition to the lack of effective management oversight of your production and laboratory operations, we found that your QU was not enabled to exercise proper authority and insufficiently implemented its responsibilities. Executive management should immediately and comprehensively assess your company’s manufacturing operations to ensure that your systems, processes, and products meet CGMP.\u003C\u002Fp>\u003Cp>Your firm’s quality systems are inadequate. See FDA’s guidance document \u003Cem>Quality Systems Approach to Pharmaceutical CGMP Regulations\u003C\u002Fem> for help in implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR parts 210 and 211, at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload.\u003C\u002Fp>\u003Cp>In response to this letter provide:\u003C\u002Fp>\u003Cul>\u003Cli>A comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\u003Cbr>o A determination of whether procedures used by your firm are robust and appropriate.\u003Cbr>o Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices.\u003Cbr>o A complete and final review of each batch and its related information before the QU disposition decision.\u003Cbr>o Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products.\u003C\u002Fli>\u003Cli>A comprehensive, independent assessment of your overall system for investigating deviations, discrepancies, complaints, out-of-specification results, and failures. Provide a detailed action plan to remediate this system. Your action plan should include, but not be limited to, significant improvements in investigation competencies, scope determination, root cause evaluation, corrective action and preventive action (CAPA) effectiveness, QU oversight, and written procedures. Address how your firm will ensure all phases of investigations are appropriately conducted.\u003C\u002Fli>\u003Cli>A comprehensive, independent assessment and CAPA plan to ensure the adequacy of your stability program. Your remediated program should include, but not be limited to:\u003Cbr>o Stability indicating methods.\u003Cbr>o Stability studies for each drug product in its marketed container-closure system before distribution is permitted.\u003Cbr>o An ongoing program in which representative batches of each product are added each year to the program to determine if the shelf-life claim remains valid.\u003Cbr>o Detailed definition of the specific attributes to be tested at each station (timepoint).\u003C\u002Fli>\u003Cli>A complete assessment of documentation systems used throughout your manufacturing and laboratory operations to determine where documentation practices are insufficient. Include a detailed CAPA plan that comprehensively remediates your firm’s documentation practices to ensure you retain attributable, legible, complete, original, accurate, contemporaneous records throughout your operation.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>Responsibilities as a Contractor\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Drugs must be manufactured in conformance with CGMP. FDA is aware that many drug manufacturers use independent contractors such as production facilities, testing laboratories, packagers, and labelers. FDA regards contractors as extensions of the manufacturer.\u003C\u002Fp>\u003Cp>You are responsible for the quality of drugs you produce as a contract facility regardless of agreements in place with product owners. You are required to ensure that drugs are made in accordance with section 501(a)(2)(B) of the FD&amp;C Act for safety, identity, strength, quality, and purity. See FDA’s guidance document \u003Cem>Contract Manufacturing Arrangements for Drugs: Quality Agreements\u003C\u002Fem> at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F86193\u002Fdownload.\u003C\u002Fp>\u003Cp>\u003Cstrong>CGMP Consultant Recommended\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Based upon the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34 to evaluate your operations and to assist your firm in meeting CGMP requirements. The qualified consultant should also perform a comprehensive six-system audit\u003Cem>\u003Cstrong>\u003Csup>1\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> of your entire operation for CGMP compliance and evaluate the completion and efficacy of your CAPAs before you pursue resolution of your firm’s compliance status with FDA.\u003C\u002Fp>\u003Cp>Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\u003Cp>Correct any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\u003C\u002Fp>\u003Cp>Failure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\u003C\u002Fp>\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\u003Cp>Send your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3014581785 and ATTN: Matthew R. Dionne, Pharm.D.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Francis Godwin\u003Cbr>Director\u003Cbr>Office of Manufacturing Quality\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003C\u002Fp>\u003Cp>_____________________\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> i.e. Quality System, Facilities &amp; Equipment System, Materials System, Production System, Packaging &amp; Labeling System, and Laboratory Control System per FDA’s guidance document Quality Systems Approach to Pharmaceutical CGMP Regulations.\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS\n\nReference #:\n\n320-25-74\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMr. Luis E. Echeverria\n\nRecipient Title\n\nPresident\n\nEvi Labs LLC\n\n9110 NW 106th Street\n\nMedley, FL 33178\n\nUnited States\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nWarning Letter 320-25-74\nMay 14, 2025\nDear Mr. Echeverria:\nThe United States Food and Drug Administration (FDA) inspected your drug manufacturing facility, Evi Labs LLC, FEI 3014581785, at 9110 NW 106th Street, Medley, Florida, from January 9 to 15, 2025.\nThis warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B).\nWe reviewed your January 30, 2025 response to our Form FDA 483 in detail. Your response is inadequate because you failed to provide supportive documentation for evaluation or adequate evidence of corrective actions taken to bring your operations into compliance with CGMP.\nDuring our inspection, our investigators observed specific violations including, but not limited to, the following.\n1. Your firm failed to have, for each batch of drug product, appropriate laboratory determination of satisfactory conformance to final specifications for the drug product, including the identity and strength of each active ingredient, prior to release (21 CFR 211.165(a)).\nYou manufacture over-the-counter (OTC) drug products, including topical drug products containing the active ingredient aluminum chlorohydrate. You released batches of drug products for distribution without conducting adequate strength and identity testing.\nIn your response, you provide test results from retained samples of Zermat brand antiperspirant deodorants. However, your response is inadequate because some results did not meet your established specifications. For example, test results for lot 291023 of Zermat Kiwi Perfumado, topical roll-on antiperspirant, showed a concentration of aluminum chlorohydrate that far exceeded the product labeled amount. Furthermore, under the OTC antiperspirant monograph (M019), aluminum chlorohydrate is permitted in concentrations up to 25%. However, the potency for lot 291023 was found to be above 25% for aluminum chlorohydrate. A topical roll-on antiperspirant drug product with a concentration above 25% for aluminum chlorohydrate is not permitted under M019. You did not include an investigation into these failing results nor provide an action plan to address violative drug product in interstate commerce within expiry.\nTesting is essential to ensure that the drug products you manufacture conform to all pre-determined quality attributes appropriate for their intended use and to ensure active ingredients meet specifications based on label claim. Because you lacked adequate testing of each batch of your drug products, you do not know whether they conform to all appropriate finished product specifications and are suitable for release to consumers.\nIn response to this letter, provide:\nA list of chemical specifications, including test methods, used to analyze each lot of your drug products before a lot disposition decision.\nAn action plan and timelines for conducting full chemical testing of retain samples to determine the quality of all batches of drug product distributed to the United States that are within expiry as of the date of this letter.\nA summary of all results obtained from testing retain samples from each batch. If such testing reveals substandard quality drug products, take rapid corrective actions, such as notifying customers and product recalls.\nA comprehensive independent assessment of your laboratory practices, procedures, methods, equipment, documentation, and analyst competencies. Based on this review, provide a detailed plan to remediate and evaluate the effectiveness of your laboratory system.\n2. Your firm failed to establish laboratory controls that include scientifically sound and appropriate specifications, standards, sampling plans, and test procedures designed to assure that components, drug product containers, closures, in-process materials, labeling, and drug products conform to appropriate standards of identity, strength, quality, and purity (21 CFR 211.160(b)).\nYour firm failed to establish adequate microbiological specifications for your OTC drug products including (b)(4) oral suspension and topical antiperspirant deodorants. For example, your microbiological specifications were set at (b)(4) times greater than the United States Pharmacopoeia (USP) guidance for each of the dosage forms. This resulted in your approval and release of antiperspirant drug products which had exceeded the microbiological quality for your products intended use.\nIn your response, you state that you have implemented microbiological limits specifications that align with USP guidance and commit to obtaining speciation for any further recovered micro-organisms. However, you have not committed to perform retrospective testing and assessing impact on previously distributed product that may not have met your newly established specifications.\nAdequate microbial specifications and testing methods to detect objectionable microorganisms in the presence of each drug product must be established to ensure that they are suitable for use by consumers.\nIn response to this letter, provide:\nA list of microbial specifications, including test methods, used to analyze each lot of your drug products before a lot disposition decision.\nAn action plan and timelines for conducting microbiological testing of retain samples to determine the quality of all batches of drug product distributed to the United States that are within expiry as of the date of this letter.\nA summary of all results obtained from testing retain samples from each batch. If such testing reveals substandard quality drug products, take rapid corrective actions, such as notifying customers and product recalls.\nClarification on whether you intend to continue production for each of your OTC drug products.\n3. Your firm failed to establish adequate written procedures for production and process control designed to assure that the drug products you manufacture have the identity, strength, quality, and purity they purport or are represented to possess, and your firm’s quality control unit did not review and approve those procedures, including any changes (21 CFR 211.100(a)).\nInadequate Water System\nYour firm uses water as a component to manufacture your OTC drug products, including aqueous drugs labeled for use in (b)(4). You failed to adequately validate your water production process to ensure it was consistently producing water of appropriate quality for its intended use, including the manufacture of oral and topical drug products. Additionally, your (b)(4) water system was not adequately designed or maintained, which could foster the development of biofilms. For example, your water system included a dead leg, was not continuously circulating, and was not subjected to validated sanitization processes. Furthermore, you failed to demonstrate that your water system was adequately monitored to ensure it consistently produced water that met appropriate chemical and microbial attributes.\nIn your response, you commit to hiring a consultant to re-design your water system. However, your response is inadequate because you have not committed to perform routine monitoring and to perform a retrospective impact assessment for products manufactured with water which failed to meet compendial standards and appropriate microbial quality.\n(b)(4) water must be suitable for its intended use and routinely tested to ensure ongoing conformance with appropriate chemical and microbiological attributes. Routine monitoring of microbial counts and identity of contamination in the system is integral to ensuring oversight of the ongoing state of control and suitability of water for use in pharmaceutical manufacturing operations.\nInadequate Process Validation\nYou have not validated the processes used to manufacture your OTC drug products.\nFurthermore, you failed to ensure adequate documentation and control over critical processing steps subject to variation (e.g., blend times, speeds, and temperatures) and proper qualification of equipment including scales used for your weight-based manufacturing processes.\nIn your response, you commit to writing validation procedures and providing critical process parameters. However, your response is inadequate because there is no assurance of completed process validation for each product, and you did not include critical attributes of a blended process dependent on variations in temperature. You also commit to calibrating your scales; however, you failed to provide supporting documentation. In addition, you did not consider a retrospective assessment of potential impact to your product distributed to the United States within expiry.\nProcess validation evaluates the soundness of design and state of control of a process throughout its lifecycle. Each significant stage of a manufacturing process must be designed appropriately and assure the quality of raw material inputs, in-process materials, and finished drugs.\nProcess qualification studies include intensive monitoring and testing throughout each significant process stage to characterize intra-batch variation and evaluates batches to determine whether an initial state of control has been established.\nSuccessful process qualification studies are necessary before commercial distribution. Thereafter, ongoing vigilant oversight of process performance and product quality is necessary to ensure you maintain a stable manufacturing operation throughout the product lifecycle. See FDA’s guidance for industry, Process Validation: General Principles and Practices, for general principles and approaches that the FDA considers appropriate elements of process validation at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71021\u002Fdownload.\nIn response to this letter, provide:\nA comprehensive, independent assessment of your water system design, control, and maintenance.\nA thorough remediation plan to install and operate a suitable water system. Include a robust ongoing control, maintenance, and monitoring program to ensure the remediated system design consistently produces water adhering to (b)(4) Water, (b)(4) monograph specifications and appropriate microbial limits.\nA detailed risk assessment addressing the potential effects of the observed water system failures on the quality of all drug product lots currently in U.S. distribution or within expiry. Specify actions that you will take in response to the risk assessment, such as customer notifications and product recalls.\nA detailed summary of your validation program for ensuring a state of control throughout the product lifecycle, along with associated procedures. Describe your program for process performance qualification (PPQ), and ongoing monitoring of both intra-batch and inter-batch variation to ensure a continuing state of control.\nA timeline for performing PPQ or each of your marketed drug products.\nProcess performance protocol(s), and written procedures for qualification of equipment and facilities.\nA detailed program for designing, validating, maintaining, controlling and monitoring each of your manufacturing processes that includes vigilant monitoring of intra-batch and inter-batch variation to ensure an ongoing state of control. Also, include your program for qualification of your equipment and facility.\n4. Your firm failed to establish an adequate quality control unit with the responsibility and authority to approve or reject all components, drug product containers, closures, in-process materials, packaging materials, labeling, and drug products and the authority to review production records to assure that no errors have occurred or, if errors have occurred, that they have been fully investigated (21 CFR 211.22(a)).\nThe records and information you provided demonstrate that your quality unit (QU) did not effectively exercise its responsibilities to oversee the quality of your drug manufacturing operations. Specifically, your QU failed to:\nEnsure the quality of active pharmaceutical ingredients used in (b)(4) oral suspension drug product (21 CFR 211.84).\nEnsure thorough investigations into unexplained discrepancies or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).\nEnsure appropriate controls over computer or related systems to assure that only authorized personnel institute changes in master production and control records, or other records (21 CFR 211.68(b)).\nEnsure establishment of a written testing program designed to assess the stability characteristics of drug products and to use results of stability testing to determine appropriate storage conditions and expiration dates (21 CFR 211.166(a)).\nFurthermore, your quality unit failed to reject topical drug products for distribution which either failed microbial limits testing or had not been subjected to finished product testing for potency.\nIn your response, you acknowledge that you lack stability data for your (b)(4) oral suspension drug product and committed to placing samples on stability. Your response is inadequate because you did not commit to retrospective testing of retained samples to support product currently in interstate commerce. Additionally, stability data provided for your topical antiperspirant drug products did not reflect your actual operations (e.g., facility, equipment, and manufacturing processes), and your proposed stability protocol did not include stability indicating methods as well as assessment for impurities or microbial quality. Furthermore, you do not commit to reviewing original data for each batch produced prior to product approval and release.\nSignificant findings in this letter demonstrate that your firm does not operate an effective quality system in accordance with CGMP. In addition to the lack of effective management oversight of your production and laboratory operations, we found that your QU was not enabled to exercise proper authority and insufficiently implemented its responsibilities. Executive management should immediately and comprehensively assess your company’s manufacturing operations to ensure that your systems, processes, and products meet CGMP.\nYour firm’s quality systems are inadequate. See FDA’s guidance document Quality Systems Approach to Pharmaceutical CGMP Regulations for help in implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR parts 210 and 211, at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload.\nIn response to this letter provide:\nA comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\no A determination of whether procedures used by your firm are robust and appropriate.\no Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices.\no A complete and final review of each batch and its related information before the QU disposition decision.\no Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products.\nA comprehensive, independent assessment of your overall system for investigating deviations, discrepancies, complaints, out-of-specification results, and failures. Provide a detailed action plan to remediate this system. Your action plan should include, but not be limited to, significant improvements in investigation competencies, scope determination, root cause evaluation, corrective action and preventive action (CAPA) effectiveness, QU oversight, and written procedures. Address how your firm will ensure all phases of investigations are appropriately conducted.\nA comprehensive, independent assessment and CAPA plan to ensure the adequacy of your stability program. Your remediated program should include, but not be limited to:\no Stability indicating methods.\no Stability studies for each drug product in its marketed container-closure system before distribution is permitted.\no An ongoing program in which representative batches of each product are added each year to the program to determine if the shelf-life claim remains valid.\no Detailed definition of the specific attributes to be tested at each station (timepoint).\nA complete assessment of documentation systems used throughout your manufacturing and laboratory operations to determine where documentation practices are insufficient. Include a detailed CAPA plan that comprehensively remediates your firm’s documentation practices to ensure you retain attributable, legible, complete, original, accurate, contemporaneous records throughout your operation.\nResponsibilities as a Contractor\nDrugs must be manufactured in conformance with CGMP. FDA is aware that many drug manufacturers use independent contractors such as production facilities, testing laboratories, packagers, and labelers. FDA regards contractors as extensions of the manufacturer.\nYou are responsible for the quality of drugs you produce as a contract facility regardless of agreements in place with product owners. You are required to ensure that drugs are made in accordance with section 501(a)(2)(B) of the FD&C Act for safety, identity, strength, quality, and purity. See FDA’s guidance document Contract Manufacturing Arrangements for Drugs: Quality Agreements at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F86193\u002Fdownload.\nCGMP Consultant Recommended\nBased upon the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34 to evaluate your operations and to assist your firm in meeting CGMP requirements. The qualified consultant should also perform a comprehensive six-system audit1 of your entire operation for CGMP compliance and evaluate the completion and efficacy of your CAPAs before you pursue resolution of your firm’s compliance status with FDA.\nYour use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\nConclusion\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\nCorrect any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\nFailure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\nSend your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3014581785 and ATTN: Matthew R. Dionne, Pharm.D.\nSincerely,\n\u002FS\u002F\nFrancis Godwin\nDirector\nOffice of Manufacturing Quality\nOffice of Compliance\nCenter for Drug Evaluation and Research\n_____________________\n1 i.e. Quality System, Facilities & Equipment System, Materials System, Production System, Packaging & Labeling System, and Laboratory Control System per FDA’s guidance document Quality Systems Approach to Pharmaceutical CGMP Regulations.","Evi Labs LLC","evi-labs-llc-705846-05142025","2026-08-18T06:42:28.676509+00:00",null,"https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fevi-labs-llc-705846-05142025","2026-10-26T08:08:37.575808+00:00","Warning Letter","Issued","2025-06-03","705846","Drugs","Mr. Luis E. Echeverria","2026-08-19T16:42:25.629+00:00","VIA UPS","320-25-74","2025-05-14",{"id":33,"raw":34,"subject":38,"body_html":39,"body_text":40,"firm_name":41,"letter_id":42,"created_at":43,"fei_number":19,"letter_url":44,"updated_at":45,"action_type":22,"case_status":23,"posted_date":46,"marcs_cms_no":47,"product_type":26,"closeout_date":19,"issuing_office":11,"recipient_name":48,"body_fetched_at":49,"delivery_method":19,"recipient_title":19,"reference_number":19,"action_taken_date":50,"medical_device_id":19,"response_letter_date":19},1282,[35,36,37,11,38,13,13,13],"\u003Ctime datetime=\"2024-09-03T13:20:00Z\">09\u002F03\u002F2024\u003C\u002Ftime>\n","\u003Ctime datetime=\"2024-08-27T04:00:00Z\">08\u002F27\u002F2024\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Feverymarket-inc-688348-08272024\">Everymarket Inc.\u003C\u002Fa>","Unapproved New Drugs\u002FMisbranded","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Christopher Baton\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                    \n            \u003Cdd>Everymarket Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>2101 E. Terra Lane\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>O’Fallon\u003C\u002Fspan>, \u003Cspan>MO\u003C\u002Fspan> \u003Cspan>63366\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:cs@everymarket.com\"> cs@everymarket.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>August 27, 2024\u003C\u002Fp>\n\n\u003Cp>RE: 688348\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Christopher Baton:\u003C\u002Fp>\n\n\u003Cp>This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website at the Internet address https:\u002F\u002Fwww.everymarket.com\u002F in July 2024 and has observed that your website offers the products “Vail-Bon Jie Yang Wan” and “Ossos-Sans” for sale in the United States. In addition, FDA has obtained samples and labeling of your “Vail-Bon Jie Yang Wan” product. As described below, “Vail-Bon Jie Yang Wan” and “Ossos-Sans” are unapproved new drugs introduced or delivered for introduction into interstate commerce in violation of sections 505(a) and 301(d) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 355(a) and 331(d). Furthermore, “Vail-Bon Jie Yang Wan” is a misbranded drug under section 502 of the FD&amp;C Act, 21 U.S.C. 352, introduced or delivered for introduction into interstate commerce in violation of section 301(a) of the FD&amp;C Act, 21 U.S.C. 331(a).\u003C\u002Fp>\n\n\u003Cp>FDA confirmed through laboratory analysis that a sample of your “Vail-Bon Jie Yang Wan” contains undeclared dexamethasone and chlorpheniramine.\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> Dexamethasone is a corticosteroid commonly used to treat inflammatory conditions. Corticosteroid use can impair a person’s ability to fight infections and can cause high blood sugar levels, muscle injuries and psychiatric problems. When corticosteroids are taken for a prolonged period, or at high doses, they can suppress the adrenal gland. This hidden drug ingredient may also interact with other medications and significantly increase the risk of adverse events.\u003C\u002Fp>\n\n\u003Cp>Chlorpheniramine is an over-the-counter (OTC) antihistamine used for allergies. Antihistamines may cause drowsiness and affect mental alertness.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Unapproved New Drugs\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your “Vail-Bon Jie Yang Wan” and “Ossos-Sans” products are drugs as defined by section 201(g)(1) of the FD&amp;C Act, 21 U.S.C. 321(g)(1) because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease and\u002For intended to affect the structure or any function of the body. Examples of claims from the labeling, including the outer packaging, that provide evidence of the intended use of these products as drugs include, but may not be limited to, the following:\u003C\u002Fp>\n\n\u003Cp>“Vail-Bon Jie Yang Wan”:\u003Cbr>\n• “Indications : [sic] Urticaria, tinea, itching due to skin diseases, including eczema, pruritus; and serum sickness; and reheumatic [sic] skin itching, itch caused by drug reaction, pruritus universalis, pruritus pregnancy.”\u003C\u002Fp>\n\n\u003Cp>“Ossos-Sans”\u003Csup>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>:\u003Cbr>\n• “Artritis” (English translation: Arthritis)\u003Cbr>\n• “Osteoporosis” (English translation: Osteoporosis)\u003Cbr>\n• “Osteoartritis” (English translation: Osteoarthritis)\u003Cbr>\n• “Fracturas” (English translation: Fractures)\u003Cbr>\n• “Inflamacion” (English translation: Inflammation)\u003Cbr>\n• “Reumos” (English translation: Rheumatisms)\u003Cbr>\n• “Golpes” (English translation: Bruises)\u003Cbr>\n• “Calambres” (English translation: Cramps)\u003Cbr>\n• “Regeneración de cartílago” (English translation: Cartilage Regeneration)\u003Cbr>\n• “Dolores Musculares” (English translation: Muscle Pains)\u003C\u002Fp>\n\n\u003Cp>“Vail-Bon Jie Yang Wan” and “Ossos-Sans” are not generally recognized as safe and effective for the above referenced uses and, therefore, are “new drugs” under section 201(p) of the FD&amp;C Act, 21 U.S.C. 321(p). Subject to certain exceptions not applicable here, a new drug may not be legally introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in sections 301(d) and 505(a) of the FD&amp;C Act, 21 U.S.C. 331(d) and 355(a). No FDA-approved applications pursuant to section 505 of the FD&amp;C Act, 21 U.S.C. 355 are in effect for these products. Accordingly, the introduction or delivery for introduction into interstate commerce of these products violate sections 301(d) and 505(a) of the FD&amp;C Act, 21 U.S.C. 331(d) and 355(a).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Misbranded Drug\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your “Vail-Bon Jie Yang Wan” product is misbranded under section 502(a) of the FD&amp;C Act, 21 U.S.C. 352(a). Under section 502(a) of the FD&amp;C Act, 21 U.S.C. 352(a), a drug is misbranded if its labeling is false or misleading in any particular. Section 201(n) of the FD&amp;C Act, 21 U.S.C. 321(n), provides that, in determining whether an article’s labeling or advertising “is misleading there shall be taken into account…not only representations made or suggested…but also the extent to which the labeling or advertising fails to reveal facts material in light of such representations.” The labeling for “Vail-Bon Jie Yang Wan” does not declare that the product contains the drug ingredients dexamethasone and chlorpheniramine. The failure to disclose the presence of dexamethasone and chlorpheniramine in the product’s labeling renders “Vail-Bon Jie Yang Wan” misbranded under section 502(a) of the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>The introduction or delivery for introduction into interstate commerce of this misbranded drug is a prohibited act under section 301(a) of the FD&amp;C Act, 21 U.S.C. 331(a).\u003C\u002Fp>\n\n\u003Cp>A list of tainted products discovered by FDA can be found at https:\u002F\u002Fwww.fda.gov\u002Fconsumers\u002Fhealth-fraud-scams\u002Fhealth-fraud-product-database.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>This letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\u003C\u002Fp>\n\n\u003Cp>Please notify FDA in writing, within fifteen working days of receipt of this letter, of the specific steps you have taken to correct any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. If you cannot complete corrective action within fifteen working days, state the reason for the delay and the time within which you will complete the correction. Your response should be sent to U.S. Food and Drug Administration, CDER\u002FOC\u002FOffice of Unapproved Drugs and Labeling Compliance by email to FDAAdvisory@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>CAPT Tina Smith\u003Cbr>\nDirector\u003Cbr>\nOffice of Unapproved Drugs and Labeling Compliance\u003Cbr>\nCenter for Drug Evaluation and Research\u003Cbr>\nFood and Drug Administration\u003C\u002Fp>\n\n\u003Cp>_________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> U.S. Food &amp; Drug Administration, \u003Cem>Public Notification: Vail-Bon Jie Yang Wan contains hidden drug ingredients\u003C\u002Fem>, (July 10, 2024), https:\u002F\u002Fwww.fda.gov\u002Fdrugs\u002Fmedication-health-fraud\u002Fvail-bon-jie-yang-wan-weianjieyangwan-contains-hidden-drug-ingredients.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> Previous FDA laboratory analysis of “Ossos-Sans” revealed that it contains the undeclared ingredients diclofenac and methocarbamol. On April 17, 2024, FDA issued a public notification, found at https:\u002F\u002Fwww.fda.gov\u002Fdrugs\u002Fmedication-health-fraud\u002Fossos-sans-contains-hidden-drug-ingredients, to consumers not to purchase or use “Ossos-Sans.” While the Agency has not sampled and tested this product from your inventory to date, be advised of our serious concern about the safety of this products and that it is your legal responsibility under federal law to ensure this product does not contain any undeclared and potentially harmful ingredients.\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Product:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nChristopher Baton\n\nEverymarket Inc.\n\n2101 E. Terra Lane\n\nO’Fallon, MO 63366\n\nUnited States\n\ncs@everymarket.com\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nWARNING LETTER\n\nAugust 27, 2024\n\nRE: 688348\n\nDear Mr. Christopher Baton:\n\nThis letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website at the Internet address https:\u002F\u002Fwww.everymarket.com\u002F in July 2024 and has observed that your website offers the products “Vail-Bon Jie Yang Wan” and “Ossos-Sans” for sale in the United States. In addition, FDA has obtained samples and labeling of your “Vail-Bon Jie Yang Wan” product. As described below, “Vail-Bon Jie Yang Wan” and “Ossos-Sans” are unapproved new drugs introduced or delivered for introduction into interstate commerce in violation of sections 505(a) and 301(d) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 355(a) and 331(d). Furthermore, “Vail-Bon Jie Yang Wan” is a misbranded drug under section 502 of the FD&C Act, 21 U.S.C. 352, introduced or delivered for introduction into interstate commerce in violation of section 301(a) of the FD&C Act, 21 U.S.C. 331(a).\n\nFDA confirmed through laboratory analysis that a sample of your “Vail-Bon Jie Yang Wan” contains undeclared dexamethasone and chlorpheniramine.1 Dexamethasone is a corticosteroid commonly used to treat inflammatory conditions. Corticosteroid use can impair a person’s ability to fight infections and can cause high blood sugar levels, muscle injuries and psychiatric problems. When corticosteroids are taken for a prolonged period, or at high doses, they can suppress the adrenal gland. This hidden drug ingredient may also interact with other medications and significantly increase the risk of adverse events.\n\nChlorpheniramine is an over-the-counter (OTC) antihistamine used for allergies. Antihistamines may cause drowsiness and affect mental alertness.\n\nUnapproved New Drugs\n\nYour “Vail-Bon Jie Yang Wan” and “Ossos-Sans” products are drugs as defined by section 201(g)(1) of the FD&C Act, 21 U.S.C. 321(g)(1) because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease and\u002For intended to affect the structure or any function of the body. Examples of claims from the labeling, including the outer packaging, that provide evidence of the intended use of these products as drugs include, but may not be limited to, the following:\n\n“Vail-Bon Jie Yang Wan”:\n\n• “Indications : [sic] Urticaria, tinea, itching due to skin diseases, including eczema, pruritus; and serum sickness; and reheumatic [sic] skin itching, itch caused by drug reaction, pruritus universalis, pruritus pregnancy.”\n\n“Ossos-Sans”2:\n\n• “Artritis” (English translation: Arthritis)\n\n• “Osteoporosis” (English translation: Osteoporosis)\n\n• “Osteoartritis” (English translation: Osteoarthritis)\n\n• “Fracturas” (English translation: Fractures)\n\n• “Inflamacion” (English translation: Inflammation)\n\n• “Reumos” (English translation: Rheumatisms)\n\n• “Golpes” (English translation: Bruises)\n\n• “Calambres” (English translation: Cramps)\n\n• “Regeneración de cartílago” (English translation: Cartilage Regeneration)\n\n• “Dolores Musculares” (English translation: Muscle Pains)\n\n“Vail-Bon Jie Yang Wan” and “Ossos-Sans” are not generally recognized as safe and effective for the above referenced uses and, therefore, are “new drugs” under section 201(p) of the FD&C Act, 21 U.S.C. 321(p). Subject to certain exceptions not applicable here, a new drug may not be legally introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in sections 301(d) and 505(a) of the FD&C Act, 21 U.S.C. 331(d) and 355(a). No FDA-approved applications pursuant to section 505 of the FD&C Act, 21 U.S.C. 355 are in effect for these products. Accordingly, the introduction or delivery for introduction into interstate commerce of these products violate sections 301(d) and 505(a) of the FD&C Act, 21 U.S.C. 331(d) and 355(a).\n\nMisbranded Drug\n\nYour “Vail-Bon Jie Yang Wan” product is misbranded under section 502(a) of the FD&C Act, 21 U.S.C. 352(a). Under section 502(a) of the FD&C Act, 21 U.S.C. 352(a), a drug is misbranded if its labeling is false or misleading in any particular. Section 201(n) of the FD&C Act, 21 U.S.C. 321(n), provides that, in determining whether an article’s labeling or advertising “is misleading there shall be taken into account…not only representations made or suggested…but also the extent to which the labeling or advertising fails to reveal facts material in light of such representations.” The labeling for “Vail-Bon Jie Yang Wan” does not declare that the product contains the drug ingredients dexamethasone and chlorpheniramine. The failure to disclose the presence of dexamethasone and chlorpheniramine in the product’s labeling renders “Vail-Bon Jie Yang Wan” misbranded under section 502(a) of the FD&C Act.\n\nThe introduction or delivery for introduction into interstate commerce of this misbranded drug is a prohibited act under section 301(a) of the FD&C Act, 21 U.S.C. 331(a).\n\nA list of tainted products discovered by FDA can be found at https:\u002F\u002Fwww.fda.gov\u002Fconsumers\u002Fhealth-fraud-scams\u002Fhealth-fraud-product-database.\n\nConclusion\n\nThis letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\n\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\n\nPlease notify FDA in writing, within fifteen working days of receipt of this letter, of the specific steps you have taken to correct any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. If you cannot complete corrective action within fifteen working days, state the reason for the delay and the time within which you will complete the correction. Your response should be sent to U.S. Food and Drug Administration, CDER\u002FOC\u002FOffice of Unapproved Drugs and Labeling Compliance by email to FDAAdvisory@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nCAPT Tina Smith\n\nDirector\n\nOffice of Unapproved Drugs and Labeling Compliance\n\nCenter for Drug Evaluation and Research\n\nFood and Drug Administration\n\n_________________\n\n1 U.S. Food & Drug Administration, Public Notification: Vail-Bon Jie Yang Wan contains hidden drug ingredients, (July 10, 2024), https:\u002F\u002Fwww.fda.gov\u002Fdrugs\u002Fmedication-health-fraud\u002Fvail-bon-jie-yang-wan-weianjieyangwan-contains-hidden-drug-ingredients.\n\n2 Previous FDA laboratory analysis of “Ossos-Sans” revealed that it contains the undeclared ingredients diclofenac and methocarbamol. On April 17, 2024, FDA issued a public notification, found at https:\u002F\u002Fwww.fda.gov\u002Fdrugs\u002Fmedication-health-fraud\u002Fossos-sans-contains-hidden-drug-ingredients, to consumers not to purchase or use “Ossos-Sans.” While the Agency has not sampled and tested this product from your inventory to date, be advised of our serious concern about the safety of this products and that it is your legal responsibility under federal law to ensure this product does not contain any undeclared and potentially harmful ingredients.","Everymarket Inc.","everymarket-inc-688348-08272024","2026-08-18T06:42:28.856152+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Feverymarket-inc-688348-08272024","2026-10-26T08:08:37.247157+00:00","2024-09-03","688348","Christopher Baton","2026-08-19T23:50:23.423+00:00","2024-08-27",{"id":52,"raw":53,"subject":58,"body_html":59,"body_text":60,"firm_name":61,"letter_id":62,"created_at":63,"fei_number":19,"letter_url":64,"updated_at":65,"action_type":22,"case_status":23,"posted_date":66,"marcs_cms_no":67,"product_type":68,"closeout_date":19,"issuing_office":57,"recipient_name":19,"body_fetched_at":69,"delivery_method":70,"recipient_title":19,"reference_number":71,"action_taken_date":72,"medical_device_id":19,"response_letter_date":19},440,[54,55,56,57,58,13,13,13],"\u003Ctime datetime=\"2025-12-03T05:00:00Z\">12\u002F03\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-10-09T04:00:00Z\">10\u002F09\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fevapekingscom-718071-10092025\">evapekings.com\u003C\u002Fa>","Center for Tobacco Products","Family Smoking Prevention and Tobacco Control Act\u002FAdulterated\u002FMisbranded","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS and Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>RW2502349\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Tobacco                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\u003C\u002Fdd>\n                    \n            \u003Cdd>evapekings.com\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>398 E Dania Beach Blvd, #255\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Dania Beach\u003C\u002Fspan>, \u003Cspan>FL\u003C\u002Fspan> \u003Cspan>33004\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:sales@evapekings.com\"> sales@evapekings.com\u003C\u002Fa>\u003C\u002Fdd>\n    \u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:evapekingss@gmail.com\"> evapekingss@gmail.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Tobacco Products\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>October 9, 2025\u003C\u002Fp>\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>To Whom It May Concern:\u003C\u002Fp>\u003Cp>The Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) recently reviewed the website https:\u002F\u002Fevapekings.com and determined that electronic nicotine delivery system (ENDS) products listed there are offered for sale or distribution to customers in the United States.\u003C\u002Fp>\u003Cp>Under section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) (21 U.S.C. § 321(rr)), these products are tobacco products because they are made or derived from tobacco or contain nicotine from any source and intended for human consumption. Certain tobacco products, including ENDS products, are subject to FDA jurisdiction under section 901(b) of the FD&amp;C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1, and are required to be in compliance with the requirements in the FD&amp;C Act.\u003C\u002Fp>\u003Cp>Please be aware that, on March 15, 2022, the President signed legislation to amend the FD&amp;C Act to extend FDA’s jurisdiction to products “containing nicotine from any source,” not just nicotine derived from tobacco. See Consolidated Appropriations Act, 2022, Public Law 117-103, Division P, Title I, Subtitle B. Specifically, this legislation expanded the definition of “tobacco product” under section 201(rr) of the FD&amp;C Act (21 U.S.C. § 321(rr)) to include products containing nicotine from any source. Tobacco products, including ENDS products, containing nicotine from any source, must be in compliance with the FD&amp;C Act and its implementing regulations. For more information, please see https:\u002F\u002Fwww.fda.gov\u002Ftobacco-products\u002Fctp-newsroom\u002Frequirements-products-made-non-tobacco-nicotine-take-effect-april-14.\u003C\u002Fp>\u003Cp>Generally, to be legally marketed in the United States, the FD&amp;C Act requires “new tobacco products” to have a premarket authorization order in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&amp;C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&amp;C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&amp;C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&amp;C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&amp;C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&amp;C Act (21 U.S.C. § 387e(j)(3)).\u003C\u002Fp>\u003Cp>\u003Cstrong>New Tobacco Products Without Required Marketing Authorization Are Adulterated and Misbranded\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>FDA has determined that you offer for sale or distribution to customers in the United States ENDS products that lack a marketing authorization order: Fume WeFume Disposable Vape Device [30K Puffs] – Dragon Fruit and Fume WeFume Disposable Vape Device [30K Puffs] – Lychee Soda.\u003C\u002Fp>\u003Cp>The tobacco products listed above are new tobacco products because they were not commercially marketed in the United States as of February 15, 2007. These products do not have FDA marketing authorization orders in effect under section 910(c)(1)(A)(i) of the FD&amp;C Act and are not otherwise exempt from the marketing authorization requirement. Therefore, these products are adulterated under section 902(6)(A) of the FD&amp;C Act (21 U.S.C. §387b(6)(A)). In addition, they are misbranded under section 903(a)(6) of the FD&amp;C Act (21 U.S.C. § 387c(a)(6)) because a notice or other information respecting these products was not provided as required by section 905(j) of the FD&amp;C Act (21 U.S.C. § 387e(j)).\u003C\u002Fp>\u003Cp>\u003Cstrong>Additional Considerations\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>FDA finds these products particularly concerning because the products’ labeling and\u002For advertising for Fume WeFume Disposable Vape Device [30K Puffs] products (see Exhibit A) may entice youth by imitating a smartphone or other smart technology (see Exhibit B).\u003C\u002Fp>\u003Cdiv>  \u003Cimg src=\"https:\u002F\u002Fwww.fda.gov\u002Ffiles\u002F718071-Evapekings.png\" alt=\"Smartphone and Vape Device\">\n\n\u003C\u002Fdiv>\n\u003Cp>In particular, youth and young adults may be enticed to the products’ design and functionalities imitating smart phones and other smart technology, including:\u003C\u002Fp>\u003Cul>\u003Cli>“The WeFume isn’t just a vaping device – it’s a smart gadget.”\u003C\u002Fli>\u003Cli>“Equipped with Bluetooth connectivity, this device allows you to sync with your smartphone and access 16 apps for making calls, playing music, and using voice assistants like Siri or Google Assistant.”\u003C\u002Fli>\u003Cli>“It’s intuitive touch screen makes it easy to navigate and customize your settings, while the voice control feature brings hands-free convenience to your vaping routine.”\u003C\u002Fli>\u003Cli>“The device also features practical tools like a built-in clock and flashlight, making it as functional as it is stylish.”\u003C\u002Fli>\u003C\u002Ful>\u003Cp>Further, the products’ design may entice youth because the design helps conceal the nature of the product as a tobacco product from parents, teachers, or other adults, and therefore could be openly carried without revealing to parents, teachers, or other adults that the products are tobacco products. FDA is concerned about the youth appeal and widespread youth use of ENDS products, which are the most common tobacco products used by students reporting current tobacco use. Any efforts to entice youth to use tobacco products are of concern to FDA. Sales of unauthorized products are prohibited, and FDA is concerned that your actions likely encourage unlawful sales, maintain or increase youth use, and contribute to the public health and safety concerns associated with ENDS products.\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion and Requested Actions\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>FDA has determined that your firm markets new tobacco products in the United States that lack premarket authorization. All new tobacco products on the market without the statutorily required premarket authorization are marketed unlawfully and are subject to enforcement action at FDA’s discretion.\u003C\u002Fp>\u003Cp>For a list of all products that have been authorized by the FDA and certain others that may be legally marketed, please visit the Searchable Tobacco Products Database: https:\u002F\u002Fwww.fda.gov\u002Fsearchtobacco.\u003C\u002Fp>\u003Cp>It is your responsibility to ensure that all tobacco products you sell and\u002For distribute in the United States and all related labeling and\u002For advertising on any websites or other media (such as e-commerce, social networking, or search engine websites), and in any retail establishments in which you advertise, comply with each applicable provision of the FD&amp;C Act and FDA’s implementing regulations. Failure to address any violations of the FD&amp;C Act, 21 U.S.C. § 301 et seq., or its implementing regulations relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, and 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&amp;C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated and\u002For misbranded may be detained or refused admission.\u003C\u002Fp>\u003Cp>The violations discussed in this letter do not necessarily constitute an exhaustive list. You should take prompt action to address any violations that are referenced above and take any necessary actions to bring these tobacco products into compliance with the FD&amp;C Act.\u003C\u002Fp>\u003Cp>Please submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring these products into compliance, including the dates on which you discontinued the violative sale and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&amp;C Act. If you believe that these products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&amp;C Act through links on FDA’s homepage at https:\u002F\u002Fwww.fda.gov.\u003C\u002Fp>\u003Cp>Please note your reference number, RW2502349, in your response and direct your response via email at CTPCompliance@fda.hhs.gov and to the following address:\u003C\u002Fp>\u003Cp>DPAL-WL Response, Office of Compliance and Enforcement&nbsp;&nbsp;\u003Cbr>FDA Center for Tobacco Products&nbsp;&nbsp;\u003Cbr>c\u002Fo Document Control Center&nbsp;&nbsp;\u003Cbr>Building 71, Room G335&nbsp;&nbsp;\u003Cbr>10903 New Hampshire Avenue&nbsp;&nbsp;\u003Cbr>Silver Spring, MD 20993-0002\u003C\u002Fp>\u003Cp>If you have any questions about the content of this letter, please contact CTPCompliance@fda.hhs.gov.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>John E. Verbeten\u003Cbr>Director\u003Cbr>Office of Compliance and Enforcement\u003Cbr>Center for Tobacco Products\u003C\u002Fp>\u003Cp>\u003Cstrong>VIA Electronic Mail\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>cc:\u003C\u002Fp>\u003Cp>GoDaddy.com, LLC\u003Cbr>abuse@godaddy.com\u003C\u002Fp>\u003Cp>Shopify, Inc.\u003Cbr>abuse@shopify.com\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS and Electronic Mail\n\nReference #:\n\nRW2502349\n\nProduct:\n\nTobacco\n\nRecipient:\n\nevapekings.com\n\n398 E Dania Beach Blvd, #255\n\nDania Beach, FL 33004\n\nUnited States\n\nsales@evapekings.com\n\nevapekingss@gmail.com\n\nIssuing Office:\n\nCenter for Tobacco Products\n\nUnited States\n\nOctober 9, 2025\nWARNING LETTER\nTo Whom It May Concern:\nThe Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) recently reviewed the website https:\u002F\u002Fevapekings.com and determined that electronic nicotine delivery system (ENDS) products listed there are offered for sale or distribution to customers in the United States.\nUnder section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. § 321(rr)), these products are tobacco products because they are made or derived from tobacco or contain nicotine from any source and intended for human consumption. Certain tobacco products, including ENDS products, are subject to FDA jurisdiction under section 901(b) of the FD&C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1, and are required to be in compliance with the requirements in the FD&C Act.\nPlease be aware that, on March 15, 2022, the President signed legislation to amend the FD&C Act to extend FDA’s jurisdiction to products “containing nicotine from any source,” not just nicotine derived from tobacco. See Consolidated Appropriations Act, 2022, Public Law 117-103, Division P, Title I, Subtitle B. Specifically, this legislation expanded the definition of “tobacco product” under section 201(rr) of the FD&C Act (21 U.S.C. § 321(rr)) to include products containing nicotine from any source. Tobacco products, including ENDS products, containing nicotine from any source, must be in compliance with the FD&C Act and its implementing regulations. For more information, please see https:\u002F\u002Fwww.fda.gov\u002Ftobacco-products\u002Fctp-newsroom\u002Frequirements-products-made-non-tobacco-nicotine-take-effect-april-14.\nGenerally, to be legally marketed in the United States, the FD&C Act requires “new tobacco products” to have a premarket authorization order in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&C Act (21 U.S.C. § 387e(j)(3)).\nNew Tobacco Products Without Required Marketing Authorization Are Adulterated and Misbranded\nFDA has determined that you offer for sale or distribution to customers in the United States ENDS products that lack a marketing authorization order: Fume WeFume Disposable Vape Device [30K Puffs] – Dragon Fruit and Fume WeFume Disposable Vape Device [30K Puffs] – Lychee Soda.\nThe tobacco products listed above are new tobacco products because they were not commercially marketed in the United States as of February 15, 2007. These products do not have FDA marketing authorization orders in effect under section 910(c)(1)(A)(i) of the FD&C Act and are not otherwise exempt from the marketing authorization requirement. Therefore, these products are adulterated under section 902(6)(A) of the FD&C Act (21 U.S.C. §387b(6)(A)). In addition, they are misbranded under section 903(a)(6) of the FD&C Act (21 U.S.C. § 387c(a)(6)) because a notice or other information respecting these products was not provided as required by section 905(j) of the FD&C Act (21 U.S.C. § 387e(j)).\nAdditional Considerations\nFDA finds these products particularly concerning because the products’ labeling and\u002For advertising for Fume WeFume Disposable Vape Device [30K Puffs] products (see Exhibit A) may entice youth by imitating a smartphone or other smart technology (see Exhibit B).\n\nIn particular, youth and young adults may be enticed to the products’ design and functionalities imitating smart phones and other smart technology, including:\n“The WeFume isn’t just a vaping device – it’s a smart gadget.”\n“Equipped with Bluetooth connectivity, this device allows you to sync with your smartphone and access 16 apps for making calls, playing music, and using voice assistants like Siri or Google Assistant.”\n“It’s intuitive touch screen makes it easy to navigate and customize your settings, while the voice control feature brings hands-free convenience to your vaping routine.”\n“The device also features practical tools like a built-in clock and flashlight, making it as functional as it is stylish.”\nFurther, the products’ design may entice youth because the design helps conceal the nature of the product as a tobacco product from parents, teachers, or other adults, and therefore could be openly carried without revealing to parents, teachers, or other adults that the products are tobacco products. FDA is concerned about the youth appeal and widespread youth use of ENDS products, which are the most common tobacco products used by students reporting current tobacco use. Any efforts to entice youth to use tobacco products are of concern to FDA. Sales of unauthorized products are prohibited, and FDA is concerned that your actions likely encourage unlawful sales, maintain or increase youth use, and contribute to the public health and safety concerns associated with ENDS products.\nConclusion and Requested Actions\nFDA has determined that your firm markets new tobacco products in the United States that lack premarket authorization. All new tobacco products on the market without the statutorily required premarket authorization are marketed unlawfully and are subject to enforcement action at FDA’s discretion.\nFor a list of all products that have been authorized by the FDA and certain others that may be legally marketed, please visit the Searchable Tobacco Products Database: https:\u002F\u002Fwww.fda.gov\u002Fsearchtobacco.\nIt is your responsibility to ensure that all tobacco products you sell and\u002For distribute in the United States and all related labeling and\u002For advertising on any websites or other media (such as e-commerce, social networking, or search engine websites), and in any retail establishments in which you advertise, comply with each applicable provision of the FD&C Act and FDA’s implementing regulations. Failure to address any violations of the FD&C Act, 21 U.S.C. § 301 et seq., or its implementing regulations relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, and 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated and\u002For misbranded may be detained or refused admission.\nThe violations discussed in this letter do not necessarily constitute an exhaustive list. You should take prompt action to address any violations that are referenced above and take any necessary actions to bring these tobacco products into compliance with the FD&C Act.\nPlease submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring these products into compliance, including the dates on which you discontinued the violative sale and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&C Act. If you believe that these products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&C Act through links on FDA’s homepage at https:\u002F\u002Fwww.fda.gov.\nPlease note your reference number, RW2502349, in your response and direct your response via email at CTPCompliance@fda.hhs.gov and to the following address:\nDPAL-WL Response, Office of Compliance and Enforcement\nFDA Center for Tobacco Products\nc\u002Fo Document Control Center\nBuilding 71, Room G335\n10903 New Hampshire Avenue\nSilver Spring, MD 20993-0002\nIf you have any questions about the content of this letter, please contact CTPCompliance@fda.hhs.gov.\nSincerely,\n\u002FS\u002F\nJohn E. Verbeten\nDirector\nOffice of Compliance and Enforcement\nCenter for Tobacco Products\nVIA Electronic Mail\ncc:\nGoDaddy.com, LLC\nabuse@godaddy.com\nShopify, Inc.\nabuse@shopify.com","evapekings.com","evapekingscom-718071-10092025","2026-08-18T06:42:28.498414+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fevapekingscom-718071-10092025","2026-10-26T08:08:37.041064+00:00","2025-12-03","718071","Tobacco","2026-08-19T11:24:33.472+00:00","VIA UPS and Electronic Mail","RW2502349","2025-10-09",{"id":74,"raw":75,"subject":80,"body_html":81,"body_text":82,"firm_name":83,"letter_id":84,"created_at":43,"fei_number":19,"letter_url":85,"updated_at":86,"action_type":22,"case_status":23,"posted_date":87,"marcs_cms_no":88,"product_type":89,"closeout_date":19,"issuing_office":79,"recipient_name":90,"body_fetched_at":91,"delivery_method":92,"recipient_title":19,"reference_number":19,"action_taken_date":93,"medical_device_id":19,"response_letter_date":19},1104,[76,77,78,79,80,13,13,13],"\u003Ctime datetime=\"2025-01-07T14:20:00Z\">01\u002F07\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2024-11-12T05:00:00Z\">11\u002F12\u002F2024\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fevolution-pets-llc-696281-11122024\">Evolution Pets LLC\u003C\u002Fa>","Center for Veterinary Medicine","New Animal Drug\u002FAdulterated","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Email\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Animal &amp; Veterinary\u003Cbr>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>William and Susanne Beckett\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                    \n            \u003Cdd>Evolution Pets LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>(b)(6)\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:info@evolutionpets.com\"> info@evolutionpets.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Veterinary Medicine\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>November 12, 2024\u003C\u002Fp>\u003Cp>Re: 696281\u003C\u002Fp>\u003Cp>Dear William and Susanne Beckett:\u003C\u002Fp>\u003Cp>This letter concerns your firm’s marketing of unapproved new animal drugs, including SeizureGuard Plus and Life Span Arthritis &amp; Mobility Advanced Enzyme Therapy for the treatment of diseases in animals, in violation of the Federal Food Drug and Cosmetic Act (FD&amp;C Act). The United States Food and Drug Administration (FDA) reviewed your website, evolutionpets.com, and your Amazon store webpages www.amazon.com\u002FSeizureGuard-Epilepsy-Supplement-Supplement-medication\u002Fdp\u002FB00HKYSXBC and www.amazon.com\u002FLifeSpan-Systemic-Enzymes-Arthritis-Mobility\u002Fdp\u002FB00A0Q0DN8 from October to November 2024, where you offer these products for sale in the United States.\u003C\u002Fp>\u003Cp>Based on our review, the claims on your website and product labeling establish that your SeizureGuard Plus and Life Span Arthritis &amp; Mobility Advanced Enzyme Therapy products are drugs under section 201(g)(1) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 321(g)(1), because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease in animals and\u002For to affect the structure or function of the body of animals.\u003C\u002Fp>\u003Cp>Your product’s names, such as SeizureGuard Plus and Life Span Arthritis &amp; Mobility Advanced Enzyme Therapy, indicate they are intended for use in treating animals with disease conditions and\u002For to affect the structure or function of the body of animals.\u003C\u002Fp>\u003Cp>You can find the FD&amp;C Act and FDA regulations through links on FDA’s homepage at www.fda.gov.\u003C\u002Fp>\u003Cp>Examples of claims FDA observed on your product labeling and product listing webpages that show the intended use of your products include, but are not limited to, the following:\u003C\u002Fp>\u003Cp>\u003Cstrong>SeizureGuard Plus\u003C\u002Fstrong>\u003Cbr>• On your webpage titled “Dog Seizure Treatment | #1 Rated Dog Seizure Medication for Epilepsy in Dog” at the URL https:\u002F\u002Fevolutionpets.com\u002Fpages\u002Fdog-seizure-prevention:\u003Cbr>&nbsp; o “Need help preventing Dog Seizures? SeizureGuard PLUS can help.”\u003Cbr>&nbsp; o “Epilepsy in dogs can shorten your pet's life significantly. Luckily SeizureGuard dog seizure medication has been shown to improve a dog's ability to guard against seizures and their damaging after affects. SeizureGuard builds up essential immune and neurological systems to protect vital organs from damage. As a result your dog will be less likely to experience a seizure. If a seizure does occur chances are good that it will last shorter and cause less damage.”\u003Cbr>&nbsp; o “All Natural, safe and proven effective.”\u003Cbr>&nbsp; o “Proven effective remedy to fight the damaging effects of canine seizures. Can be used alone or in combination with prescription medications such as phenobarbital.”\u003C\u002Fp>\u003Cp>• On your product webpage at the URL https:\u002F\u002Fevolutionpets.com\u002Fproducts\u002Fseizureguard-plus?variant=44146971443487:\u003Cbr>&nbsp; o “SeizureGuard rebalances and increases your dog's immune, neurological, kidney, circulatory, and defensive systems up to optimal performance. As a result your dog will be less likely to experience a seizure, and when a seizure does occur, chances are good that it will last shorter and cause less damage. And perhaps the most critical benefit of SeizureGuard is that, when a seizure does occur, your dog will be able to recover quickly from it. It is in this phase where most permanent damage and life threatening effects occur – when a dog cannot recovery [sic] from an epileptic attack.”\u003Cbr>&nbsp; o “Protease: Protease acts as a catalyst to repair damaged proteins, reduces blood toxins after a canine epileptic attack, rebalances the immune system by modulating protein levels, supports increased blood flow essential after an attack resulting from epilepsy, and speeds tissue and muscle repair.”\u003Cbr>&nbsp; o “Amylase: Amylase is one of the best defensives against many diseases including epilepsy in dogs. After an attack, Amylase successfully works in muscle building and improving immune system in order to burn the calories and fight against those chronic diseases. Lastly it has great calming benefits that will help your pet to stop shaking during seizures in dogs.”\u003Cbr>\u003Cbr>• On your webpage titled “About Us” at the URL https:\u002F\u002Fevolutionpets.com\u002Fpages\u002Fabout-us:\u003Cbr>&nbsp; o “SeizureGuard Plus is an all-natural dog seizure medication that can be used alone or in combination with veterinarian prescribed medications. SeizureGuard not only helps to reduce the frequency of epileptic attacks but also aids in quick recovery of seizures. We also have older dogs covered.”\u003C\u002Fp>\u003Cp>• On your blog post titled “How to Treat Dog Seizures with Natural Supplements” at the URL https:\u002F\u002Fevolutionpets.com\u002Fblogs\u002Fnews\u002Ffirst-time-dog-owners-need-to-know-these-things:\u003Cbr>&nbsp; o “SeizureGuard is highly recommended as a natural dog seizure medication and has helped thousands of dog owners better manage the symptoms and effects of epilepsy in dogs.”\u003Cbr>&nbsp; o “Giving your dog a natural dog seizure medication can have a noticeable impact on their quality of life. That’s because some naturally-derived supplements can improve the severity and frequency of dog seizures. They amy [sic] even help control epilepsy in dogs well enough that they can be weaned off of side-effect-causing pharmaceuticals.”\u003Cbr>&nbsp; o “SeizureGuard is the top rated veterinarian recommended natural dog seizure medication, mainly because it contains all these supplements, plus many others that help dogs feel better between seizures.”\u003C\u002Fp>\u003Cp>• On your Amazon store webpage at the URL https:\u002F\u002Fwww.amazon.com\u002FSeizureGuard-Epilepsy-Supplement-Supplement-medication\u002Fdp\u002FB00HKYSXBC:\u003Cbr>&nbsp; o “Builds a strong immune system to limit damage caused by epileptic attacks in dogs. Amazing supplement for dogs with seizures. Works Great!”\u003Cbr>&nbsp; o “Safe and Effective to help prevent dog seizures | All natural remedy and best dog seizures treatment for canine seizures and epilepsy. Top RATED dog seizure medication.”\u003Cbr>&nbsp; o “All natural remedy to help control and seziures in dogs. Can be used along with other medicine for canine eplipesy &amp; seizures”\u003Cbr>&nbsp; o #1 RATED Seizure Medication for Dogs. GUARANTEED or our [sic] your money bac\u003Ca>k”\u003C\u002Fa>\u003C\u002Fp>\u003Cp>\u003Cstrong>Life Span Arthritis &amp; Mobility Advanced Enzyme Therapy\u003C\u002Fstrong>\u003Cbr>\u003Cbr>• On your product webpage at the URL https:\u002F\u002Fevolutionpets.com\u002Fproducts\u002Flifespan-arthritis-mobility-systemic-enzymes?variant=44174415659295:\u003Cbr>&nbsp; o “Dog Arthritis, Hip Dysplasia, and a lack of mobility will continue to worsen as inflammation and fibrin deposits around your dog's joints continue to increase. Systemic Enzymes are the latest proven choice to end pain, reduce swelling and increase mobility by breaking up the fibrin deposits around dog's joints and muscles. At the same time they help to rebalance the production of Synovial Fluid which is vital for the lubrication of joints.”\u003Cbr>&nbsp; o “LifeSpan also helps counter degeneration of cartridge and slow down the normal aging process with the same Living Enzymes currently produced in a dog's body.”\u003Cbr>&nbsp; o “Enzymes have helped tens of thousands of pets (and humans) with pain, arthritis, and hip dysplasia. In fact it is the most successful alternate remedy to prescription drugs.”\u003C\u002Fp>\u003Cp>• On your Amazon store webpage at the URL https:\u002F\u002Fwww.amazon.com\u002FLifeSpan-Systemic-Enzymes-Arthritis-Mobility\u002Fdp\u002FB00A0Q0DN8:\u003Cbr>&nbsp; o “Systematic Enzymes significantly help control Dog Arthritis, Hip Dysplasia. Increases mobility by breaking up the fibrin deposits around dog's joints and muscles.”\u003Cbr>&nbsp; o “Effective against inflammation and fibrin deposits around your dog's joints. Proven to reduce pain”\u003Cbr>&nbsp; o “LifeSpan also helps counter degeneration of cartridge and slow down the normal aging process with the same Living Enzymes currently produced in a dog's body. Great for working dogs &amp; older dogs”\u003Cbr>&nbsp; o “Has helped tens of thousands of pets with pain, arthritis, and hip dysplasia.”\u003C\u002Fp>\u003Cp>These products are \"new animal drugs\" under section 201(v) of the FD&amp;C Act, 21 U.S.C. 321(v), because they are not generally recognized, among experts qualified by scientific training and experience to evaluate the safety and effectiveness of animal drugs, as safe and effective for use under the conditions prescribed, recommended, or suggested in the labeling.\u003C\u002Fp>\u003Cp>To be legally marketed, new animal drugs must have an approved new animal drug application, conditionally approved new animal drug application, or index listing under section 512, 571, or 572 of the FD&amp;C Act, 21 U.S.C. § 360b, 360ccc, or 360ccc-1, respectively. These products are not the subject of an approved new animal drug application, conditionally approved new animal drug application, or index listing by the FDA, and therefore are considered unsafe under section 512(a) of the FD&amp;C Act, 21 U.S.C. 360b(a) and adulterated under section 501(a)(5) of the FD&amp;C Act, 21 U.S.C. 351(a)(5). The introduction or delivery for introduction into interstate commerce of an adulterated drug is prohibited under section 301(a) of the FD&amp;C Act [21 U.S.C. § 331(a)].\u003C\u002Fp>\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to address this matter may lead to legal action without further notice, including, without limitation, seizure and\u002For injunction.\u003C\u002Fp>\u003Cp>This letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products or operations. Our review of your website indicates that you are offering for sale unapproved animal drugs in addition to those listed above. If FDA takes legal action, the action may address all of your unapproved new animal drugs, not just those listed above. It is your responsibility to ensure that your firm complies with all requirements of federal law and FDA’s implementing regulations.\u003C\u002Fp>\u003Cp>Within fifteen (15) working days of receipt of this letter, please notify this office in writing of the specific steps you have taken to correct any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective action within fifteen (15) working days, state the reason for the delay and the time within which you will complete the correction. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\u003Cp>Please direct your response to the U.S. Food and Drug Administration, Center for Veterinary Medicine, Office of Surveillance and Compliance, Division of Drug Compliance, by email to CVMUnapprovedDrugs@fda.hhs.gov. Please include “Reference 696281” in the subject line of your email.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Neal Bataller, ME, DVM\u003Cbr>Director\u003Cbr>Division of Drug Compliance\u003Cbr>Office of Surveillance and Compliance\u003Cbr>Center for Veterinary Medicine\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Email\n\nProduct:\n\nAnimal & Veterinary\nDrugs\n\nRecipient:\n\nRecipient Name\n\nWilliam and Susanne Beckett\n\nEvolution Pets LLC\n\n(b)(6)\n\nUnited States\n\ninfo@evolutionpets.com\n\nIssuing Office:\n\nCenter for Veterinary Medicine\n\nUnited States\n\nWARNING LETTER\nNovember 12, 2024\nRe: 696281\nDear William and Susanne Beckett:\nThis letter concerns your firm’s marketing of unapproved new animal drugs, including SeizureGuard Plus and Life Span Arthritis & Mobility Advanced Enzyme Therapy for the treatment of diseases in animals, in violation of the Federal Food Drug and Cosmetic Act (FD&C Act). The United States Food and Drug Administration (FDA) reviewed your website, evolutionpets.com, and your Amazon store webpages www.amazon.com\u002FSeizureGuard-Epilepsy-Supplement-Supplement-medication\u002Fdp\u002FB00HKYSXBC and www.amazon.com\u002FLifeSpan-Systemic-Enzymes-Arthritis-Mobility\u002Fdp\u002FB00A0Q0DN8 from October to November 2024, where you offer these products for sale in the United States.\nBased on our review, the claims on your website and product labeling establish that your SeizureGuard Plus and Life Span Arthritis & Mobility Advanced Enzyme Therapy products are drugs under section 201(g)(1) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 321(g)(1), because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease in animals and\u002For to affect the structure or function of the body of animals.\nYour product’s names, such as SeizureGuard Plus and Life Span Arthritis & Mobility Advanced Enzyme Therapy, indicate they are intended for use in treating animals with disease conditions and\u002For to affect the structure or function of the body of animals.\nYou can find the FD&C Act and FDA regulations through links on FDA’s homepage at www.fda.gov.\nExamples of claims FDA observed on your product labeling and product listing webpages that show the intended use of your products include, but are not limited to, the following:\nSeizureGuard Plus\n• On your webpage titled “Dog Seizure Treatment | #1 Rated Dog Seizure Medication for Epilepsy in Dog” at the URL https:\u002F\u002Fevolutionpets.com\u002Fpages\u002Fdog-seizure-prevention:\no “Need help preventing Dog Seizures? SeizureGuard PLUS can help.”\no “Epilepsy in dogs can shorten your pet's life significantly. Luckily SeizureGuard dog seizure medication has been shown to improve a dog's ability to guard against seizures and their damaging after affects. SeizureGuard builds up essential immune and neurological systems to protect vital organs from damage. As a result your dog will be less likely to experience a seizure. If a seizure does occur chances are good that it will last shorter and cause less damage.”\no “All Natural, safe and proven effective.”\no “Proven effective remedy to fight the damaging effects of canine seizures. Can be used alone or in combination with prescription medications such as phenobarbital.”\n• On your product webpage at the URL https:\u002F\u002Fevolutionpets.com\u002Fproducts\u002Fseizureguard-plus?variant=44146971443487:\no “SeizureGuard rebalances and increases your dog's immune, neurological, kidney, circulatory, and defensive systems up to optimal performance. As a result your dog will be less likely to experience a seizure, and when a seizure does occur, chances are good that it will last shorter and cause less damage. And perhaps the most critical benefit of SeizureGuard is that, when a seizure does occur, your dog will be able to recover quickly from it. It is in this phase where most permanent damage and life threatening effects occur – when a dog cannot recovery [sic] from an epileptic attack.”\no “Protease: Protease acts as a catalyst to repair damaged proteins, reduces blood toxins after a canine epileptic attack, rebalances the immune system by modulating protein levels, supports increased blood flow essential after an attack resulting from epilepsy, and speeds tissue and muscle repair.”\no “Amylase: Amylase is one of the best defensives against many diseases including epilepsy in dogs. After an attack, Amylase successfully works in muscle building and improving immune system in order to burn the calories and fight against those chronic diseases. Lastly it has great calming benefits that will help your pet to stop shaking during seizures in dogs.”\n\n• On your webpage titled “About Us” at the URL https:\u002F\u002Fevolutionpets.com\u002Fpages\u002Fabout-us:\no “SeizureGuard Plus is an all-natural dog seizure medication that can be used alone or in combination with veterinarian prescribed medications. SeizureGuard not only helps to reduce the frequency of epileptic attacks but also aids in quick recovery of seizures. We also have older dogs covered.”\n• On your blog post titled “How to Treat Dog Seizures with Natural Supplements” at the URL https:\u002F\u002Fevolutionpets.com\u002Fblogs\u002Fnews\u002Ffirst-time-dog-owners-need-to-know-these-things:\no “SeizureGuard is highly recommended as a natural dog seizure medication and has helped thousands of dog owners better manage the symptoms and effects of epilepsy in dogs.”\no “Giving your dog a natural dog seizure medication can have a noticeable impact on their quality of life. That’s because some naturally-derived supplements can improve the severity and frequency of dog seizures. They amy [sic] even help control epilepsy in dogs well enough that they can be weaned off of side-effect-causing pharmaceuticals.”\no “SeizureGuard is the top rated veterinarian recommended natural dog seizure medication, mainly because it contains all these supplements, plus many others that help dogs feel better between seizures.”\n• On your Amazon store webpage at the URL https:\u002F\u002Fwww.amazon.com\u002FSeizureGuard-Epilepsy-Supplement-Supplement-medication\u002Fdp\u002FB00HKYSXBC:\no “Builds a strong immune system to limit damage caused by epileptic attacks in dogs. Amazing supplement for dogs with seizures. Works Great!”\no “Safe and Effective to help prevent dog seizures | All natural remedy and best dog seizures treatment for canine seizures and epilepsy. Top RATED dog seizure medication.”\no “All natural remedy to help control and seziures in dogs. Can be used along with other medicine for canine eplipesy & seizures”\no #1 RATED Seizure Medication for Dogs. GUARANTEED or our [sic] your money back”\nLife Span Arthritis & Mobility Advanced Enzyme Therapy\n\n• On your product webpage at the URL https:\u002F\u002Fevolutionpets.com\u002Fproducts\u002Flifespan-arthritis-mobility-systemic-enzymes?variant=44174415659295:\no “Dog Arthritis, Hip Dysplasia, and a lack of mobility will continue to worsen as inflammation and fibrin deposits around your dog's joints continue to increase. Systemic Enzymes are the latest proven choice to end pain, reduce swelling and increase mobility by breaking up the fibrin deposits around dog's joints and muscles. At the same time they help to rebalance the production of Synovial Fluid which is vital for the lubrication of joints.”\no “LifeSpan also helps counter degeneration of cartridge and slow down the normal aging process with the same Living Enzymes currently produced in a dog's body.”\no “Enzymes have helped tens of thousands of pets (and humans) with pain, arthritis, and hip dysplasia. In fact it is the most successful alternate remedy to prescription drugs.”\n• On your Amazon store webpage at the URL https:\u002F\u002Fwww.amazon.com\u002FLifeSpan-Systemic-Enzymes-Arthritis-Mobility\u002Fdp\u002FB00A0Q0DN8:\no “Systematic Enzymes significantly help control Dog Arthritis, Hip Dysplasia. Increases mobility by breaking up the fibrin deposits around dog's joints and muscles.”\no “Effective against inflammation and fibrin deposits around your dog's joints. Proven to reduce pain”\no “LifeSpan also helps counter degeneration of cartridge and slow down the normal aging process with the same Living Enzymes currently produced in a dog's body. Great for working dogs & older dogs”\no “Has helped tens of thousands of pets with pain, arthritis, and hip dysplasia.”\nThese products are \"new animal drugs\" under section 201(v) of the FD&C Act, 21 U.S.C. 321(v), because they are not generally recognized, among experts qualified by scientific training and experience to evaluate the safety and effectiveness of animal drugs, as safe and effective for use under the conditions prescribed, recommended, or suggested in the labeling.\nTo be legally marketed, new animal drugs must have an approved new animal drug application, conditionally approved new animal drug application, or index listing under section 512, 571, or 572 of the FD&C Act, 21 U.S.C. § 360b, 360ccc, or 360ccc-1, respectively. These products are not the subject of an approved new animal drug application, conditionally approved new animal drug application, or index listing by the FDA, and therefore are considered unsafe under section 512(a) of the FD&C Act, 21 U.S.C. 360b(a) and adulterated under section 501(a)(5) of the FD&C Act, 21 U.S.C. 351(a)(5). The introduction or delivery for introduction into interstate commerce of an adulterated drug is prohibited under section 301(a) of the FD&C Act [21 U.S.C. § 331(a)].\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to address this matter may lead to legal action without further notice, including, without limitation, seizure and\u002For injunction.\nThis letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products or operations. Our review of your website indicates that you are offering for sale unapproved animal drugs in addition to those listed above. If FDA takes legal action, the action may address all of your unapproved new animal drugs, not just those listed above. It is your responsibility to ensure that your firm complies with all requirements of federal law and FDA’s implementing regulations.\nWithin fifteen (15) working days of receipt of this letter, please notify this office in writing of the specific steps you have taken to correct any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective action within fifteen (15) working days, state the reason for the delay and the time within which you will complete the correction. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration.\nPlease direct your response to the U.S. Food and Drug Administration, Center for Veterinary Medicine, Office of Surveillance and Compliance, Division of Drug Compliance, by email to CVMUnapprovedDrugs@fda.hhs.gov. Please include “Reference 696281” in the subject line of your email.\nSincerely,\n\u002FS\u002F\nNeal Bataller, ME, DVM\nDirector\nDivision of Drug Compliance\nOffice of Surveillance and Compliance\nCenter for Veterinary Medicine","Evolution Pets LLC","evolution-pets-llc-696281-11122024","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fevolution-pets-llc-696281-11122024","2026-10-26T08:08:37.796717+00:00","2025-01-07","696281","Animal & VeterinaryDrugs","William and Susanne Beckett","2026-08-19T17:05:41.497+00:00","Via Email","2024-11-12",{"id":95,"raw":96,"subject":101,"body_html":102,"body_text":103,"firm_name":104,"letter_id":105,"created_at":18,"fei_number":19,"letter_url":106,"updated_at":107,"action_type":22,"case_status":23,"posted_date":108,"marcs_cms_no":109,"product_type":110,"closeout_date":19,"issuing_office":100,"recipient_name":111,"body_fetched_at":112,"delivery_method":113,"recipient_title":19,"reference_number":19,"action_taken_date":114,"medical_device_id":19,"response_letter_date":19},561,[97,98,99,100,101,13,13,13],"\u003Ctime datetime=\"2025-09-30T04:00:00Z\">09\u002F30\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-09-12T04:00:00Z\">09\u002F12\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fever-rich-foods-llc-715321-09122025\">Ever Rich Foods LLC\u003C\u002Fa>","Division of Northeast Imports","Foreign Supplier Verification Program (FSVP)","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Food &amp; Beverages                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Sanjay Krishnamurthy\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>US Owner\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Ever Rich Foods LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>345 Plainfield Ave Ste 206\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Edison\u003C\u002Fspan>, \u003Cspan>NJ\u003C\u002Fspan> \u003Cspan>08817-3119\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:(b)(6)\"> (b)(6)\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Division of Northeast Imports\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>September 12, 2025\u003C\u002Fp>\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>RE: CMS# 715321\u003C\u002Fp>\u003Cp>Dear Mr. Krishnamurthy:\u003C\u002Fp>\u003Cp>On July 25, 2025, the Food and Drug Administration (FDA) conducted a Foreign Supplier Verification Program (FSVP) inspection of Ever Rich Foods LLC located at 345 Plainfield Ave Ste 206 Edison, NJ 08817-3119. FSVP inspections were also conducted by FDA from December 05 through December 27, 2024, and July 27 through August 14, 2023. This inspection was conducted to determine compliance with the requirements of section 805 of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) (21 U.S.C. 384a) and the implementing FSVP regulation in 21 CFR part 1, subpart L.\u003C\u002Fp>\u003Cp>The FSVP regulation requires that importers perform certain risk-based activities to verify that human and\u002For animal food they import into the United States has been produced in a manner that meets applicable U.S. food safety standards. You may find information relating to the FSVP regulation and your responsibilities to comply with the regulation through links in FDA’s FSVP web page at https:\u002F\u002Fwww.fda.gov\u002Ffood\u002Ffood-safetymodernization-act-fsma\u002Ffsma-final-rule-foreign-supplier-verification-programs-fsvp-importers-food-humans-and-animals.\u003C\u002Fp>\u003Cp>During the most recent inspection, we found that you are not in compliance with the requirements of 21 CFR part 1, subpart L for the foods you import. Because of these significant violations, you are not in compliance with section 805 of the FD&amp;C Act. At the conclusion of the inspection, our investigator provided you with a Form FDA 483a FSVP Observations. We acknowledge your response received August 5th, 2025. Your response did not include any FSVP documentation to provide evidence to demonstrate the deviations were corrected.\u003C\u002Fp>\u003Cp>Your significant violations of the FSVP regulation are as follows:\u003C\u002Fp>\u003Cp>You did not develop, maintain, and follow an FSVP as required by section 805 of the FD&amp;C Act and 21 CFR part 1.502(a). Specifically, you did not develop an FSVP for any of the foods you import including the following foods:\u003C\u002Fp>\u003Cul>\u003Cli>Sweet Kala Jamoon from the foreign supplier \u003Cstrong>(b)(4)\u003C\u002Fstrong> located in \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fli>\u003Cli>Kaju Pista Roll – Sweets from the foreign supplier \u003Cstrong>(b)(4)\u003C\u002Fstrong> located in \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fli>\u003Cli>Motichoor Ladoo from the foreign supplier \u003Cstrong>(b)(4)\u003C\u002Fstrong> located in \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>The above violations are not intended to be an all-inclusive list of violations of the FSVP requirements. It is your responsibility to ensure that you are in compliance with section 805 of the FD&amp;C Act and the implementing regulation in 21 CFR part 1, subpart L.\u003C\u002Fp>\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. If you do not adequately address this matter, we may take further action. For instance, we may take action under section 801(a)(3) of the FD&amp;C Act (21 U.S.C. 381(a)(3)) to refuse admission of the food you import for which you appear to be in violation of section 805. We may place the foods you import into the United States from foreign suppliers on detention without physical examination (DWPE) when you import the foods. You can find DWPE information relating to FSVP in Import Alert # 99-41 at http:\u002F\u002Fwww.accessdata.fda.gov\u002Fcms_ia\u002Fialist.html. In addition, the importation or offering for importation into the United States of an article of food without the importer having an FSVP that meets the requirements of section 805 of the FD&amp;C Act or the FSVP regulation is prohibited under section 301(zz) of the FD&amp;C Act (21 U.S.C. 331(zz)).\u003C\u002Fp>\u003Cp>You should respond in writing within fifteen (15) working days from your receipt of this letter. Your response should address the specific things you are doing to correct any violations. You should include in your response documentation and information that would assist us in evaluating your corrections (e.g., documentation of changes you made, such as a copy of your FSVP, records to demonstrate implementation of your FSVP), and any additional information that you wish to supply relevant to your compliance with the FSVP regulation. If you believe that you are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. If you cannot complete all corrections within 15 working days, you should explain the reason for your delay and state when you will correct any remaining violations.\u003C\u002Fp>\u003Cp>Please send your reply to Food and Drug Administration, Attention: Stanley Nelson, Compliance Officer, Division of Northeast Imports: oiioiodneiwlresponses@fda.hhs.gov. Please also cc (carbon copy) Stanley.Nelson@fda.hhs.gov. If you have any questions regarding this letter, you may contact Compliance Officer Nelson via email at Stanley.Nelson@fda.hhs.gov. Please reference CMS # 715321 on any documents or records you provide to us and on the subject line of any email correspondence you send to us.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>CDR Joseph S. Tomao\u003Cbr>Program Division Director\u003Cbr>Division of Northeast Imports\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA Electronic Mail\n\nProduct:\n\nFood & Beverages\n\nRecipient:\n\nRecipient Name\n\nSanjay Krishnamurthy\n\nRecipient Title\n\nUS Owner\n\nEver Rich Foods LLC\n\n345 Plainfield Ave Ste 206\n\nEdison, NJ 08817-3119\n\nUnited States\n\n(b)(6)\n\nIssuing Office:\n\nDivision of Northeast Imports\n\nUnited States\n\nSeptember 12, 2025\nWARNING LETTER\nRE: CMS# 715321\nDear Mr. Krishnamurthy:\nOn July 25, 2025, the Food and Drug Administration (FDA) conducted a Foreign Supplier Verification Program (FSVP) inspection of Ever Rich Foods LLC located at 345 Plainfield Ave Ste 206 Edison, NJ 08817-3119. FSVP inspections were also conducted by FDA from December 05 through December 27, 2024, and July 27 through August 14, 2023. This inspection was conducted to determine compliance with the requirements of section 805 of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. 384a) and the implementing FSVP regulation in 21 CFR part 1, subpart L.\nThe FSVP regulation requires that importers perform certain risk-based activities to verify that human and\u002For animal food they import into the United States has been produced in a manner that meets applicable U.S. food safety standards. You may find information relating to the FSVP regulation and your responsibilities to comply with the regulation through links in FDA’s FSVP web page at https:\u002F\u002Fwww.fda.gov\u002Ffood\u002Ffood-safetymodernization-act-fsma\u002Ffsma-final-rule-foreign-supplier-verification-programs-fsvp-importers-food-humans-and-animals.\nDuring the most recent inspection, we found that you are not in compliance with the requirements of 21 CFR part 1, subpart L for the foods you import. Because of these significant violations, you are not in compliance with section 805 of the FD&C Act. At the conclusion of the inspection, our investigator provided you with a Form FDA 483a FSVP Observations. We acknowledge your response received August 5th, 2025. Your response did not include any FSVP documentation to provide evidence to demonstrate the deviations were corrected.\nYour significant violations of the FSVP regulation are as follows:\nYou did not develop, maintain, and follow an FSVP as required by section 805 of the FD&C Act and 21 CFR part 1.502(a). Specifically, you did not develop an FSVP for any of the foods you import including the following foods:\nSweet Kala Jamoon from the foreign supplier (b)(4) located in (b)(4).\nKaju Pista Roll – Sweets from the foreign supplier (b)(4) located in (b)(4).\nMotichoor Ladoo from the foreign supplier (b)(4) located in (b)(4).\nThe above violations are not intended to be an all-inclusive list of violations of the FSVP requirements. It is your responsibility to ensure that you are in compliance with section 805 of the FD&C Act and the implementing regulation in 21 CFR part 1, subpart L.\nThis letter notifies you of our concerns and provides you an opportunity to address them. If you do not adequately address this matter, we may take further action. For instance, we may take action under section 801(a)(3) of the FD&C Act (21 U.S.C. 381(a)(3)) to refuse admission of the food you import for which you appear to be in violation of section 805. We may place the foods you import into the United States from foreign suppliers on detention without physical examination (DWPE) when you import the foods. You can find DWPE information relating to FSVP in Import Alert # 99-41 at http:\u002F\u002Fwww.accessdata.fda.gov\u002Fcms_ia\u002Fialist.html. In addition, the importation or offering for importation into the United States of an article of food without the importer having an FSVP that meets the requirements of section 805 of the FD&C Act or the FSVP regulation is prohibited under section 301(zz) of the FD&C Act (21 U.S.C. 331(zz)).\nYou should respond in writing within fifteen (15) working days from your receipt of this letter. Your response should address the specific things you are doing to correct any violations. You should include in your response documentation and information that would assist us in evaluating your corrections (e.g., documentation of changes you made, such as a copy of your FSVP, records to demonstrate implementation of your FSVP), and any additional information that you wish to supply relevant to your compliance with the FSVP regulation. If you believe that you are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. If you cannot complete all corrections within 15 working days, you should explain the reason for your delay and state when you will correct any remaining violations.\nPlease send your reply to Food and Drug Administration, Attention: Stanley Nelson, Compliance Officer, Division of Northeast Imports: oiioiodneiwlresponses@fda.hhs.gov. Please also cc (carbon copy) Stanley.Nelson@fda.hhs.gov. If you have any questions regarding this letter, you may contact Compliance Officer Nelson via email at Stanley.Nelson@fda.hhs.gov. Please reference CMS # 715321 on any documents or records you provide to us and on the subject line of any email correspondence you send to us.\nSincerely,\n\u002FS\u002F\nCDR Joseph S. Tomao\nProgram Division Director\nDivision of Northeast Imports","Ever Rich Foods LLC","ever-rich-foods-llc-715321-09122025","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fever-rich-foods-llc-715321-09122025","2026-10-26T08:08:37.081094+00:00","2025-09-30","715321","Food & Beverages","Sanjay Krishnamurthy","2026-08-19T16:16:02.704+00:00","VIA Electronic Mail","2025-09-12",{"id":116,"raw":117,"subject":122,"body_html":123,"body_text":124,"firm_name":125,"letter_id":126,"created_at":127,"fei_number":19,"letter_url":128,"updated_at":129,"action_type":22,"case_status":23,"posted_date":130,"marcs_cms_no":131,"product_type":132,"closeout_date":19,"issuing_office":121,"recipient_name":133,"body_fetched_at":134,"delivery_method":135,"recipient_title":19,"reference_number":19,"action_taken_date":136,"medical_device_id":19,"response_letter_date":19},2671,[118,119,120,121,122,13,13,13],"\u003Ctime datetime=\"2022-05-17T13:20:00Z\">05\u002F17\u002F2022\u003C\u002Ftime>\n","\u003Ctime datetime=\"2022-04-21T04:00:00Z\">04\u002F21\u002F2022\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fevans-farms-feed-625841-04212022\">Evans Farms Feed\u003C\u002Fa>","Division of Human and Animal Food Operations West III","CGMP\u002FFood for Animals\u002FPrepared, Packed or Held Under Insanitary Conditions\u002FAdulterated","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Overnight Delivery\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Animal &amp; Veterinary\u003Cbr>Food &amp; Beverages                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. John E. Evans\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Vice President\u002FCo-owner\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Evans Farms Feed\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>537 Lilley Road\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Alvin\u003C\u002Fspan>, \u003Cspan>TX\u003C\u002Fspan> \u003Cspan>77511-7143\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Division of Human and Animal Food Operations West III\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>April 21, 2022\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>REF # 625841\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Dear Mr. John E. Evans:\u003C\u002Fp>\n\n\u003Cp>The U.S. Food and Drug Administration (FDA) inspected your animal food manufacturing facility (feed mill) located at 537 Lilley Road, Alvin, Texas on November 30, 2021 through December 9, 2021. This inspection was conducted as a follow-up to a consumer complaint received by FDA on October 26, 2021. The complaint was received \u003Cstrong>(b)(4)\u003C\u002Fstrong> reporting multiple horses at two locations that became ill, with some being hospitalized and one death, after consuming food manufactured by your facility. Private testing reportedly showed levels of fumonisin \u003Cstrong>(b)(4)\u003C\u002Fstrong> in the implicated horse food.\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> Follow-up testing by the Office of the Texas State Chemist found \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Fumonisin levels above 1.0 ppm are known to cause liver disease and fatal nervous system damage in horses.\u003C\u002Fp>\n\n\u003Cp>Our inspection revealed evidence of significant violations of the Current Good Manufacturing Practice, Hazard Analysis, and Risk-Based Preventive Controls for Food for Animals (PCAF) regulation, Title 21, Code of Federal Regulations, Part 507 (21 CFR Part 507) which cause your products to be adulterated.\u003Csup>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> The doing of any act to a food after shipment of the food and\u002For its components in interstate commerce and while the food is held for sale (whether or not the first sale) that results in the food being adulterated or misbranded is prohibited.\u003Csup>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> Furthermore, failure of the owner, operator, or agent in charge of a covered facility to comply with the preventive controls provision of 21 CFR Part 507 (located in subparts A, C, D, E, and F of Part 507) is also a prohibited act.\u003Csup>\u003Cem>\u003Cstrong>4 \u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>You may find the FD&amp;C Act and FDA’s regulations through links on FDA’s homepage at \u003Ca>www.fda.gov.\u003C\u002Fa>\u003C\u002Fp>\n\n\u003Cp>At the close of the inspection, you were issued a Form FDA 483, Inspectional Observations (FDA 483). We have not received a response to the FDA 483 as of the date on this letter.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Hazard Analysis and Risk-Based Preventive Controls Requirements\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your animal food facility is subject to the hazard analysis and risk-based preventive controls requirements found in 21 CFR Part 507, subparts A, C, D, E, and F. During the inspection of your facility, the FDA Investigator noted evidence of significant violations of these requirements, which included but were not limited to the following:\u003C\u002Fp>\n\n\u003Cp>1. You did not prepare, or have prepared, and did not implement a written food safety plan, as required by 21 CFR 507.31. The preparation of the food safety plan must be overseen by your preventive controls qualified individual (PCQI) and must include the following:\u003C\u002Fp>\n\n\u003Cp>a) The written hazard analysis as required by 21 CFR 507.33(a)(2).\u003Cbr>\nb) The written preventive controls as required by 21 CFR 507.34(b).\u003Cbr>\nc) The written supply-chain program as required by subpart E of 21 CFR Part 507.\u003Cbr>\nd) The written recall plan as required by 21 CFR 507.38(a)(1).\u003Cbr>\ne) The written procedures for monitoring the implementation of the preventive controls as required by 21 CFR 507.40(a).\u003Cbr>\nf) The written corrective action procedures as required by 21 CFR 507.42(a)(1).\u003Cbr>\ng) The written verification procedures as required by 21 CFR 507.49(b).\u003C\u002Fp>\n\n\u003Cp>Specifically, you told the FDA Investigator that you did not have a food safety plan, although you and your PCQI have begun to develop one.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Current Good Manufacturing Practices (CGMP) Requirements\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your animal food facility is subject to the CGMP requirements found in 21 CFR Part 507, subparts A, B, and F. During the inspection of your facility, the FDA Investigator noted evidence of significant violations of these requirements, which included but were not limited to the following:\u003C\u002Fp>\n\n\u003Cp>2. Your firm failed to evaluate and use raw materials and other ingredients susceptible to contamination with mycotoxins or other natural toxins in a manner that does not result in animal food that can cause injury or illness to animals or humans, as required by 21 CFR 507.25(b)(2).\u003C\u002Fp>\n\n\u003Cp>Specifically, you do not have procedures or conduct testing to determine whether mycotoxins such as aflatoxin, fumonisin, or deoxynivalenol (DON) are present in the grains and grain coproducts that you receive and use in your products. Your facility produces animal food for multiple species, including horses, poultry, deer, sheep, goats, rabbits, cattle, and swine, all of which are known to be negatively affected by mycotoxins. The primary components of your animal foods are grains and grain co-products, which are susceptible to mycotoxin contamination.\u003C\u002Fp>\n\n\u003Cp>Furthermore, we found no evidence that you had evaluated whether your firm was the cause of the fumonisin level above FDA’s recommended 1 ppm limit in finished animal food for equids,\u003Csup>\u003Cem>\u003Cstrong>5\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> reported to you on October 29, 2021, by the Office of the Texas State Chemist \u003Cstrong>(b)(4)\u003C\u002Fstrong>. In addition, you did not evaluate the potential for contamination in other products using the same corn ingredients.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>This letter is not intended to be an all-inclusive statement of violations that may exist at your facility or in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that you comply with all requirements of federal law and FDA regulations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. You should take prompt action to correct any violations. Failure to adequately address this matter may lead to legal or regulatory action, including without limitation, seizure and injunction.\u003C\u002Fp>\n\n\u003Cp>For more information about FDA’s current thinking on the requirements of 21 CFR Part 507, see:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>Guidance for Industry #235: “Current Good Manufacturing Practice Requirements for Food for Animals” \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F97464\u002Fdownload\">https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F97464\u002Fdownload\u003C\u002Fa>\u003C\u002Fli>\n\t\u003Cli>Draft Guidance for Industry #245: “Hazard Analysis and Risk-Based Preventive Controls for Food for Animals” \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F110477\u002Fdownload\">https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F110477\u002Fdownload\u003C\u002Fa>\u003C\u002Fli>\n\t\u003Cli>Draft Guidance for Industry #246: “Hazard Analysis and Risk-Based Preventive Controls for Food for Animals: Supply Chain Program” \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F113923\u002Fdownload\">https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F113923\u002Fdownload\u003C\u002Fa>\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>Within fifteen (15) working days of receipt of this letter, please notify this office in writing of the specific steps that you have taken to correct any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within fifteen (15) working days, state the reason for the delay and the time frame within which you will complete the correction. If you believe that you have complied with the FD&amp;C Act and FDA regulations, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\n\n\u003Cp>Your response should be sent to Dana Lewis, Compliance Officer, U.S. Food and Drug Administration at the following email: dana.lewis@fda.hhs.gov (preferred) or you may mail a hard copy, addressed to Dana Lewis, Compliance Officer, U.S. Food and Drug Administration at 1201 Main Street, Suite 7200, Dallas, TX 75202. If you have any further questions, please contact me at 214-253-5205 or by email.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Edmundo Garcia, Jr.\u003Cbr>\nProgram Division Director HAF West 3\u003Cbr>\nDallas District Director\u003C\u002Fp>\n\n\u003Cp>Cc: Mary Sasser, Program Director\u003Cbr>\nOffice of the Texas State Chemist\u003Cbr>\n445 Agronomy Road\u003Cbr>\nCollege Station, Texas 77843\u003C\u002Fp>\n\n\u003Cp>________________________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> Fumonisin is a mycotoxin produced by fungi that can contaminate corn and corn products.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> See Section 402(a)(4) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) [21 U.S.C. § 342(a)(4)] and 21 CFR 507.1(a)(1)(ii).\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem> See Section 301(k) of the FD&amp;C Act [21 U.S.C. § 331(k)].\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>4\u003C\u002Fstrong>\u003C\u002Fem> See Section 301(uu) of the FD&amp;C Act [21 U.S.C. § 331(uu)].\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>5\u003C\u002Fstrong>\u003C\u002Fem> See “Guidance for Industry: Fumonisin Levels in Human Foods and Animal Feeds,” available at \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fguidance-industry-fumonisin-levels-human-foods-and-animal-feeds\">https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fguidance-industry-fumonisin-levels-human-foods-and-animal-feeds\u003C\u002Fa>.\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Overnight Delivery\n\nProduct:\n\nAnimal & Veterinary\nFood & Beverages\n\nRecipient:\n\nRecipient Name\n\nMr. John E. Evans\n\nRecipient Title\n\nVice President\u002FCo-owner\n\nEvans Farms Feed\n\n537 Lilley Road\n\nAlvin, TX 77511-7143\n\nUnited States\n\nIssuing Office:\n\nDivision of Human and Animal Food Operations West III\n\nUnited States\n\nWARNING LETTER\n\nApril 21, 2022\n\nREF # 625841\n\nDear Mr. John E. Evans:\n\nThe U.S. Food and Drug Administration (FDA) inspected your animal food manufacturing facility (feed mill) located at 537 Lilley Road, Alvin, Texas on November 30, 2021 through December 9, 2021. This inspection was conducted as a follow-up to a consumer complaint received by FDA on October 26, 2021. The complaint was received (b)(4) reporting multiple horses at two locations that became ill, with some being hospitalized and one death, after consuming food manufactured by your facility. Private testing reportedly showed levels of fumonisin (b)(4) in the implicated horse food.1 Follow-up testing by the Office of the Texas State Chemist found (b)(4). Fumonisin levels above 1.0 ppm are known to cause liver disease and fatal nervous system damage in horses.\n\nOur inspection revealed evidence of significant violations of the Current Good Manufacturing Practice, Hazard Analysis, and Risk-Based Preventive Controls for Food for Animals (PCAF) regulation, Title 21, Code of Federal Regulations, Part 507 (21 CFR Part 507) which cause your products to be adulterated.2 The doing of any act to a food after shipment of the food and\u002For its components in interstate commerce and while the food is held for sale (whether or not the first sale) that results in the food being adulterated or misbranded is prohibited.3 Furthermore, failure of the owner, operator, or agent in charge of a covered facility to comply with the preventive controls provision of 21 CFR Part 507 (located in subparts A, C, D, E, and F of Part 507) is also a prohibited act.4 You may find the FD&C Act and FDA’s regulations through links on FDA’s homepage at www.fda.gov.\n\nAt the close of the inspection, you were issued a Form FDA 483, Inspectional Observations (FDA 483). We have not received a response to the FDA 483 as of the date on this letter.\n\nHazard Analysis and Risk-Based Preventive Controls Requirements\n\nYour animal food facility is subject to the hazard analysis and risk-based preventive controls requirements found in 21 CFR Part 507, subparts A, C, D, E, and F. During the inspection of your facility, the FDA Investigator noted evidence of significant violations of these requirements, which included but were not limited to the following:\n\n1. You did not prepare, or have prepared, and did not implement a written food safety plan, as required by 21 CFR 507.31. The preparation of the food safety plan must be overseen by your preventive controls qualified individual (PCQI) and must include the following:\n\na) The written hazard analysis as required by 21 CFR 507.33(a)(2).\n\nb) The written preventive controls as required by 21 CFR 507.34(b).\n\nc) The written supply-chain program as required by subpart E of 21 CFR Part 507.\n\nd) The written recall plan as required by 21 CFR 507.38(a)(1).\n\ne) The written procedures for monitoring the implementation of the preventive controls as required by 21 CFR 507.40(a).\n\nf) The written corrective action procedures as required by 21 CFR 507.42(a)(1).\n\ng) The written verification procedures as required by 21 CFR 507.49(b).\n\nSpecifically, you told the FDA Investigator that you did not have a food safety plan, although you and your PCQI have begun to develop one.\n\nCurrent Good Manufacturing Practices (CGMP) Requirements\n\nYour animal food facility is subject to the CGMP requirements found in 21 CFR Part 507, subparts A, B, and F. During the inspection of your facility, the FDA Investigator noted evidence of significant violations of these requirements, which included but were not limited to the following:\n\n2. Your firm failed to evaluate and use raw materials and other ingredients susceptible to contamination with mycotoxins or other natural toxins in a manner that does not result in animal food that can cause injury or illness to animals or humans, as required by 21 CFR 507.25(b)(2).\n\nSpecifically, you do not have procedures or conduct testing to determine whether mycotoxins such as aflatoxin, fumonisin, or deoxynivalenol (DON) are present in the grains and grain coproducts that you receive and use in your products. Your facility produces animal food for multiple species, including horses, poultry, deer, sheep, goats, rabbits, cattle, and swine, all of which are known to be negatively affected by mycotoxins. The primary components of your animal foods are grains and grain co-products, which are susceptible to mycotoxin contamination.\n\nFurthermore, we found no evidence that you had evaluated whether your firm was the cause of the fumonisin level above FDA’s recommended 1 ppm limit in finished animal food for equids,5 reported to you on October 29, 2021, by the Office of the Texas State Chemist (b)(4). In addition, you did not evaluate the potential for contamination in other products using the same corn ingredients.\n\nConclusion\n\nThis letter is not intended to be an all-inclusive statement of violations that may exist at your facility or in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that you comply with all requirements of federal law and FDA regulations.\n\nThis letter notifies you of our concerns and provides you an opportunity to address them. You should take prompt action to correct any violations. Failure to adequately address this matter may lead to legal or regulatory action, including without limitation, seizure and injunction.\n\nFor more information about FDA’s current thinking on the requirements of 21 CFR Part 507, see:\n\nGuidance for Industry #235: “Current Good Manufacturing Practice Requirements for Food for Animals” https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F97464\u002Fdownload\n\nDraft Guidance for Industry #245: “Hazard Analysis and Risk-Based Preventive Controls for Food for Animals” https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F110477\u002Fdownload\n\nDraft Guidance for Industry #246: “Hazard Analysis and Risk-Based Preventive Controls for Food for Animals: Supply Chain Program” https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F113923\u002Fdownload\n\nWithin fifteen (15) working days of receipt of this letter, please notify this office in writing of the specific steps that you have taken to correct any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within fifteen (15) working days, state the reason for the delay and the time frame within which you will complete the correction. If you believe that you have complied with the FD&C Act and FDA regulations, include your reasoning and any supporting information for our consideration.\n\nYour response should be sent to Dana Lewis, Compliance Officer, U.S. Food and Drug Administration at the following email: dana.lewis@fda.hhs.gov (preferred) or you may mail a hard copy, addressed to Dana Lewis, Compliance Officer, U.S. Food and Drug Administration at 1201 Main Street, Suite 7200, Dallas, TX 75202. If you have any further questions, please contact me at 214-253-5205 or by email.\n\nSincerely,\n\n\u002FS\u002F\n\nEdmundo Garcia, Jr.\n\nProgram Division Director HAF West 3\n\nDallas District Director\n\nCc: Mary Sasser, Program Director\n\nOffice of the Texas State Chemist\n\n445 Agronomy Road\n\nCollege Station, Texas 77843\n\n________________________________\n\n1 Fumonisin is a mycotoxin produced by fungi that can contaminate corn and corn products.\n\n2 See Section 402(a)(4) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) [21 U.S.C. § 342(a)(4)] and 21 CFR 507.1(a)(1)(ii).\n\n3 See Section 301(k) of the FD&C Act [21 U.S.C. § 331(k)].\n\n4 See Section 301(uu) of the FD&C Act [21 U.S.C. § 331(uu)].\n\n5 See “Guidance for Industry: Fumonisin Levels in Human Foods and Animal Feeds,” available at https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fguidance-industry-fumonisin-levels-human-foods-and-animal-feeds.","Evans Farms Feed","evans-farms-feed-625841-04212022","2026-08-18T06:42:29.262718+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fevans-farms-feed-625841-04212022","2026-10-26T08:08:36.965782+00:00","2022-05-17","625841","Animal & VeterinaryFood & Beverages","Mr. John E. Evans","2026-08-20T01:53:51.044+00:00","Via Overnight Delivery","2022-04-21",{"id":138,"raw":139,"subject":143,"body_html":144,"body_text":145,"firm_name":146,"letter_id":147,"created_at":18,"fei_number":19,"letter_url":148,"updated_at":149,"action_type":22,"case_status":23,"posted_date":150,"marcs_cms_no":151,"product_type":26,"closeout_date":19,"issuing_office":11,"recipient_name":19,"body_fetched_at":152,"delivery_method":153,"recipient_title":19,"reference_number":19,"action_taken_date":154,"medical_device_id":19,"response_letter_date":19},638,[140,141,142,11,143,13,13,13],"\u003Ctime datetime=\"2025-09-16T04:00:00Z\">09\u002F16\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-09-09T04:00:00Z\">09\u002F09\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fevolife-wellness-715507-09092025\">EvoLife Wellness\u003C\u002Fa>","Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth)","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Electronic Mail - Delivery and Read Receipt Requested\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\u003C\u002Fdd>\n                    \n            \u003Cdd>EvoLife Wellness\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>777 Glades Rd, Ste 100\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Boca Raton\u003C\u002Fspan>, \u003Cspan>FL\u003C\u002Fspan> \u003Cspan>33434\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:info@evolifewellness.com\"> info@evolifewellness.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>September 9, 2025\u003C\u002Fp>\u003Cp>EvoLife Wellness:\u003C\u002Fp>\u003Cp>This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https:\u002F\u002Fevolifewellness.com in August 2025 and has observed that your website offers various compounded drug products, including semaglutide and tirzepatide.\u003Cem>\u003Cstrong>\u003Csup>1\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> As described below, your claims concerning compounded semaglutide and tirzepatide products are false or misleading under sections 502(a) and 502(bb) of the Federal Food, Drug, and Cosmetic Act (FDCA) [21 U.S.C. §§ 352(a) and 352(bb)], resulting in products being introduced or delivered for introduction into interstate commerce in violation of section 301(a) of the FDCA [21 U.S.C. § 331(a)].\u003C\u002Fp>\u003Cp>Under section 502(a) of the FDCA [21 U.S.C. § 352(a)] a drug is misbranded if its labeling is false or misleading in any particular. Furthermore, under section 502(bb) of the FDCA [21 U.S.C. § 352(bb)], a compounded drug is misbranded if its advertising or promotion is false or misleading in any particular.\u003C\u002Fp>\u003Cp>The following claims concerning compounded semaglutide and tirzepatide products appear on your website:\u003C\u002Fp>\u003Cul>\u003Cli>“FDA-Approved”\u003C\u002Fli>\u003Cli>“Clinically Proven: Semaglutide is FDA-approved for chronic weight management….”\u003C\u002Fli>\u003C\u002Ful>\u003Cp>Compounded drug products are not FDA-approved. Your claims imply that your products are the same as an FDA-approved product when they are not. As a result, these claims are false or misleading and your products are therefore misbranded under sections 502(a) and 502(bb) of the FDCA [21 U.S.C. §§ 352(a) and (bb)].\u003C\u002Fp>\u003Cp>The introduction or delivery for introduction into interstate commerce of these misbranded products is a prohibited act under section 301(a) of the FDCA [21 U.S.C. § 331(a)]. The claims identified in this letter put you on notice of our concerns but do not represent an exhaustive list of misbranding violations.\u003Cstrong>\u003Csup>2\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>For the reasons discussed above, your compounded semaglutide and tirzepatide products are misbranded drugs under sections 502(a) and 502(bb) of the FDCA [21 U.S.C. §§ 352(a) and 352(bb)], introduced or delivered for introduction into interstate commerce in violation of section 301(a) of the FDCA [21 U.S.C. § 331(a)]. Please be advised, the receipt in interstate commerce of misbranded drugs, and the delivery or proffered delivery thereof, is also a violation of section 301(c) of the FDCA [21 U.S.C. § 331(c)].\u003C\u002Fp>\u003Cp>As previously stated, the violations cited in this letter are not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your operations comply with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\u003Cp>You should take immediate action to address any violations (including, for example, ceasing and desisting from using the language cited above that misbrands the product). Failure to adequately address any violations may result in legal action without further notice, including, without limitation, seizure and injunction.\u003C\u002Fp>\u003Cp>Within fifteen (15) working days of receipt of this letter, please provide a written response to the Office of Compounding Quality and Compliance (OCQC) within the Center for Drug Evaluation and Research (CDER)’s Office of Compliance describing the specific steps you have taken to address any violations. Please include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. This letter notifies you of our concerns and provides you an opportunity to address them. If you believe your products are not in violation of the FDCA, include your reasoning and any supporting information for our consideration. If you cannot completely address this matter within fifteen (15) working days, state the reason for the delay and the time within which you will do so.\u003C\u002Fp>\u003Cp>If you are not located in the U.S., please note that products that appear to be misbranded may be detained or refused admission. We may advise the appropriate regulatory officials in the country from which you operate that your products referenced above appear to be misbranded drugs that cannot be legally sold to consumers in the U.S.\u003C\u002Fp>\u003Cp>All correspondence should include a subject line that clearly identifies the submission as a Response to Warning Letter. If you have questions regarding the contents of this letter, please contact compoundinginspections@fda.hhs.gov.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003Cbr>George Tidmarsh, M.D., Ph.D.\u003Cbr>Director\u003Cbr>Center for Drug Evaluation and Research\u003Cbr>U.S. Food and Drug Administration\u003C\u002Fp>\u003Cp>________________________\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> The semaglutide and tirzepatide products offered on your website are drugs within the meaning of section 201(g) of the FDCA [21 U.S.C. § 321(g)] because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of diseases and\u002For because they are intended to affect the structure or any function of the body. Further, they are “new drugs” within the meaning of section 201(p) of the FDCA [21 U.S.C. § 321(p)] because they are not generally recognized as safe and effective for their labeled uses.\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> Overstatements of efficacy or minimization of risk are of particular concern and may constitute misbranding.\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Electronic Mail - Delivery and Read Receipt Requested\n\nProduct:\n\nDrugs\n\nRecipient:\n\nEvoLife Wellness\n\n777 Glades Rd, Ste 100\n\nBoca Raton, FL 33434\n\nUnited States\n\ninfo@evolifewellness.com\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nWARNING LETTER\nSeptember 9, 2025\nEvoLife Wellness:\nThis letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https:\u002F\u002Fevolifewellness.com in August 2025 and has observed that your website offers various compounded drug products, including semaglutide and tirzepatide.1 As described below, your claims concerning compounded semaglutide and tirzepatide products are false or misleading under sections 502(a) and 502(bb) of the Federal Food, Drug, and Cosmetic Act (FDCA) [21 U.S.C. §§ 352(a) and 352(bb)], resulting in products being introduced or delivered for introduction into interstate commerce in violation of section 301(a) of the FDCA [21 U.S.C. § 331(a)].\nUnder section 502(a) of the FDCA [21 U.S.C. § 352(a)] a drug is misbranded if its labeling is false or misleading in any particular. Furthermore, under section 502(bb) of the FDCA [21 U.S.C. § 352(bb)], a compounded drug is misbranded if its advertising or promotion is false or misleading in any particular.\nThe following claims concerning compounded semaglutide and tirzepatide products appear on your website:\n“FDA-Approved”\n“Clinically Proven: Semaglutide is FDA-approved for chronic weight management….”\nCompounded drug products are not FDA-approved. Your claims imply that your products are the same as an FDA-approved product when they are not. As a result, these claims are false or misleading and your products are therefore misbranded under sections 502(a) and 502(bb) of the FDCA [21 U.S.C. §§ 352(a) and (bb)].\nThe introduction or delivery for introduction into interstate commerce of these misbranded products is a prohibited act under section 301(a) of the FDCA [21 U.S.C. § 331(a)]. The claims identified in this letter put you on notice of our concerns but do not represent an exhaustive list of misbranding violations.2\nFor the reasons discussed above, your compounded semaglutide and tirzepatide products are misbranded drugs under sections 502(a) and 502(bb) of the FDCA [21 U.S.C. §§ 352(a) and 352(bb)], introduced or delivered for introduction into interstate commerce in violation of section 301(a) of the FDCA [21 U.S.C. § 331(a)]. Please be advised, the receipt in interstate commerce of misbranded drugs, and the delivery or proffered delivery thereof, is also a violation of section 301(c) of the FDCA [21 U.S.C. § 331(c)].\nAs previously stated, the violations cited in this letter are not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your operations comply with all requirements of federal law, including FDA regulations.\nYou should take immediate action to address any violations (including, for example, ceasing and desisting from using the language cited above that misbrands the product). Failure to adequately address any violations may result in legal action without further notice, including, without limitation, seizure and injunction.\nWithin fifteen (15) working days of receipt of this letter, please provide a written response to the Office of Compounding Quality and Compliance (OCQC) within the Center for Drug Evaluation and Research (CDER)’s Office of Compliance describing the specific steps you have taken to address any violations. Please include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. This letter notifies you of our concerns and provides you an opportunity to address them. If you believe your products are not in violation of the FDCA, include your reasoning and any supporting information for our consideration. If you cannot completely address this matter within fifteen (15) working days, state the reason for the delay and the time within which you will do so.\nIf you are not located in the U.S., please note that products that appear to be misbranded may be detained or refused admission. We may advise the appropriate regulatory officials in the country from which you operate that your products referenced above appear to be misbranded drugs that cannot be legally sold to consumers in the U.S.\nAll correspondence should include a subject line that clearly identifies the submission as a Response to Warning Letter. If you have questions regarding the contents of this letter, please contact compoundinginspections@fda.hhs.gov.\nSincerely,\n\u002FS\u002F\nGeorge Tidmarsh, M.D., Ph.D.\nDirector\nCenter for Drug Evaluation and Research\nU.S. Food and Drug Administration\n________________________\n1 The semaglutide and tirzepatide products offered on your website are drugs within the meaning of section 201(g) of the FDCA [21 U.S.C. § 321(g)] because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of diseases and\u002For because they are intended to affect the structure or any function of the body. Further, they are “new drugs” within the meaning of section 201(p) of the FDCA [21 U.S.C. § 321(p)] because they are not generally recognized as safe and effective for their labeled uses.\n2 Overstatements of efficacy or minimization of risk are of particular concern and may constitute misbranding.","EvoLife Wellness","evolife-wellness-715507-09092025","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fevolife-wellness-715507-09092025","2026-10-26T08:08:37.743856+00:00","2025-09-16","715507","2026-08-19T16:21:04.805+00:00","Via Electronic Mail - Delivery and Read Receipt Requested","2025-09-09",{"id":156,"raw":157,"subject":58,"body_html":161,"body_text":162,"firm_name":163,"letter_id":164,"created_at":165,"fei_number":19,"letter_url":166,"updated_at":167,"action_type":22,"case_status":23,"posted_date":168,"marcs_cms_no":169,"product_type":68,"closeout_date":19,"issuing_office":57,"recipient_name":170,"body_fetched_at":171,"delivery_method":70,"recipient_title":19,"reference_number":19,"action_taken_date":168,"medical_device_id":19,"response_letter_date":19},2060,[158,159,160,57,58,13,13,13],"\u003Ctime datetime=\"2023-06-08T19:00:00Z\">06\u002F08\u002F2023\u003C\u002Ftime>\n","\u003Ctime datetime=\"2023-06-08T04:00:00Z\">06\u002F08\u002F2023\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Feverything-vapor-656319-06082023\">Everything Vapor\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS and Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Tobacco                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Tammy Garrison\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Owner\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Everything Vapor\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>2340 East 20th Street\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Farmington\u003C\u002Fspan>, \u003Cspan>NM\u003C\u002Fspan> \u003Cspan>87401\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:garrison@animas.net\"> garrison@animas.net\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Tobacco Products\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>June 8, 2023\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Dear Ms. Garrison:\u003C\u002Fp>\n\n\u003Cp>The Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) has reviewed your submissions to the FDA and our inspection records, and determined that Everything Vapor manufactures and distributes e-liquids products for commercial distribution in the United States, and that the e-liquid products are manufactured and offered for sale or distribution to customers in the United States.\u003C\u002Fp>\n\n\u003Cp>Under section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) (21 U.S.C. § 321(rr)), these products are tobacco products because they are made or derived from tobacco or contain nicotine from any source, and intended for human consumption. Certain tobacco products, including e-liquid products, are subject to FDA jurisdiction under section 901(b) of the FD&amp;C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1, and are required to be in compliance with the requirements in the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>Please be aware that, on March 15, 2022, the President signed legislation to amend the FD&amp;C Act to extend FDA’s jurisdiction to products “containing nicotine from any source,” not just nicotine derived from tobacco. See Consolidated Appropriations Act, 2022, Public Law 117-103, Division P, Title I, Subtitle B. Specifically, this legislation expanded the definition of “tobacco product” under section 201(rr) of the FD&amp;C Act (21 U.S.C. § 321(rr)) to include products containing nicotine from any source. Tobacco products, including e-liquid products, containing nicotine from any source, must be in compliance with the FD&amp;C Act and its implementing regulations. For more information, please see https:\u002F\u002Fwww.fda.gov\u002Ftobacco-products\u002Fctp-newsroom\u002Frequirements-products-made-non-tobacco-nicotine-take-effect-april-14.\u003C\u002Fp>\n\n\u003Cp>Generally, to be legally marketed in the United States, the FD&amp;C Act requires “new tobacco products” to have a premarket authorization in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&amp;C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&amp;C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&amp;C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&amp;C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&amp;C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&amp;C Act (21 U.S.C. § 387e(j)(3)).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>New Tobacco Products Without Required Marketing Authorization Is Adulterated and Misbranded\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>FDA has determined that you manufacture, import, sell, and\u002For distribute to customers in the United States e-liquid products without a marketing authorization order, including House Juice #11 Blackberry.\u003C\u002Fp>\n\n\u003Cp>The e-liquid products listed above are new tobacco products because they were not commercially marketed in the United States as of February 15, 2007. These products do not have FDA marketing authorization orders in effect under section 910(c)(1)(A)(i) of the FD&amp;C Act and are not otherwise exempt from the marketing authorization requirement. Therefore, these products are adulterated under section 902(6)(A) of the FD&amp;C Act (21 U.S.C. § 387b(6)(A)). In addition, they are misbranded under section 903(a)(6) of the FD&amp;C Act (21 U.S.C. § 387c(a)(6)) because a notice or other information respecting these products was not provided as required by section 905(j) of the FD&amp;C Act. The doing of any act with respect to a tobacco product while such article is held for sale after shipment in interstate commerce which results in such product being adulterated or misbranded is a prohibited act under section 301(k) of the FD&amp;C Act (21 U.S.C. § 331(k)). Additionally, to the extent that a report was required under section 905(j) of the FD&amp;C Act, the failure to provide such report is a prohibited act under section 301(p) of the FD&amp;C Act (21 U.S.C. § 331(p)).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion and Requested Actions\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>FDA has determined that your firm markets new tobacco products lacking premarket authorization in the United States. All new tobacco products on the market without the statutorily required premarket authorization are marketed unlawfully and are subject to enforcement action at FDA’s discretion.\u003C\u002Fp>\n\n\u003Cp>It is your responsibility to ensure that all of your tobacco products comply with each applicable provision of the FD&amp;C Act and FDA’s implementing regulations. Failure to address any violations of the FD&amp;C Act, 21 U.S.C. § 301 et seq., Chapter IX, relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, and 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&amp;C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated and\u002For misbranded may be detained or refused admission.\u003C\u002Fp>\n\n\u003Cp>The violations discussed in this letter do not necessarily constitute an exhaustive list. You should take prompt action to address any violations that are referenced above, as well as violations that are the same as or similar to the ones stated above, and take any necessary actions to bring your tobacco products into compliance with the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>Please submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring your products into compliance, including the dates on which you discontinued the violative sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&amp;C Act. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&amp;C Act through links on FDA’s homepage at \u003Ca href=\"http:\u002F\u002Fwww.fda.gov.\u002F\">http:\u002F\u002Fwww.fda.gov.\u003C\u002Fa>\u003C\u002Fp>\n\n\u003Cp>Please note your reference number, ER2300825, in your response and direct your response to the following address:\u003C\u002Fp>\n\n\u003Cp>DEM-WL Response, Office of Compliance and Enforcement\u003Cbr>\nFDA Center for Tobacco Products\u003Cbr>\nc\u002Fo Document Control Center\u003Cbr>\nBuilding 71, Room G335\u003Cbr>\n10903 New Hampshire Avenue\u003Cbr>\nSilver Spring, MD 20993-0002\u003C\u002Fp>\n\n\u003Cp>If you have any questions about the content of this letter, please contact CTPCompliance@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Ann Simoneau, J.D.\u003Cbr>\nDirector\u003Cbr>\nOffice of Compliance and Enforcement\u003Cbr>\nCenter for Tobacco Products\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS and Electronic Mail\n\nProduct:\n\nTobacco\n\nRecipient:\n\nRecipient Name\n\nTammy Garrison\n\nRecipient Title\n\nOwner\n\nEverything Vapor\n\n2340 East 20th Street\n\nFarmington, NM 87401\n\nUnited States\n\ngarrison@animas.net\n\nIssuing Office:\n\nCenter for Tobacco Products\n\nUnited States\n\nJune 8, 2023\n\nWARNING LETTER\n\nDear Ms. Garrison:\n\nThe Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) has reviewed your submissions to the FDA and our inspection records, and determined that Everything Vapor manufactures and distributes e-liquids products for commercial distribution in the United States, and that the e-liquid products are manufactured and offered for sale or distribution to customers in the United States.\n\nUnder section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. § 321(rr)), these products are tobacco products because they are made or derived from tobacco or contain nicotine from any source, and intended for human consumption. Certain tobacco products, including e-liquid products, are subject to FDA jurisdiction under section 901(b) of the FD&C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1, and are required to be in compliance with the requirements in the FD&C Act.\n\nPlease be aware that, on March 15, 2022, the President signed legislation to amend the FD&C Act to extend FDA’s jurisdiction to products “containing nicotine from any source,” not just nicotine derived from tobacco. See Consolidated Appropriations Act, 2022, Public Law 117-103, Division P, Title I, Subtitle B. Specifically, this legislation expanded the definition of “tobacco product” under section 201(rr) of the FD&C Act (21 U.S.C. § 321(rr)) to include products containing nicotine from any source. Tobacco products, including e-liquid products, containing nicotine from any source, must be in compliance with the FD&C Act and its implementing regulations. For more information, please see https:\u002F\u002Fwww.fda.gov\u002Ftobacco-products\u002Fctp-newsroom\u002Frequirements-products-made-non-tobacco-nicotine-take-effect-april-14.\n\nGenerally, to be legally marketed in the United States, the FD&C Act requires “new tobacco products” to have a premarket authorization in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&C Act (21 U.S.C. § 387e(j)(3)).\n\nNew Tobacco Products Without Required Marketing Authorization Is Adulterated and Misbranded\n\nFDA has determined that you manufacture, import, sell, and\u002For distribute to customers in the United States e-liquid products without a marketing authorization order, including House Juice #11 Blackberry.\n\nThe e-liquid products listed above are new tobacco products because they were not commercially marketed in the United States as of February 15, 2007. These products do not have FDA marketing authorization orders in effect under section 910(c)(1)(A)(i) of the FD&C Act and are not otherwise exempt from the marketing authorization requirement. Therefore, these products are adulterated under section 902(6)(A) of the FD&C Act (21 U.S.C. § 387b(6)(A)). In addition, they are misbranded under section 903(a)(6) of the FD&C Act (21 U.S.C. § 387c(a)(6)) because a notice or other information respecting these products was not provided as required by section 905(j) of the FD&C Act. The doing of any act with respect to a tobacco product while such article is held for sale after shipment in interstate commerce which results in such product being adulterated or misbranded is a prohibited act under section 301(k) of the FD&C Act (21 U.S.C. § 331(k)). Additionally, to the extent that a report was required under section 905(j) of the FD&C Act, the failure to provide such report is a prohibited act under section 301(p) of the FD&C Act (21 U.S.C. § 331(p)).\n\nConclusion and Requested Actions\n\nFDA has determined that your firm markets new tobacco products lacking premarket authorization in the United States. All new tobacco products on the market without the statutorily required premarket authorization are marketed unlawfully and are subject to enforcement action at FDA’s discretion.\n\nIt is your responsibility to ensure that all of your tobacco products comply with each applicable provision of the FD&C Act and FDA’s implementing regulations. Failure to address any violations of the FD&C Act, 21 U.S.C. § 301 et seq., Chapter IX, relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, and 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated and\u002For misbranded may be detained or refused admission.\n\nThe violations discussed in this letter do not necessarily constitute an exhaustive list. You should take prompt action to address any violations that are referenced above, as well as violations that are the same as or similar to the ones stated above, and take any necessary actions to bring your tobacco products into compliance with the FD&C Act.\n\nPlease submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring your products into compliance, including the dates on which you discontinued the violative sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&C Act. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&C Act through links on FDA’s homepage at http:\u002F\u002Fwww.fda.gov.\n\nPlease note your reference number, ER2300825, in your response and direct your response to the following address:\n\nDEM-WL Response, Office of Compliance and Enforcement\n\nFDA Center for Tobacco Products\n\nc\u002Fo Document Control Center\n\nBuilding 71, Room G335\n\n10903 New Hampshire Avenue\n\nSilver Spring, MD 20993-0002\n\nIf you have any questions about the content of this letter, please contact CTPCompliance@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nAnn Simoneau, J.D.\n\nDirector\n\nOffice of Compliance and Enforcement\n\nCenter for Tobacco Products","Everything Vapor","everything-vapor-656319-06082023","2026-08-18T06:42:29.145918+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Feverything-vapor-656319-06082023","2026-10-26T08:08:37.403788+00:00","2023-06-08","656319","Tammy Garrison","2026-08-20T01:03:35.339+00:00",{"id":173,"raw":174,"subject":179,"body_html":180,"body_text":181,"firm_name":182,"letter_id":183,"created_at":184,"fei_number":19,"letter_url":185,"updated_at":186,"action_type":22,"case_status":23,"posted_date":187,"marcs_cms_no":188,"product_type":110,"closeout_date":19,"issuing_office":178,"recipient_name":189,"body_fetched_at":190,"delivery_method":19,"recipient_title":19,"reference_number":19,"action_taken_date":191,"medical_device_id":19,"response_letter_date":19},3314,[175,176,177,178,179,13,13,13],"\u003Ctime datetime=\"2021-06-08T13:20:00Z\">06\u002F08\u002F2021\u003C\u002Ftime>\n","\u003Ctime datetime=\"2021-05-24T04:00:00Z\">05\u002F24\u002F2021\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Feverything-health-llc-613718-05242021\">Everything Health LLC\u003C\u002Fa>","Center for Food Safety and Applied Nutrition","Unapproved and Misbranded Products Related to Coronavirus Disease 2019(COVID-19)","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Food &amp; Beverages                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Tamika Moseley\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                    \n            \u003Cdd>Everything Health LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>1445 293rd Ave NE\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Carnation\u003C\u002Fspan>, \u003Cspan>WA\u003C\u002Fspan> \u003Cspan>98014\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:info@ssnaturalhealing.com\"> info@ssnaturalhealing.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Food Safety and Applied Nutrition\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n         \n          \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan> Federal Trade Commission\u003C\u002Fdd>\n\n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Date: May 24, 2021\u003C\u002Fp>\n\n\u003Cp>RE: Unapproved and Misbranded Products Related to Coronavirus Disease 2019(COVID-19)\u003C\u002Fp>\n\n\u003Cp>This is to advise you that the United States Food and Drug Administration (FDA) and the Federal Trade Commission (FTC) reviewed your website at the Internet address https:\u002F\u002Fssnaturalhealing.com on February 23, 2021 and May 11, 2021, respectively. We also reviewed your social media websites at https:\u002F\u002Fwww.facebook.com\u002Fssdallastx\u002F, https:\u002F\u002Fwww.instagram.com\u002Ftamikamoseley\u002F, and https:\u002F\u002Ftwitter.com\u002Fsicklesolution, where you direct consumers to your website https:\u002F\u002Fssnaturalhealing.com to purchase your products. The FDA has observed that your website offers the product CoronaBox for sale in the United States and that this product is intended to mitigate, prevent, treat, diagnose, or cure COVID-19\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> in people. Based on our review, this product is an unapproved new drug sold in violation of section 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. § 355(a). Furthermore, this product is a misbranded drug under section 502 of the FD&amp;C Act, 21 U.S.C. § 352. The introduction or delivery for introduction of this product into interstate commerce is prohibited under sections 301(a) and (d) of the FD&amp;C Act, 21 U.S.C. § 331(a) and (d).\u003C\u002Fp>\n\n\u003Cp>There is currently a global outbreak of respiratory disease caused by a novel coronavirus that has been named “severe acute respiratory syndrome coronavirus 2” (SARS-CoV-2). The disease caused by the virus has been named “Coronavirus Disease 2019” (COVID-19). On January 31, 2020, the Department of Health and Human Services (HHS) issued a declaration of a public health emergency related to COVID-19 and mobilized the Operating Divisions of HHS.\u003Csup>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> In addition, on March 13, 2020, there was a Presidential declaration of a national emergency in response to COVID-19.\u003Csup>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> Therefore, FDA is taking urgent measures to protect consumers from certain products that, without approval or authorization by FDA, claim to mitigate, prevent, treat, diagnose, or cure COVID-19 in people. As described below, you sell a product that is intended to mitigate, prevent, treat, diagnose, or cure COVID-19 in people. We request that you take immediate action to cease the sale of any unapproved and unauthorized products for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19.\u003C\u002Fp>\n\n\u003Cp>According to your website, your CoronaBox product consists of the products Cordyceps, Vitamin D3\u002FK2 Magnesium, Ginger Root, Probiotics, and Sea Moss Gel. Your websites also refer to the CoronaBox product as the “corona basket,” “Corona box,” “coronavirus boxes,” “(orona box,” and “the regimen.” Some examples of the claims on your websites that establish the intended use of your product and misleadingly represent it as safe and\u002For effective for the treatment or prevention of COVID-19 include:\u003C\u002Fp>\n\n\u003Cp>• “Coronavirus disease 2019 (COVID-19) is a disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).\u003C\u002Fp>\n\n\u003Cp>Let’s take a look at natural alternatives we can apply to our daily lives to protect the body and prevent against this virus. The main areas we want to focus on are: gut, immune, and respiratory health . . .\u003C\u002Fp>\n\n\u003Cp>Cordyceps . . . It has been used for centuries in Asia as a tonic to soothe the lung for the treatment of respiratory disease.” [from your webpage https:\u002F\u002Fwww.ssnaturalhealing.com\u002Fcoronavirusprevention-tips]\u003C\u002Fp>\n\n\u003Cp>• “The Corona box is all you need to kick that nasty virus! . . . If you have questions while taking the regimen, please do not hesitate to email me: info@ssnaturalhealing.com.” [from your CoronaBox product webpage, https:\u002F\u002Fwww.ssnaturalhealing.com\u002Fproduct-page\u002Fcoronabox]\u003C\u002Fp>\n\n\u003Cp>• “The corona baskets are $99.00 with FREE shipping and will come with a step by step regimen for getting over corona and also a maintenance regimen to follow AFTER corona to PREVENT BEING A COVID LONG HAULER!!!! . . . The corona basket will contain (probiotic,D3\u002Fk2\u002Fmag, ginger, cordyceps, and sea moss gel) www.ssnaturalhealing.com” [from a December 31, 2020 post on your social media webpage https:\u002F\u002Ffacebook.com\u002Fssdallastx\u002F]\u003C\u002Fp>\n\n\u003Cp>• “I want to let the world know! I have coronavirus boxes that I ship out daily!!!! I am reversing corona by using GODS [SIC] MEDICINE CABINET. . .” [from a February 2, 2021 post on your social media webpage https:\u002F\u002Ffacebook.com\u002Fssdallastx\u002F]\u003C\u002Fp>\n\n\u003Cp>• “Anyone can order a (corona [sic] box by sending 99.00 to my PayPal . . . We simply do not have to suffer from this virus! Once we boost the immune system, boost the gut and alkaline the body – the virus will die! No sickness can survive in an alkaline environment! [from a January 9, 2021 post on your social media webpage https:\u002F\u002Finstagram.com\u002Ftamikamoseley\u002F]\u003C\u002Fp>\n\n\u003Cp>• “I was exposed to the coronavirus at work . . . After two days of being tested, I received my results, and I was positive for the coronavirus. My son and my mom had to get tested as well. They were exposed from being around me everyday. Both of them were positive as well. I reached out to Tamika and did a consultation with her. My mom, my son and I did the regimen that was given by Tamika. After a few days of doing her regimen, we ended up with negative results. If we didn’t do the regimen from Tamika, I would not have known how we would have survived it.” [from a December 5, 2020 post on your social media webpage https:\u002F\u002Ftwitter.com\u002Fsicklesolution, in which you posted a testimonial by “Anonymous”]\u003C\u002Fp>\n\n\u003Cp>• “As long as the people will take what they need to take to prevent corona, and we talked about this, probiotics, natural antibiotics, D3 K2 Magnesium, vitamin C, sea moss, all these things, all reverse corona on a daily basis.” [from 0:39-0:56 of a February 1, 2021 YouTube video that “Everything Health with Tamika” posted on the webpage https:\u002F\u002Fyoutube.com\u002Fwatch?v=nCQItNnhCdE. During this statement, the screen shows the following: “THE TRUTH ABOUT COVID”]\u003C\u002Fp>\n\n\u003Cp>You should take immediate action to address the violations cited in this letter. This letter is not meant to be an all-inclusive list of violations that exist in connection with your products or operations. It is your responsibility to ensure that the products you sell are in compliance with the FD&amp;C Act and FDA's implementing regulations. We advise you to review your websites, product labels, and other labeling and promotional materials to ensure that you are not misleadingly representing your products as safe and effective for a COVID-19-related use for which they have not been approved by FDA and that you do not make claims that misbrand the products in violation of the FD&amp;C Act. \u003Cstrong>Within 48 hours, please send an email to COVID-19-Task-Force-CFSAN@fda.hhs.gov\u003C\u002Fstrong> describing the specific steps you have taken to address these violations. Include an explanation of each step being taken to prevent the recurrence of any violations, as well as copies of related documentation. Failure to adequately correct any violations may result in legal action, including, without limitation, seizure and injunction.\u003C\u002Fp>\n\n\u003Cp>FDA is advising consumers not to purchase or use certain products that have not been approved, cleared, or authorized by FDA and that are being misleadingly represented as safe and\u002For effective for the treatment or prevention of COVID-19. Your firm will be added to a published list on FDA’s website of firms and websites that have received warning letters from FDA concerning the sale or distribution of COVID-19 related products in violation of the FD&amp;C Act. This list can be found at&nbsp;http:\u002F\u002Fwww.fda.gov\u002Fconsumers\u002Fhealth-fraud-scams\u002Ffraudulent-coronavirus-disease-covid-19-products. Once you have taken actions to address the sale of your unapproved and unauthorized products for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19, and any appropriate corrective actions have been confirmed by the FDA, the published list will be updated to indicate that your firm has taken such corrective actions.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our concerns and provides you with an opportunity to address them. If you cannot take action to address this matter completely within 48 hours, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\n\n\u003Cp>If you are not located in the United States, please note that products that appear to be misbranded or unapproved new drugs may be detained or refused admission if they are offered for importation into the United States. We may advise the appropriate regulatory officials in the country from which you operate that FDA considers your product(s) referenced above to be unapproved and misbranded products that cannot be legally sold to consumers in the United States.\u003C\u002Fp>\n\n\u003Cp>Please direct any inquiries to FDA at COVID-19-Task-Force-CFSAN@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>In addition, it is unlawful under the FTC Act, 15 U.S.C. 41 et seq., to advertise that a product can prevent, treat, or cure human disease unless you possess competent and reliable scientific evidence, including, when appropriate, well-controlled human clinical studies, substantiating that the claims are true at the time they are made. For COVID-19, no such study is currently known to exist for the product identified above. Thus, any coronavirus-related prevention or treatment claims regarding such product are not supported by competent and reliable scientific evidence. You must immediately cease making all such claims. Violations of the FTC Act may result in legal action seeking a Federal District Court injunction. In addition, pursuant to the COVID-19 Consumer Protection Act, Section 1401, Division FF, of the Consolidated Appropriations Act, 2021, P.L. 116-260, marketers who make deceptive claims about the treatment, cure, prevention, or mitigation of COVID-19 are subject to a civil penalty of up to $43,792 per violation and may be required to pay refunds to consumers or provide other relief pursuant to Section 19(b) of the FTC Act, 15 U.S.C. § 57b(b). Within 48 hours, please send an email to Richard Cleland, Assistant Director of the FTC’s Division of Advertising Practices, via electronic mail at rcleland@ftc.gov describing the specific actions you have taken to address the FTC’s concerns. If you have any questions regarding compliance with the FTC Act, please contact Mr. Cleland at 202-326-3088.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Michael W. Roosevelt\u003Cbr>\nActing Director\u003Cbr>\nOffice of Compliance\u003Cbr>\nCenter for Food Safety\u003Cbr>\n&nbsp; &nbsp; and Applied Nutrition\u003Cbr>\nFood and Drug Administration\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Serena Viswanathan\u003Cbr>\nAssociate Director\u003Cbr>\nDivision of Advertising Practices\u003Cbr>\nFederal Trade Commission\u003C\u002Fp>\n\n\u003Cp>_____________________________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> As explained in the next paragraph, there is currently an outbreak of a respiratory disease named “Coronavirus Disease 2019” (COVID-19).\u003Cbr>\n\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> Secretary of Health and Human Services, Determination that a Public Health Emergency Exists (originally issued Jan. 31, 2020, and subsequently renewed), available at https:\u002F\u002Fwww.phe.gov\u002Femergency\u002Fnews\u002Fhealthactions\u002Fphe\u002FPages\u002Fdefault.aspx.\u003Cbr>\n\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem> Proclamation on Declaring a National Emergency Concerning the Novel Coronavirus Disease (COVID-19) Outbreak (Mar. 13, 2020), available at https:\u002F\u002Ftrumpwhitehouse.archives.gov\u002Fpresidential-actions\u002Fproclamationdeclaring-national-emergency-concerning-novel-coronavirus-disease-covid-19-outbreak\u002F.\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Product:\n\nFood & Beverages\n\nRecipient:\n\nRecipient Name\n\nTamika Moseley\n\nEverything Health LLC\n\n1445 293rd Ave NE\n\nCarnation, WA 98014\n\nUnited States\n\ninfo@ssnaturalhealing.com\n\nIssuing Office:\n\nCenter for Food Safety and Applied Nutrition\n\nUnited States\n\nFederal Trade Commission\n\nWARNING LETTER\n\nDate: May 24, 2021\n\nRE: Unapproved and Misbranded Products Related to Coronavirus Disease 2019(COVID-19)\n\nThis is to advise you that the United States Food and Drug Administration (FDA) and the Federal Trade Commission (FTC) reviewed your website at the Internet address https:\u002F\u002Fssnaturalhealing.com on February 23, 2021 and May 11, 2021, respectively. We also reviewed your social media websites at https:\u002F\u002Fwww.facebook.com\u002Fssdallastx\u002F, https:\u002F\u002Fwww.instagram.com\u002Ftamikamoseley\u002F, and https:\u002F\u002Ftwitter.com\u002Fsicklesolution, where you direct consumers to your website https:\u002F\u002Fssnaturalhealing.com to purchase your products. The FDA has observed that your website offers the product CoronaBox for sale in the United States and that this product is intended to mitigate, prevent, treat, diagnose, or cure COVID-191 in people. Based on our review, this product is an unapproved new drug sold in violation of section 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. § 355(a). Furthermore, this product is a misbranded drug under section 502 of the FD&C Act, 21 U.S.C. § 352. The introduction or delivery for introduction of this product into interstate commerce is prohibited under sections 301(a) and (d) of the FD&C Act, 21 U.S.C. § 331(a) and (d).\n\nThere is currently a global outbreak of respiratory disease caused by a novel coronavirus that has been named “severe acute respiratory syndrome coronavirus 2” (SARS-CoV-2). The disease caused by the virus has been named “Coronavirus Disease 2019” (COVID-19). On January 31, 2020, the Department of Health and Human Services (HHS) issued a declaration of a public health emergency related to COVID-19 and mobilized the Operating Divisions of HHS.2 In addition, on March 13, 2020, there was a Presidential declaration of a national emergency in response to COVID-19.3 Therefore, FDA is taking urgent measures to protect consumers from certain products that, without approval or authorization by FDA, claim to mitigate, prevent, treat, diagnose, or cure COVID-19 in people. As described below, you sell a product that is intended to mitigate, prevent, treat, diagnose, or cure COVID-19 in people. We request that you take immediate action to cease the sale of any unapproved and unauthorized products for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19.\n\nAccording to your website, your CoronaBox product consists of the products Cordyceps, Vitamin D3\u002FK2 Magnesium, Ginger Root, Probiotics, and Sea Moss Gel. Your websites also refer to the CoronaBox product as the “corona basket,” “Corona box,” “coronavirus boxes,” “(orona box,” and “the regimen.” Some examples of the claims on your websites that establish the intended use of your product and misleadingly represent it as safe and\u002For effective for the treatment or prevention of COVID-19 include:\n\n• “Coronavirus disease 2019 (COVID-19) is a disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).\n\nLet’s take a look at natural alternatives we can apply to our daily lives to protect the body and prevent against this virus. The main areas we want to focus on are: gut, immune, and respiratory health . . .\n\nCordyceps . . . It has been used for centuries in Asia as a tonic to soothe the lung for the treatment of respiratory disease.” [from your webpage https:\u002F\u002Fwww.ssnaturalhealing.com\u002Fcoronavirusprevention-tips]\n\n• “The Corona box is all you need to kick that nasty virus! . . . If you have questions while taking the regimen, please do not hesitate to email me: info@ssnaturalhealing.com.” [from your CoronaBox product webpage, https:\u002F\u002Fwww.ssnaturalhealing.com\u002Fproduct-page\u002Fcoronabox]\n\n• “The corona baskets are $99.00 with FREE shipping and will come with a step by step regimen for getting over corona and also a maintenance regimen to follow AFTER corona to PREVENT BEING A COVID LONG HAULER!!!! . . . The corona basket will contain (probiotic,D3\u002Fk2\u002Fmag, ginger, cordyceps, and sea moss gel) www.ssnaturalhealing.com” [from a December 31, 2020 post on your social media webpage https:\u002F\u002Ffacebook.com\u002Fssdallastx\u002F]\n\n• “I want to let the world know! I have coronavirus boxes that I ship out daily!!!! I am reversing corona by using GODS [SIC] MEDICINE CABINET. . .” [from a February 2, 2021 post on your social media webpage https:\u002F\u002Ffacebook.com\u002Fssdallastx\u002F]\n\n• “Anyone can order a (corona [sic] box by sending 99.00 to my PayPal . . . We simply do not have to suffer from this virus! Once we boost the immune system, boost the gut and alkaline the body – the virus will die! No sickness can survive in an alkaline environment! [from a January 9, 2021 post on your social media webpage https:\u002F\u002Finstagram.com\u002Ftamikamoseley\u002F]\n\n• “I was exposed to the coronavirus at work . . . After two days of being tested, I received my results, and I was positive for the coronavirus. My son and my mom had to get tested as well. They were exposed from being around me everyday. Both of them were positive as well. I reached out to Tamika and did a consultation with her. My mom, my son and I did the regimen that was given by Tamika. After a few days of doing her regimen, we ended up with negative results. If we didn’t do the regimen from Tamika, I would not have known how we would have survived it.” [from a December 5, 2020 post on your social media webpage https:\u002F\u002Ftwitter.com\u002Fsicklesolution, in which you posted a testimonial by “Anonymous”]\n\n• “As long as the people will take what they need to take to prevent corona, and we talked about this, probiotics, natural antibiotics, D3 K2 Magnesium, vitamin C, sea moss, all these things, all reverse corona on a daily basis.” [from 0:39-0:56 of a February 1, 2021 YouTube video that “Everything Health with Tamika” posted on the webpage https:\u002F\u002Fyoutube.com\u002Fwatch?v=nCQItNnhCdE. During this statement, the screen shows the following: “THE TRUTH ABOUT COVID”]\n\nYou should take immediate action to address the violations cited in this letter. This letter is not meant to be an all-inclusive list of violations that exist in connection with your products or operations. It is your responsibility to ensure that the products you sell are in compliance with the FD&C Act and FDA's implementing regulations. We advise you to review your websites, product labels, and other labeling and promotional materials to ensure that you are not misleadingly representing your products as safe and effective for a COVID-19-related use for which they have not been approved by FDA and that you do not make claims that misbrand the products in violation of the FD&C Act. Within 48 hours, please send an email to COVID-19-Task-Force-CFSAN@fda.hhs.gov describing the specific steps you have taken to address these violations. Include an explanation of each step being taken to prevent the recurrence of any violations, as well as copies of related documentation. Failure to adequately correct any violations may result in legal action, including, without limitation, seizure and injunction.\n\nFDA is advising consumers not to purchase or use certain products that have not been approved, cleared, or authorized by FDA and that are being misleadingly represented as safe and\u002For effective for the treatment or prevention of COVID-19. Your firm will be added to a published list on FDA’s website of firms and websites that have received warning letters from FDA concerning the sale or distribution of COVID-19 related products in violation of the FD&C Act. This list can be found at http:\u002F\u002Fwww.fda.gov\u002Fconsumers\u002Fhealth-fraud-scams\u002Ffraudulent-coronavirus-disease-covid-19-products. Once you have taken actions to address the sale of your unapproved and unauthorized products for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19, and any appropriate corrective actions have been confirmed by the FDA, the published list will be updated to indicate that your firm has taken such corrective actions.\n\nThis letter notifies you of our concerns and provides you with an opportunity to address them. If you cannot take action to address this matter completely within 48 hours, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration.\n\nIf you are not located in the United States, please note that products that appear to be misbranded or unapproved new drugs may be detained or refused admission if they are offered for importation into the United States. We may advise the appropriate regulatory officials in the country from which you operate that FDA considers your product(s) referenced above to be unapproved and misbranded products that cannot be legally sold to consumers in the United States.\n\nPlease direct any inquiries to FDA at COVID-19-Task-Force-CFSAN@fda.hhs.gov.\n\nIn addition, it is unlawful under the FTC Act, 15 U.S.C. 41 et seq., to advertise that a product can prevent, treat, or cure human disease unless you possess competent and reliable scientific evidence, including, when appropriate, well-controlled human clinical studies, substantiating that the claims are true at the time they are made. For COVID-19, no such study is currently known to exist for the product identified above. Thus, any coronavirus-related prevention or treatment claims regarding such product are not supported by competent and reliable scientific evidence. You must immediately cease making all such claims. Violations of the FTC Act may result in legal action seeking a Federal District Court injunction. In addition, pursuant to the COVID-19 Consumer Protection Act, Section 1401, Division FF, of the Consolidated Appropriations Act, 2021, P.L. 116-260, marketers who make deceptive claims about the treatment, cure, prevention, or mitigation of COVID-19 are subject to a civil penalty of up to $43,792 per violation and may be required to pay refunds to consumers or provide other relief pursuant to Section 19(b) of the FTC Act, 15 U.S.C. § 57b(b). Within 48 hours, please send an email to Richard Cleland, Assistant Director of the FTC’s Division of Advertising Practices, via electronic mail at rcleland@ftc.gov describing the specific actions you have taken to address the FTC’s concerns. If you have any questions regarding compliance with the FTC Act, please contact Mr. Cleland at 202-326-3088.\n\nSincerely,\n\n\u002FS\u002F\n\nMichael W. Roosevelt\n\nActing Director\n\nOffice of Compliance\n\nCenter for Food Safety\n\nand Applied Nutrition\n\nFood and Drug Administration\n\nSincerely,\n\n\u002FS\u002F\n\nSerena Viswanathan\n\nAssociate Director\n\nDivision of Advertising Practices\n\nFederal Trade Commission\n\n_____________________________________\n\n1 As explained in the next paragraph, there is currently an outbreak of a respiratory disease named “Coronavirus Disease 2019” (COVID-19).\n\n2 Secretary of Health and Human Services, Determination that a Public Health Emergency Exists (originally issued Jan. 31, 2020, and subsequently renewed), available at https:\u002F\u002Fwww.phe.gov\u002Femergency\u002Fnews\u002Fhealthactions\u002Fphe\u002FPages\u002Fdefault.aspx.\n\n3 Proclamation on Declaring a National Emergency Concerning the Novel Coronavirus Disease (COVID-19) Outbreak (Mar. 13, 2020), available at https:\u002F\u002Ftrumpwhitehouse.archives.gov\u002Fpresidential-actions\u002Fproclamationdeclaring-national-emergency-concerning-novel-coronavirus-disease-covid-19-outbreak\u002F.","Everything Health LLC","everything-health-llc-613718-05242021","2026-08-18T06:42:29.386127+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Feverything-health-llc-613718-05242021","2026-10-26T08:08:37.318272+00:00","2021-06-08","613718","Tamika Moseley","2026-08-20T03:04:51.884+00:00","2021-05-24",{"id":193,"raw":194,"subject":199,"body_html":200,"body_text":201,"firm_name":202,"letter_id":203,"created_at":18,"fei_number":19,"letter_url":204,"updated_at":205,"action_type":22,"case_status":23,"posted_date":24,"marcs_cms_no":206,"product_type":110,"closeout_date":19,"issuing_office":197,"recipient_name":207,"body_fetched_at":208,"delivery_method":92,"recipient_title":19,"reference_number":19,"action_taken_date":209,"medical_device_id":19,"response_letter_date":19},860,[8,195,196,197,198,13,13,13],"\u003Ctime datetime=\"2025-03-28T04:00:00Z\">03\u002F28\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Feverything-sprouts-llc-699480-03282025\">Everything Sprouts, LLC\u003C\u002Fa>","Human Foods Program","CGMP\u002FFood\u002FPrepared, Packed or Held Under Insanitary Conditions\u002FAdulterated\u003Cbr \u002F>\r\n","CGMP\u002FFood\u002FPrepared, Packed or Held Under Insanitary Conditions\u002FAdulterated","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Email\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Food &amp; Beverages                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Melissa L. Mann\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Owner\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Everything Sprouts, LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>2751 Minnehaha Ave.\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Minneapolis\u003C\u002Fspan>, \u003Cspan>MN\u003C\u002Fspan> \u003Cspan>55406-1546\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Human Foods Program\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>March 28, 2025\u003C\u002Fp>\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Dear Ms. Mann:\u003C\u002Fp>\u003Cp>The U.S. Food and Drug Administration (FDA) inspected your sprouting operation, located at 2751 Minnehaha Ave., Minneapolis, MN 55406-1546 on October 30, 2024, through November 14, 2024. The inspection revealed serious violations of the Standards for the Growing, Harvesting, Packing, and Holding of Produce for Human Consumption regulation (Produce Safety Regulation or PSR), Title 21, Code of Federal Regulations, Part 112 (21 CFR Part 112).\u003C\u002Fp>\u003Cp>Based on our inspectional findings, we have determined that your mung bean, soybean, and green sprout products are adulterated within the meaning of section 402(a)(4) of the Federal Food, Drug, and Cosmetic Act (the Act) [21 U.S.C. § 342(a)(4)], in that they have been prepared, packed, or held under insanitary conditions whereby they may have become contaminated with filth, or whereby they may have been rendered injurious to heath. In addition, failure to comply with the PSR is a prohibited act under section 301(vv) of the Act [21 U.S.C. § 331(vv)]. You can find the Act and FDA regulations through links on FDA's home page at www.fda.gov.\u003C\u002Fp>\u003Cp>At the conclusion of the inspection on November 14, 2024, our investigator provided you with a Form FDA 483, Inspectional Observations (FDA 483). We received your written responses dated December 5, 2024, and December 6, 2024, which describe your completed and planned corrective actions to the Form FDA 483. We address your responses below.\u003C\u002Fp>\u003Cp>During the inspection, FDA investigators observed the following significant violations of the Produce Safety regulation, 21 CFR Part 112:\u003C\u002Fp>\u003Cp>1. You did not implement measures to prevent contamination of your covered produce and food contact surfaces through walls, ceilings, fixtures, ducts, pipes, drip, and condensate, as required by 21 CFR 112.126(b).\u003C\u002Fp>\u003Cp>Specifically, on October 31, 2024, our investigator observed the roof leaking through the ceiling tiles in the middle of the production room approximately four feet from the packaging tables. Water from the leak was observed dripping onto the totes of cooled, exposed mung bean sprouts as pallets were transferred through the area for packaging. On November 4, 2024, our investigator observed a roof leak in the warehouse, with water dripping near a rack of clean smocks prepared to be worn by employees directly in contact with covered produce. In addition, our investigator observed condensate dripping from the condenser units inside the in-process and finished product coolers storing mung bean sprouts, as well as dripping onto the door frame and into the finished product cooler.\u003C\u002Fp>\u003Cp>We acknowledge your responses dated December 5, 2024, and December 6, 2024, detailing your corrective actions; however, we are unable to evaluate the adequacy of your corrective actions. Your response stated your firm’s intent to create a standard operating procedure (SOP) to respond to leaks, including specific procedures such as blocking off the affected area or utilizing drain tarps to mitigate contamination. Additionally, your response stated that you will address dripping condensate through daily inspections and the use of a squeegee, with long-term plans to install drip pans or replace the condensing units. During previous FDA inspections of your sprout operation conducted in 2023 and in 2018, while your sprout operation was under different ownership but still operating within the same facility, our investigators observed dripping condenser units. You have not included, as a part of your response, any information that addresses how you will prevent the contamination by preventing the source of the leak, such as addressing the disrepair of the roof. You indicated to our investigator that you rent this building and that your landlord would repair the roof as a long-term project. However, you did not provide an estimated date of repair. As a covered farm, you must ensure compliance with applicable provisions of the Produce Safety Rule, including implementing measures necessary to prevent contamination of covered produce and food contact surfaces as required by 21 CFR 112.126(b). We will evaluate the adequacy of your corrective actions at our next inspection.\u003C\u002Fp>\u003Cp>2. You did not clean and sanitize food contact surfaces that you use to grow, harvest, pack, or hold sprouts before contact with sprouts or seeds or beans used to grow sprouts, as required by 21 CFR 112.143(b).\u003C\u002Fp>\u003Cp>“Food contact surfaces” are defined as those surfaces that contact human food and those surfaces from which drainage, or other transfer, onto the food or onto surfaces that contact the food ordinarily occurs during the normal course of operations. “Food contact surfaces” includes food contact surfaces of equipment and tools used during harvest, packing, and holding. (See 21 CFR 112.3).\u003C\u002Fp>\u003Cp>During the inspection, our investigator observed dripping condensate on the underside of the water supply apparatus on the overhead irrigation system and rails, which passes directly over exposed mung bean sprouts in the growing cabins. Additionally, our investigator observed a build-up of black organic matter on the hose of the overhead irrigation system used for soy sprouts, which passed directly over exposed soy sprouts. Our investigator also observed white build-up on the interior surface of black plastic sheets enclosing soy sprout growing cabins, which was ripped in several places. Our investigator noted attempts to improperly repair these concerns with tape, with sprouts adhered to tape in multiple locations throughout the facility.&nbsp;\u003C\u002Fp>\u003Cp>We acknowledge your responses dated December 5, 2024, and December 6, 2024; however, we are unable to evaluate the adequacy of the corrective actions detailed in your responses. Specifically, your response indicates that condensate will be squeegeed, repairs and alternate methods of plugging gaps will be made, and that the black plastic sheeting will be changed out as needed. However, we note that fully addressing the sources of damage to your facility may be required to avoid contamination of covered produce, as incomplete repairs to gaps and other structural deficiencies within food contact surfaces may create harborage points for pathogens and make it increasingly difficult to properly sanitize the surface. We will evaluate the adequacy of your corrective actions at our next inspection.\u003C\u002Fp>\u003Cp>This letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\u003Cp>This letter notifies you of our concerns and provides you with an opportunity to address them. Failure to adequately address this matter may result in legal action by the FDA without further notice, including, without limitation, seizure and\u002For injunction\u003C\u002Fp>\u003Cp>We also offer the following comment:\u003C\u002Fp>\u003Cul>\u003Cli>During the inspection, our investigator observed that visibly soiled strip curtains separating the mung bean growing and production rooms came in direct contact with harvested mung bean sprouts as they moved between rooms for washing. In addition, the investigator noted flaking paint and visible soil on the motor house and cinderbrick walls in the pass-through area between the mung bean growing and production rooms, which is located directly above the conveyor belt that transfers exposed, harvested mung bean sprouts. We acknowledge your responses dated December 5, 2024, and December 6, 2024, in which you state that you will clean your plastic strip curtains. However, your responses did not provide supporting evidence for us to assess your corrections to the strip curtains or address the disrepair of the surfaces around the conveyor belt. As a reminder, it is your responsibility to inspect, maintain, and clean, and when necessary and appropriate, sanitize all food contact surfaces of equipment and tools used in covered activities as frequently as reasonably necessary to protect against the contamination of covered produce, as required by 21 CFR 112.123(d)(1).\u003C\u002Fli>\u003C\u002Ful>\u003Cp>Within fifteen (15) working days of receipt of this letter, please notify this office in writing of the specific steps that you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective action within fifteen (15) working days, state the reason for the delay and the time within which you will complete the correction. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\u003Cp>Your written reply should be directed to Rochelle Blair via email at HFP-OCEProduce@fda.hhs.gov. If you have any questions, you may email HFP-OCEProduce@fda.hhs.gov.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Laura Akowuah, JD, MPH\u003Cbr>Acting Director, Office of Enforcement\u003Cbr>Office of Compliance and Enforcement\u003Cbr>Human Foods Program\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Email\n\nProduct:\n\nFood & Beverages\n\nRecipient:\n\nRecipient Name\n\nMelissa L. Mann\n\nRecipient Title\n\nOwner\n\nEverything Sprouts, LLC\n\n2751 Minnehaha Ave.\n\nMinneapolis, MN 55406-1546\n\nUnited States\n\nIssuing Office:\n\nHuman Foods Program\n\nUnited States\n\nMarch 28, 2025\nWARNING LETTER\nDear Ms. Mann:\nThe U.S. Food and Drug Administration (FDA) inspected your sprouting operation, located at 2751 Minnehaha Ave., Minneapolis, MN 55406-1546 on October 30, 2024, through November 14, 2024. The inspection revealed serious violations of the Standards for the Growing, Harvesting, Packing, and Holding of Produce for Human Consumption regulation (Produce Safety Regulation or PSR), Title 21, Code of Federal Regulations, Part 112 (21 CFR Part 112).\nBased on our inspectional findings, we have determined that your mung bean, soybean, and green sprout products are adulterated within the meaning of section 402(a)(4) of the Federal Food, Drug, and Cosmetic Act (the Act) [21 U.S.C. § 342(a)(4)], in that they have been prepared, packed, or held under insanitary conditions whereby they may have become contaminated with filth, or whereby they may have been rendered injurious to heath. In addition, failure to comply with the PSR is a prohibited act under section 301(vv) of the Act [21 U.S.C. § 331(vv)]. You can find the Act and FDA regulations through links on FDA's home page at www.fda.gov.\nAt the conclusion of the inspection on November 14, 2024, our investigator provided you with a Form FDA 483, Inspectional Observations (FDA 483). We received your written responses dated December 5, 2024, and December 6, 2024, which describe your completed and planned corrective actions to the Form FDA 483. We address your responses below.\nDuring the inspection, FDA investigators observed the following significant violations of the Produce Safety regulation, 21 CFR Part 112:\n1. You did not implement measures to prevent contamination of your covered produce and food contact surfaces through walls, ceilings, fixtures, ducts, pipes, drip, and condensate, as required by 21 CFR 112.126(b).\nSpecifically, on October 31, 2024, our investigator observed the roof leaking through the ceiling tiles in the middle of the production room approximately four feet from the packaging tables. Water from the leak was observed dripping onto the totes of cooled, exposed mung bean sprouts as pallets were transferred through the area for packaging. On November 4, 2024, our investigator observed a roof leak in the warehouse, with water dripping near a rack of clean smocks prepared to be worn by employees directly in contact with covered produce. In addition, our investigator observed condensate dripping from the condenser units inside the in-process and finished product coolers storing mung bean sprouts, as well as dripping onto the door frame and into the finished product cooler.\nWe acknowledge your responses dated December 5, 2024, and December 6, 2024, detailing your corrective actions; however, we are unable to evaluate the adequacy of your corrective actions. Your response stated your firm’s intent to create a standard operating procedure (SOP) to respond to leaks, including specific procedures such as blocking off the affected area or utilizing drain tarps to mitigate contamination. Additionally, your response stated that you will address dripping condensate through daily inspections and the use of a squeegee, with long-term plans to install drip pans or replace the condensing units. During previous FDA inspections of your sprout operation conducted in 2023 and in 2018, while your sprout operation was under different ownership but still operating within the same facility, our investigators observed dripping condenser units. You have not included, as a part of your response, any information that addresses how you will prevent the contamination by preventing the source of the leak, such as addressing the disrepair of the roof. You indicated to our investigator that you rent this building and that your landlord would repair the roof as a long-term project. However, you did not provide an estimated date of repair. As a covered farm, you must ensure compliance with applicable provisions of the Produce Safety Rule, including implementing measures necessary to prevent contamination of covered produce and food contact surfaces as required by 21 CFR 112.126(b). We will evaluate the adequacy of your corrective actions at our next inspection.\n2. You did not clean and sanitize food contact surfaces that you use to grow, harvest, pack, or hold sprouts before contact with sprouts or seeds or beans used to grow sprouts, as required by 21 CFR 112.143(b).\n“Food contact surfaces” are defined as those surfaces that contact human food and those surfaces from which drainage, or other transfer, onto the food or onto surfaces that contact the food ordinarily occurs during the normal course of operations. “Food contact surfaces” includes food contact surfaces of equipment and tools used during harvest, packing, and holding. (See 21 CFR 112.3).\nDuring the inspection, our investigator observed dripping condensate on the underside of the water supply apparatus on the overhead irrigation system and rails, which passes directly over exposed mung bean sprouts in the growing cabins. Additionally, our investigator observed a build-up of black organic matter on the hose of the overhead irrigation system used for soy sprouts, which passed directly over exposed soy sprouts. Our investigator also observed white build-up on the interior surface of black plastic sheets enclosing soy sprout growing cabins, which was ripped in several places. Our investigator noted attempts to improperly repair these concerns with tape, with sprouts adhered to tape in multiple locations throughout the facility.\nWe acknowledge your responses dated December 5, 2024, and December 6, 2024; however, we are unable to evaluate the adequacy of the corrective actions detailed in your responses. Specifically, your response indicates that condensate will be squeegeed, repairs and alternate methods of plugging gaps will be made, and that the black plastic sheeting will be changed out as needed. However, we note that fully addressing the sources of damage to your facility may be required to avoid contamination of covered produce, as incomplete repairs to gaps and other structural deficiencies within food contact surfaces may create harborage points for pathogens and make it increasingly difficult to properly sanitize the surface. We will evaluate the adequacy of your corrective actions at our next inspection.\nThis letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\nThis letter notifies you of our concerns and provides you with an opportunity to address them. Failure to adequately address this matter may result in legal action by the FDA without further notice, including, without limitation, seizure and\u002For injunction\nWe also offer the following comment:\nDuring the inspection, our investigator observed that visibly soiled strip curtains separating the mung bean growing and production rooms came in direct contact with harvested mung bean sprouts as they moved between rooms for washing. In addition, the investigator noted flaking paint and visible soil on the motor house and cinderbrick walls in the pass-through area between the mung bean growing and production rooms, which is located directly above the conveyor belt that transfers exposed, harvested mung bean sprouts. We acknowledge your responses dated December 5, 2024, and December 6, 2024, in which you state that you will clean your plastic strip curtains. However, your responses did not provide supporting evidence for us to assess your corrections to the strip curtains or address the disrepair of the surfaces around the conveyor belt. As a reminder, it is your responsibility to inspect, maintain, and clean, and when necessary and appropriate, sanitize all food contact surfaces of equipment and tools used in covered activities as frequently as reasonably necessary to protect against the contamination of covered produce, as required by 21 CFR 112.123(d)(1).\nWithin fifteen (15) working days of receipt of this letter, please notify this office in writing of the specific steps that you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective action within fifteen (15) working days, state the reason for the delay and the time within which you will complete the correction. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration.\nYour written reply should be directed to Rochelle Blair via email at HFP-OCEProduce@fda.hhs.gov. If you have any questions, you may email HFP-OCEProduce@fda.hhs.gov.\nSincerely,\n\u002FS\u002F\nLaura Akowuah, JD, MPH\nActing Director, Office of Enforcement\nOffice of Compliance and Enforcement\nHuman Foods Program","Everything Sprouts, LLC","everything-sprouts-llc-699480-03282025","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Feverything-sprouts-llc-699480-03282025","2026-10-26T08:08:37.359759+00:00","699480","Melissa L. Mann","2026-08-19T16:42:18.211+00:00","2025-03-28",{"id":211,"raw":212,"subject":58,"body_html":216,"body_text":217,"firm_name":218,"letter_id":219,"created_at":18,"fei_number":19,"letter_url":220,"updated_at":221,"action_type":22,"case_status":23,"posted_date":222,"marcs_cms_no":223,"product_type":68,"closeout_date":19,"issuing_office":57,"recipient_name":19,"body_fetched_at":224,"delivery_method":70,"recipient_title":19,"reference_number":225,"action_taken_date":226,"medical_device_id":19,"response_letter_date":19},910,[213,214,215,57,58,13,13,13],"\u003Ctime datetime=\"2025-05-13T04:00:00Z\">05\u002F13\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-05-02T04:00:00Z\">05\u002F02\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Feverythingvapescom-707701-05022025\">everythingvapes.com\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS and Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>RW2502284\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Tobacco                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\u003C\u002Fdd>\n                    \n            \u003Cdd>everythingvapes.com\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>398 E Dania Beach Blvd, Suite 255\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Dania Beach\u003C\u002Fspan>, \u003Cspan>FL\u003C\u002Fspan> \u003Cspan>33004\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:sales@everythingvapes.com\"> sales@everythingvapes.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Tobacco Products\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>May 2, 2025\u003C\u002Fp>\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>To Whom it May Concern:\u003C\u002Fp>\u003Cp>The Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) recently reviewed the website https:\u002F\u002Feverythingvapes.com and determined that electronic nicotine delivery system (ENDS) products listed there are offered for sale or distribution to customers in the United States.\u003C\u002Fp>\u003Cp>Under section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) (21 U.S.C. § 321(rr)), these products are tobacco products because they are made or derived from tobacco or contain nicotine from any source and intended for human consumption. Certain tobacco products, including ENDS products, are subject to FDA jurisdiction under section 901(b) of the FD&amp;C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1, and are required to be in compliance with the requirements in the FD&amp;C Act.\u003C\u002Fp>\u003Cp>Please be aware that, on March 15, 2022, the President signed legislation to amend the FD&amp;C Act to extend FDA’s jurisdiction to products “containing nicotine from any source,” not just nicotine derived from tobacco. See Consolidated Appropriations Act, 2022, Public Law 117-103, Division P, Title I, Subtitle B. Specifically, this legislation expanded the definition of “tobacco product” under section 201(rr) of the FD&amp;C Act (21 U.S.C. § 321(rr)) to include products containing nicotine from any source. Tobacco products, including ENDS products, containing nicotine from any source, must be in compliance with the FD&amp;C Act and its implementing regulations. For more information, please see https:\u002F\u002Fwww.fda.gov\u002Ftobacco-products\u002Fctpnewsroom\u002Frequirements-products-made-non-tobacco-nicotine-take-effect-april-14.\u003C\u002Fp>\u003Cp>Generally, to be legally marketed in the United States, the FD&amp;C Act requires “new tobacco products” to have a premarket authorization order in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&amp;C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&amp;C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&amp;C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&amp;C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&amp;C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&amp;C Act (21 U.S.C. § 387e(j)(3)).\u003C\u002Fp>\u003Cp>\u003Cstrong>New Tobacco Products Without Required Marketing Authorization Are Adulterated and Misbranded\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>FDA has determined that you offer for sale or distribution to customers in the United States ENDS products that lack a marketing authorization order: Funky Republic Ti7000 Disposable Vape Device – Tropical Island and Lost Mary MO5000 Disposable Vape Device – Lemon Sparkling Wine.\u003C\u002Fp>\u003Cp>The tobacco products listed above are new tobacco products because they were not commercially marketed in the United States as of February 15, 2007. These products do not have FDA marketing authorization orders in effect under section 910(c)(1)(A)(i) of the FD&amp;C Act and are not otherwise exempt from the marketing authorization requirement. Therefore, these products are adulterated under section 902(6)(A) of the FD&amp;C Act. In addition, they are misbranded under section 903(a)(6) of the FD&amp;C Act (21 U.S.C. § 387c(a)(6)) because a notice or other information respecting these products was not provided as required by section 905(j) of the FD&amp;C Act (21 U.S.C. § 387e(j)).\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion and Requested Actions\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>FDA has determined that your firm markets new tobacco products in the United States that lack premarket authorization. All new tobacco products on the market without the statutorily required premarket authorization are marketed unlawfully and are subject to enforcement action at FDA’s discretion.\u003C\u002Fp>\u003Cp>For a list of all products that have been authorized by the FDA and certain others that may be legally marketed, please visit the Searchable Tobacco Products Database: http:\u002F\u002Fwww.fda.gov\u002Fsearchtobacco.\u003C\u002Fp>\u003Cp>It is your responsibility to ensure that all tobacco products you sell and\u002For distribute in the United States and all related labeling and\u002For advertising on any websites or other media (such as e-commerce, social networking, or search engine websites), and in any retail establishments in which you advertise, comply with each applicable provision of the FD&amp;C Act and FDA’s implementing regulations. Failure to adequately address any violations of the FD&amp;C Act, 21 U.S.C. § 301 et seq., or its implementing regulations relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, and 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&amp;C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated or misbranded may be detained or refused admission.\u003C\u002Fp>\u003Cp>The violations discussed in this letter do not necessarily constitute an exhaustive list. You should take prompt action to address any violations that are referenced above and take any necessary actions to bring these tobacco products into compliance with the FD&amp;C Act.\u003C\u002Fp>\u003Cp>Please submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring these products into compliance, including the dates on which you discontinued the violative sale and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&amp;C Act. If you believe that these products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&amp;C Act through links on FDA’s homepage at http:\u002F\u002Fwww.fda.gov.\u003C\u002Fp>\u003Cp>Please note your reference number, RW2502284, in your response and direct your response via email at CTPCompliance@fda.hhs.gov and to the following address:\u003C\u002Fp>\u003Cp>DPAL-WL Response, Office of Compliance and Enforcement\u003Cbr>FDA Center for Tobacco Products\u003Cbr>c\u002Fo Document Control Center\u003Cbr>Building 71, Room G335\u003Cbr>10903 New Hampshire Avenue\u003Cbr>Silver Spring, MD 20993-0002\u003C\u002Fp>\u003Cp>If you have any questions about the content of this letter, please contact CTPCompliance@fda.hhs.gov.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>John E. Verbeten\u003Cbr>Director\u003Cbr>Office of Compliance and Enforcement\u003Cbr>Center for Tobacco Products\u003C\u002Fp>\u003Cp>\u003Cstrong>VIA UPS and Electronic Mail\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>cc:\u003C\u002Fp>\u003Cp>Incorp Services, Inc.\u003Cbr>c\u002Fo Everything Vapes, LLC\u003Cbr>131 Continental Drive, Suite 301\u003Cbr>Newark, DE 19713\u003C\u002Fp>\u003Cp>Everything Vapes LLC\u003Cbr>1600 Middleford Rd\u003Cbr>Seaford, DE 19973\u003C\u002Fp>\u003Cp>Everything Vapes\u003Cbr>955 South Federal Highway, 4th Floor #555\u003Cbr>Fort Lauderdale, FL 33316\u003C\u002Fp>\u003Cp>GoDaddy.com, LLC\u003Cbr>abuse@godaddy.com\u003C\u002Fp>\u003Cp>Shopify, Inc.\u003Cbr>abuse@shopify.com\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS and Electronic Mail\n\nReference #:\n\nRW2502284\n\nProduct:\n\nTobacco\n\nRecipient:\n\neverythingvapes.com\n\n398 E Dania Beach Blvd, Suite 255\n\nDania Beach, FL 33004\n\nUnited States\n\nsales@everythingvapes.com\n\nIssuing Office:\n\nCenter for Tobacco Products\n\nUnited States\n\nMay 2, 2025\nWARNING LETTER\nTo Whom it May Concern:\nThe Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) recently reviewed the website https:\u002F\u002Feverythingvapes.com and determined that electronic nicotine delivery system (ENDS) products listed there are offered for sale or distribution to customers in the United States.\nUnder section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. § 321(rr)), these products are tobacco products because they are made or derived from tobacco or contain nicotine from any source and intended for human consumption. Certain tobacco products, including ENDS products, are subject to FDA jurisdiction under section 901(b) of the FD&C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1, and are required to be in compliance with the requirements in the FD&C Act.\nPlease be aware that, on March 15, 2022, the President signed legislation to amend the FD&C Act to extend FDA’s jurisdiction to products “containing nicotine from any source,” not just nicotine derived from tobacco. See Consolidated Appropriations Act, 2022, Public Law 117-103, Division P, Title I, Subtitle B. Specifically, this legislation expanded the definition of “tobacco product” under section 201(rr) of the FD&C Act (21 U.S.C. § 321(rr)) to include products containing nicotine from any source. Tobacco products, including ENDS products, containing nicotine from any source, must be in compliance with the FD&C Act and its implementing regulations. For more information, please see https:\u002F\u002Fwww.fda.gov\u002Ftobacco-products\u002Fctpnewsroom\u002Frequirements-products-made-non-tobacco-nicotine-take-effect-april-14.\nGenerally, to be legally marketed in the United States, the FD&C Act requires “new tobacco products” to have a premarket authorization order in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&C Act (21 U.S.C. § 387e(j)(3)).\nNew Tobacco Products Without Required Marketing Authorization Are Adulterated and Misbranded\nFDA has determined that you offer for sale or distribution to customers in the United States ENDS products that lack a marketing authorization order: Funky Republic Ti7000 Disposable Vape Device – Tropical Island and Lost Mary MO5000 Disposable Vape Device – Lemon Sparkling Wine.\nThe tobacco products listed above are new tobacco products because they were not commercially marketed in the United States as of February 15, 2007. These products do not have FDA marketing authorization orders in effect under section 910(c)(1)(A)(i) of the FD&C Act and are not otherwise exempt from the marketing authorization requirement. Therefore, these products are adulterated under section 902(6)(A) of the FD&C Act. In addition, they are misbranded under section 903(a)(6) of the FD&C Act (21 U.S.C. § 387c(a)(6)) because a notice or other information respecting these products was not provided as required by section 905(j) of the FD&C Act (21 U.S.C. § 387e(j)).\nConclusion and Requested Actions\nFDA has determined that your firm markets new tobacco products in the United States that lack premarket authorization. All new tobacco products on the market without the statutorily required premarket authorization are marketed unlawfully and are subject to enforcement action at FDA’s discretion.\nFor a list of all products that have been authorized by the FDA and certain others that may be legally marketed, please visit the Searchable Tobacco Products Database: http:\u002F\u002Fwww.fda.gov\u002Fsearchtobacco.\nIt is your responsibility to ensure that all tobacco products you sell and\u002For distribute in the United States and all related labeling and\u002For advertising on any websites or other media (such as e-commerce, social networking, or search engine websites), and in any retail establishments in which you advertise, comply with each applicable provision of the FD&C Act and FDA’s implementing regulations. Failure to adequately address any violations of the FD&C Act, 21 U.S.C. § 301 et seq., or its implementing regulations relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, and 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated or misbranded may be detained or refused admission.\nThe violations discussed in this letter do not necessarily constitute an exhaustive list. You should take prompt action to address any violations that are referenced above and take any necessary actions to bring these tobacco products into compliance with the FD&C Act.\nPlease submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring these products into compliance, including the dates on which you discontinued the violative sale and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&C Act. If you believe that these products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&C Act through links on FDA’s homepage at http:\u002F\u002Fwww.fda.gov.\nPlease note your reference number, RW2502284, in your response and direct your response via email at CTPCompliance@fda.hhs.gov and to the following address:\nDPAL-WL Response, Office of Compliance and Enforcement\nFDA Center for Tobacco Products\nc\u002Fo Document Control Center\nBuilding 71, Room G335\n10903 New Hampshire Avenue\nSilver Spring, MD 20993-0002\nIf you have any questions about the content of this letter, please contact CTPCompliance@fda.hhs.gov.\nSincerely,\n\u002FS\u002F\nJohn E. Verbeten\nDirector\nOffice of Compliance and Enforcement\nCenter for Tobacco Products\nVIA UPS and Electronic Mail\ncc:\nIncorp Services, Inc.\nc\u002Fo Everything Vapes, LLC\n131 Continental Drive, Suite 301\nNewark, DE 19713\nEverything Vapes LLC\n1600 Middleford Rd\nSeaford, DE 19973\nEverything Vapes\n955 South Federal Highway, 4th Floor #555\nFort Lauderdale, FL 33316\nGoDaddy.com, LLC\nabuse@godaddy.com\nShopify, Inc.\nabuse@shopify.com","everythingvapes.com","everythingvapescom-707701-05022025","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Feverythingvapescom-707701-05022025","2026-10-26T08:08:37.502866+00:00","2025-05-13","707701","2026-08-19T16:47:54.801+00:00","RW2502284","2025-05-02",{"id":228,"raw":229,"subject":234,"body_html":235,"body_text":236,"firm_name":237,"letter_id":238,"created_at":165,"fei_number":19,"letter_url":239,"updated_at":240,"action_type":22,"case_status":23,"posted_date":241,"marcs_cms_no":242,"product_type":243,"closeout_date":19,"issuing_office":244,"recipient_name":245,"body_fetched_at":246,"delivery_method":247,"recipient_title":19,"reference_number":19,"action_taken_date":248,"medical_device_id":19,"response_letter_date":19},2241,[230,231,232,233,234,13,13,13],"\u003Ctime datetime=\"2023-01-24T14:20:00Z\">01\u002F24\u002F2023\u003C\u002Ftime>\n","\u003Ctime datetime=\"2022-11-16T05:00:00Z\">11\u002F16\u002F2022\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fevimeria-el-aztecano-inc-624797-11162022\">Evimeria El Aztecano, Inc.\u003C\u002Fa>"," Division of Human and Animal Food Operations West V ","Dietary Supplement\u002FMisbranded","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UNITED PARCEL SERVICE\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Dietary Supplements                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Michael A. Vizcarrondo\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Owner\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Evimeria El Aztecano, Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>1460 W. 135th St.\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Gardena\u003C\u002Fspan>, \u003Cspan>CA\u003C\u002Fspan> \u003Cspan>90249-2218\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd> Division of Human and Animal Food Operations West V \u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003Cbr>\n\u003Cbr>\n\u003Cstrong>WL 624797\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>November 16, 2022\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Vizcarrondo:\u003C\u002Fp>\n\n\u003Cp>This is to advise you that the U.S. Food and Drug Administration (FDA) conducted an inspection of your facility, located at 1460 W. 135th St., Gardena, CA from November 2, 2021, through November 10, 2021. During the inspection, our investigators collected labeling for your “Yerbas Finas Leche de Alpiste con Guanabana y Omega-3” dietary supplement. Based on our subsequent review of the product labeling, we have concluded that this product is in violation of section 403 of the Federal Food, Drug and Cosmetic Act (the Act) and the regulations contained within Title 21, Code of Federal Regulations, Part 101 (21 CFR Part 101). FDA received your response to FDA’s Form 483, Inspectional Observations, on February 4, 2022. You can find the Act and FDA regulations through links on the FDA’s home page at \u003Ca href=\"http:\u002F\u002Fwww.fda.gov.\u002F\">http:\u002F\u002Fwww.fda.gov.\u003C\u002Fa>\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Misbranded Dietary Supplements\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>1. Your “Yerbas Finas Leche de Alpiste con Guanabana y Omega-3” product is misbranded within the meaning of section 403(a)(1) of the Act [21 U.S.C. 343(a)(1)] because its labeling is false or misleading. Specifically:\u003C\u002Fp>\n\n\u003Cp>a) Our sampling analysis of your “Yerbas Finas Leche de Alpiste con Guanabana y Omega-3” dietary supplement \u003Cstrong>(b)(4)\u003C\u002Fstrong> independent determinations of potassium. Magnesium and potassium are Class II minerals as defined in 21 CFR 101.9(g)(3). Because your “Yerbas Finas Leche de Alpiste con Guanabana y Omega-3” dietary supplement does not contain levels of magnesium or potassium at least equal to 80 percent of the value declared on the label for each nutrient, as required by 21 CFR 101.9(g)(4)(ii), the product’s label is false or misleading.\u003C\u002Fp>\n\n\u003Cp>2. Your “Yerbas Finas Leche de Alpiste con Guanabana y Omega-3” is misbranded within the meaning of section 403(r)(1)(A) of the Act [21 U.S.C. § 343(r)(1)(A)] because the product label bears nutrient content claims but does not meet the requirements to bear such claims. Under sections 403(r)(1)(A) and (2)(A)(i) of the Act, a claim that characterizes the level of a nutrient which is of the type required to be in the labeling of the food must be made in accordance with a regulation authorizing the use of such a claim. Under 21 CFR 101.13(b), a claim that expressly or implicitly characterizes the level of a nutrient of the type required to be in nutrition labeling under 21 CFR 101.9 or under 21 CFR 101.36 (that is, a nutrient content claim) may not be made on the label or in labeling of foods unless the claim is made in accordance with 21 CFR 101.13 and with the applicable regulations in 21 CFR Part 101 subpart D or in Part 105 or Part 107. An implied nutrient content claim includes any claim that describes the food or an ingredient therein in a manner that suggests that a nutrient is absent or present in a certain amount (21 CFR 101.13(b)(2)(i)). Characterizing the level of a nutrient in the food labeling of a product without complying with the specific requirements pertaining to nutrient content claims for that nutrient misbrands the product under section 403(r)(1)(A) of the Act. Specifically,\u003C\u002Fp>\n\n\u003Cp>a) Your “Yerbas Finas Leche de Alpiste con Guanabana y Omega-3” product label displays the following claim “Canary Seed … is high in protein content.” In the context of this label, FDA considers the claim “Canary Seed . . . is high in protein content” to be an implied claim about the food itself. In accordance with 21 CFR 101.54(b), the terms “high,” “rich in,” or “excellent source of” may be used to characterize the level of a nutrient on the label and in the labeling of foods provided that the food contains 20 percent or more of the Reference Daily Intake (RDI) or the Daily Reference Value (DRV) per reference amount customarily consumed (RACC). The DRV for protein is 50 grams (g), and the RACC for your product is 2 Tablespoons. According to the Supplement Facts label, your product contains 2.6 g of protein per 2 Tablespoons, which is only 5% of the DRV (rounded to the nearest whole percent). We also note that elsewhere on the Supplement Facts label indicates that protein per 2 Tablespoons is 12% with no clear indication as to what the percentage relates.\u003C\u002Fp>\n\n\u003Cp>b) Your “Yerbas Finas Leche de Alpiste con Guanabana y Omega-3” product label displays the following claim “Canary seed … It contains as much protein as meat …” In the context of this label, FDA considers this claim about canary seed, an ingredient in the food, to be an implied claim about the food itself. In accordance with 21 CFR 101.65(c)(2), the phrases “contains the same amount of [nutrient] as a [food]” and “as much [nutrient] as a [food]” may be used on the label or in the labeling of foods, provided that the amount of the nutrient in the reference food is enough to qualify that food as a “good source” of that nutrient, and the labeled food, on a per serving basis, is an equivalent, good source of that nutrient (e.g., “as much fiber as an apple,” “Contains the same amount of Vitamin C as an 8 oz. glass of orange juice.”). Under 21 CFR 101.54(c), the term “good source” may be used to characterize the level of a nutrient on the label and in the labeling of foods provided that the food contains 10 to 19 percent of the RDI or the DRV per RACC. As stated previously, the Supplement Facts label declares 2.6 g of protein per 2 Tablespoons of the product, which is only 5% of the DRV for protein; 5% protein is not within 10 to 19% of the DRV for protein and, therefore, your product does not qualify to be “an equivalent, good source.”\u003C\u002Fp>\n\n\u003Cp>3. Your “Yerbas Finas Leche de Alpiste con Guanabana y Omega-3” product is misbranded within the meaning of section 403(q)(5)(F) of the Act [21 U.S.C. § 343(q)(5)(F)] in that the presentation of the nutritional information on the labeling of your product does not comply with 21 CFR 101.36. For example:\u003C\u002Fp>\n\n\u003Cp>a) The product label declares “Proprietary Blend … 610g”, that being the total net contents of the product. The use of “Proprietary Blend” with its quantitative amount is permitted in the Supplement Facts label but relative to the serving size. Furthermore, any “Proprietary Blend” declaration with its quantitative amount must be in accordance with 21 CFR 101.36(b)(3)(iii)(c).\u003C\u002Fp>\n\n\u003Cp>b) The label fails to declare dietary ingredients by the correct name and in the correct order and format, per 21 CFR 101.36.\u003C\u002Fp>\n\n\u003Cp>c) The declaration of calories is not in accordance with 21 CFR 101.36(b)(2) and 101.9(c)(1) in that the caloric content per serving is not expressed to the nearest 5-calorie increment up to and including 50 calories. Furthermore, the declaration does not appear to correlate with the declared quantitative amounts for the listed macronutrients.\u003C\u002Fp>\n\n\u003Cp>d) The label fails to declare the quantitative amount by weight per serving of each dietary ingredient either in a separate column aligned to the right of the column of names or immediately following the listing of names within the same column. When information on the percent of Daily Values is listed, this information must be presented in one column aligned under the heading of \"% Daily Value\" and to the right of the column of amounts. The headings \"% Daily Value (DV),\" \"% DV,\" \"Percent Daily Value,\" or \"Percent DV\" may be substituted for \"% Daily Value.\" The heading \"% Daily Value\" must be placed on the same line as the heading \"Amount Per Serving.\" [21 CFR 101.36(b)(2)(iii)(A)]\u003C\u002Fp>\n\n\u003Cp>e) Each quantitative amount declared for the carbohydrates, protein, and fat fail to use the level of significance given in 21 CFR 101.9(c)(8)(iv), in accordance with 21 CFR 101.36(b)(2)(ii)(B).\u003C\u002Fp>\n\n\u003Cp>f) The label fails to include a heavy bar under “Servings per Container, as required by 21 CFR 101.36(e)(6).\u003C\u002Fp>\n\n\u003Cp>g) The label fails to list (b)(2)-dietary ingredients in the correct order, as required by 21 CFR 101.36(b)(2)(i).\u003C\u002Fp>\n\n\u003Cp>h) The title and all headings are not bolded to distinguish them from the other information, as required by 21 CFR 101.36(e)(1).\u003C\u002Fp>\n\n\u003Cp>i) The label declares 0% for Vitamin A, Vitamin D, Vitamin B12, and cholesterol. Any (b)(2)-dietary ingredient not present, or in amounts that can be declared as zero in 101.9(c), shall not be declared (e.g., amounts corresponding to less than 2 percent of the RDI for vitamins and minerals) in accordance with 21 CFR 101.36(b)(2)(i).\u003C\u002Fp>\n\n\u003Cp>j) The declared % Daily Values for protein and carbohydrate do not correlate with the quantitative amounts declared for each macronutrient.\u003C\u002Fp>\n\n\u003Cp>k) The label declares “*Percent of daily value are based on a 2,000 calorie diet. Your daily value may be higher or lower depending on your calorie needs. Daily value has not been established.” There is no provision in the regulation for the “Your daily value may be higher or lower depending on your calorie needs.” in the Supplement Facts label. Other dietary ingredients (also known as (b)(3)-dietary ingredients) must bear a symbol (different than the symbol used for the 2,000 calorie diet statement) under the heading of the % Daily Value that refers to the same symbol placed at the bottom of the nutrition label and followed by the statement “Daily Value not established.”\u003C\u002Fp>\n\n\u003Cp>4. Your “Yerbas Finas Leche de Alpiste con Guanabana y Omega-3” product is misbranded within the meaning of section 403(f) of the Act [21 U.S.C. § 343(f)] because the product label contains information in two languages but does not repeat all of the required information in both languages. As required by 21 CFR 101.15(c), if a product label contains any representation in a foreign language, all words, statements, and other information required by or under authority of the Act to appear on the label must appear in the foreign language. The product includes foreign language on the label but fails to declare the product name, all information in the Supplements Facts label, and the name and address of the responsible party in both languages.\u003C\u002Fp>\n\n\u003Cp>5. Your “Yerbas Finas Leche de Alpiste con Guanabana y Omega-3” product is misbranded within the meaning of section 403(q)(1)(A) of the Act [21 U.S.C. § 343(q)(1)(A)] because the serving size declared on the label is incomplete. Specifically, the product’s label fails to declare the equivalent metric quantity in parenthesis (fluids in milliliters and all other foods in grams) following the common household measure, as required by 21 CFR 101.9(b)(7).\u003C\u002Fp>\n\n\u003Cp>6. Your “Yerbas Finas Leche de Alpiste con Guanabana y Omega-3” product is misbranded within the meaning of section 403(s)(2)(C) of the Act [21 U.S.C. § 343(s)(2)(C)] because the label fails to identify the part of the plant (e.g., root, leaves) from which each botanical dietary ingredient in the product is derived, as required by 21 CFR 101.4(h)(1).\u003C\u002Fp>\n\n\u003Cp>7. Your “Yerbas Finas Leche de Alpiste con Guanabana y Omega-3” product is misbranded within the meaning of section 403(i)(2) of the Act [21 U.S.C. § 343(i)(2)] in that the label fails to declare the common or usual name of each ingredient used as required by 21 CFR 101.36 and 21 CFR 101.4(a) and (h). For example, the product’s batch product record indicates “canary seed (\u003Cem>Phalaris canariensis\u003C\u002Fem>).” The standardized common name for \u003Cem>Phalaris canariensis\u003C\u002Fem> is “canary grass”, as noted in Herbs of Commerce. Furthermore, the Supplement Facts label lists “guanabana” which is not a standardized common name listed in the reference Herbs of Commerce; soursop is the standardized common name for guanabana.” In addition, the batch record indicates “guanabana leaf powder”.\u003C\u002Fp>\n\n\u003Cp>8. Your “Yerbas Finas Leche de Alpiste con Guanabana y Omega-3” product is misbranded within the meaning of Section 403(r)(6) of the Act [21 U.S.C. § 343(r)(6)] because the labeling makes structure\u002Ffunction claims but fails to bear the required dietary supplement disclaimer in accordance with 21 CFR 101.93(b) and (c). Under section 403(r)(6) of the Act, a dietary supplement may bear certain claims, generally called \"structure\u002Ffunction claims,\" on its label or in its labeling provided that the firm has substantiation that the claim is truthful and not misleading; the firm has notified FDA within 30 days of marketing the product bearing the claim; and the claim includes the mandatory disclaimer.\u003C\u002Fp>\n\n\u003Cp>This letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\u003C\u002Fp>\n\n\u003Cp>We also offer the following comments:\u003C\u002Fp>\n\n\u003Cp>1. Your “Yerbas Finas Leche de Alpiste con Guanabana y Omega-3” product label’s dietary supplement statement of identity is not presented in bold type on the principal display panel and in a size reasonably related to the most prominent printed matter on the principal display panel. (see 21 CFR 101.3(d))\u003C\u002Fp>\n\n\u003Cp>2. Your “Yerbas Finas Leche de Alpiste con Guanabana y Omega-3” product label is not based upon the revised nutrition labeling regulation which became effective July 26, 2016. Labels were to comply with the revised labeling regulation by January 1, 2020, or January 1, 2021, depending upon the annual food sales of the manufacturer. When making revisions to your product label, you must comply with the current regulations. (see 21 CFR 101.9, 101.30, and 101.36)\u003C\u002Fp>\n\n\u003Cp>3. Your “Yerbas Finas Leche de Alpiste con Guanabana y Omega-3” product label declares Vitamin C at a level of 214% Daily Value (DV) per serving; however, a review of the batch production record, packing slip and certificate of analysis for this product does not appear to indicate that the product contains ingredient(s) that would provide Vitamin C at a level of 214% DV per serving.\u003C\u002Fp>\n\n\u003Cp>Please notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\n\n\u003Cp>Your written response should be directed to:\u003C\u002Fp>\n\n\u003Cp>Sergio Chavez, Director Compliance Branch\u003Cbr>\nFood and Drug Administration\u003Cbr>\nOffice of Human and Animal Foods Division West 5\u003Cbr>\nLos Angeles District Office\u003Cbr>\n19701 Fairchild\u003Cbr>\nIrvine, CA 92612\u003C\u002Fp>\n\n\u003Cp>Or emailed to ORAHAFWEST5FirmResponses@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Refer to the Unique Identification Number CMS 624797 when replying.\u003C\u002Fp>\n\n\u003Cp>If you have questions regarding this letter, please contact Rochelle R. Blair, Compliance Officer at rochelle.blair@FDA.hhs.gov, or (949) 608-4496.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Darla R. Bracy\u003Cbr>\nDistrict Director | FDA San Francisco District\u003Cbr>\nProgram Division Director\u003Cbr>\nOffice of Human and Animal Food Operations- West Division 5\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UNITED PARCEL SERVICE\n\nProduct:\n\nDietary Supplements\n\nRecipient:\n\nRecipient Name\n\nMichael A. Vizcarrondo\n\nRecipient Title\n\nOwner\n\nEvimeria El Aztecano, Inc.\n\n1460 W. 135th St.\n\nGardena, CA 90249-2218\n\nUnited States\n\nIssuing Office:\n\nDivision of Human and Animal Food Operations West V\n\nUnited States\n\nWARNING LETTER\n\nWL 624797\n\nNovember 16, 2022\n\nDear Mr. Vizcarrondo:\n\nThis is to advise you that the U.S. Food and Drug Administration (FDA) conducted an inspection of your facility, located at 1460 W. 135th St., Gardena, CA from November 2, 2021, through November 10, 2021. During the inspection, our investigators collected labeling for your “Yerbas Finas Leche de Alpiste con Guanabana y Omega-3” dietary supplement. Based on our subsequent review of the product labeling, we have concluded that this product is in violation of section 403 of the Federal Food, Drug and Cosmetic Act (the Act) and the regulations contained within Title 21, Code of Federal Regulations, Part 101 (21 CFR Part 101). FDA received your response to FDA’s Form 483, Inspectional Observations, on February 4, 2022. You can find the Act and FDA regulations through links on the FDA’s home page at http:\u002F\u002Fwww.fda.gov.\n\nMisbranded Dietary Supplements\n\n1. Your “Yerbas Finas Leche de Alpiste con Guanabana y Omega-3” product is misbranded within the meaning of section 403(a)(1) of the Act [21 U.S.C. 343(a)(1)] because its labeling is false or misleading. Specifically:\n\na) Our sampling analysis of your “Yerbas Finas Leche de Alpiste con Guanabana y Omega-3” dietary supplement (b)(4) independent determinations of potassium. Magnesium and potassium are Class II minerals as defined in 21 CFR 101.9(g)(3). Because your “Yerbas Finas Leche de Alpiste con Guanabana y Omega-3” dietary supplement does not contain levels of magnesium or potassium at least equal to 80 percent of the value declared on the label for each nutrient, as required by 21 CFR 101.9(g)(4)(ii), the product’s label is false or misleading.\n\n2. Your “Yerbas Finas Leche de Alpiste con Guanabana y Omega-3” is misbranded within the meaning of section 403(r)(1)(A) of the Act [21 U.S.C. § 343(r)(1)(A)] because the product label bears nutrient content claims but does not meet the requirements to bear such claims. Under sections 403(r)(1)(A) and (2)(A)(i) of the Act, a claim that characterizes the level of a nutrient which is of the type required to be in the labeling of the food must be made in accordance with a regulation authorizing the use of such a claim. Under 21 CFR 101.13(b), a claim that expressly or implicitly characterizes the level of a nutrient of the type required to be in nutrition labeling under 21 CFR 101.9 or under 21 CFR 101.36 (that is, a nutrient content claim) may not be made on the label or in labeling of foods unless the claim is made in accordance with 21 CFR 101.13 and with the applicable regulations in 21 CFR Part 101 subpart D or in Part 105 or Part 107. An implied nutrient content claim includes any claim that describes the food or an ingredient therein in a manner that suggests that a nutrient is absent or present in a certain amount (21 CFR 101.13(b)(2)(i)). Characterizing the level of a nutrient in the food labeling of a product without complying with the specific requirements pertaining to nutrient content claims for that nutrient misbrands the product under section 403(r)(1)(A) of the Act. Specifically,\n\na) Your “Yerbas Finas Leche de Alpiste con Guanabana y Omega-3” product label displays the following claim “Canary Seed … is high in protein content.” In the context of this label, FDA considers the claim “Canary Seed . . . is high in protein content” to be an implied claim about the food itself. In accordance with 21 CFR 101.54(b), the terms “high,” “rich in,” or “excellent source of” may be used to characterize the level of a nutrient on the label and in the labeling of foods provided that the food contains 20 percent or more of the Reference Daily Intake (RDI) or the Daily Reference Value (DRV) per reference amount customarily consumed (RACC). The DRV for protein is 50 grams (g), and the RACC for your product is 2 Tablespoons. According to the Supplement Facts label, your product contains 2.6 g of protein per 2 Tablespoons, which is only 5% of the DRV (rounded to the nearest whole percent). We also note that elsewhere on the Supplement Facts label indicates that protein per 2 Tablespoons is 12% with no clear indication as to what the percentage relates.\n\nb) Your “Yerbas Finas Leche de Alpiste con Guanabana y Omega-3” product label displays the following claim “Canary seed … It contains as much protein as meat …” In the context of this label, FDA considers this claim about canary seed, an ingredient in the food, to be an implied claim about the food itself. In accordance with 21 CFR 101.65(c)(2), the phrases “contains the same amount of [nutrient] as a [food]” and “as much [nutrient] as a [food]” may be used on the label or in the labeling of foods, provided that the amount of the nutrient in the reference food is enough to qualify that food as a “good source” of that nutrient, and the labeled food, on a per serving basis, is an equivalent, good source of that nutrient (e.g., “as much fiber as an apple,” “Contains the same amount of Vitamin C as an 8 oz. glass of orange juice.”). Under 21 CFR 101.54(c), the term “good source” may be used to characterize the level of a nutrient on the label and in the labeling of foods provided that the food contains 10 to 19 percent of the RDI or the DRV per RACC. As stated previously, the Supplement Facts label declares 2.6 g of protein per 2 Tablespoons of the product, which is only 5% of the DRV for protein; 5% protein is not within 10 to 19% of the DRV for protein and, therefore, your product does not qualify to be “an equivalent, good source.”\n\n3. Your “Yerbas Finas Leche de Alpiste con Guanabana y Omega-3” product is misbranded within the meaning of section 403(q)(5)(F) of the Act [21 U.S.C. § 343(q)(5)(F)] in that the presentation of the nutritional information on the labeling of your product does not comply with 21 CFR 101.36. For example:\n\na) The product label declares “Proprietary Blend … 610g”, that being the total net contents of the product. The use of “Proprietary Blend” with its quantitative amount is permitted in the Supplement Facts label but relative to the serving size. Furthermore, any “Proprietary Blend” declaration with its quantitative amount must be in accordance with 21 CFR 101.36(b)(3)(iii)(c).\n\nb) The label fails to declare dietary ingredients by the correct name and in the correct order and format, per 21 CFR 101.36.\n\nc) The declaration of calories is not in accordance with 21 CFR 101.36(b)(2) and 101.9(c)(1) in that the caloric content per serving is not expressed to the nearest 5-calorie increment up to and including 50 calories. Furthermore, the declaration does not appear to correlate with the declared quantitative amounts for the listed macronutrients.\n\nd) The label fails to declare the quantitative amount by weight per serving of each dietary ingredient either in a separate column aligned to the right of the column of names or immediately following the listing of names within the same column. When information on the percent of Daily Values is listed, this information must be presented in one column aligned under the heading of \"% Daily Value\" and to the right of the column of amounts. The headings \"% Daily Value (DV),\" \"% DV,\" \"Percent Daily Value,\" or \"Percent DV\" may be substituted for \"% Daily Value.\" The heading \"% Daily Value\" must be placed on the same line as the heading \"Amount Per Serving.\" [21 CFR 101.36(b)(2)(iii)(A)]\n\ne) Each quantitative amount declared for the carbohydrates, protein, and fat fail to use the level of significance given in 21 CFR 101.9(c)(8)(iv), in accordance with 21 CFR 101.36(b)(2)(ii)(B).\n\nf) The label fails to include a heavy bar under “Servings per Container, as required by 21 CFR 101.36(e)(6).\n\ng) The label fails to list (b)(2)-dietary ingredients in the correct order, as required by 21 CFR 101.36(b)(2)(i).\n\nh) The title and all headings are not bolded to distinguish them from the other information, as required by 21 CFR 101.36(e)(1).\n\ni) The label declares 0% for Vitamin A, Vitamin D, Vitamin B12, and cholesterol. Any (b)(2)-dietary ingredient not present, or in amounts that can be declared as zero in 101.9(c), shall not be declared (e.g., amounts corresponding to less than 2 percent of the RDI for vitamins and minerals) in accordance with 21 CFR 101.36(b)(2)(i).\n\nj) The declared % Daily Values for protein and carbohydrate do not correlate with the quantitative amounts declared for each macronutrient.\n\nk) The label declares “*Percent of daily value are based on a 2,000 calorie diet. Your daily value may be higher or lower depending on your calorie needs. Daily value has not been established.” There is no provision in the regulation for the “Your daily value may be higher or lower depending on your calorie needs.” in the Supplement Facts label. Other dietary ingredients (also known as (b)(3)-dietary ingredients) must bear a symbol (different than the symbol used for the 2,000 calorie diet statement) under the heading of the % Daily Value that refers to the same symbol placed at the bottom of the nutrition label and followed by the statement “Daily Value not established.”\n\n4. Your “Yerbas Finas Leche de Alpiste con Guanabana y Omega-3” product is misbranded within the meaning of section 403(f) of the Act [21 U.S.C. § 343(f)] because the product label contains information in two languages but does not repeat all of the required information in both languages. As required by 21 CFR 101.15(c), if a product label contains any representation in a foreign language, all words, statements, and other information required by or under authority of the Act to appear on the label must appear in the foreign language. The product includes foreign language on the label but fails to declare the product name, all information in the Supplements Facts label, and the name and address of the responsible party in both languages.\n\n5. Your “Yerbas Finas Leche de Alpiste con Guanabana y Omega-3” product is misbranded within the meaning of section 403(q)(1)(A) of the Act [21 U.S.C. § 343(q)(1)(A)] because the serving size declared on the label is incomplete. Specifically, the product’s label fails to declare the equivalent metric quantity in parenthesis (fluids in milliliters and all other foods in grams) following the common household measure, as required by 21 CFR 101.9(b)(7).\n\n6. Your “Yerbas Finas Leche de Alpiste con Guanabana y Omega-3” product is misbranded within the meaning of section 403(s)(2)(C) of the Act [21 U.S.C. § 343(s)(2)(C)] because the label fails to identify the part of the plant (e.g., root, leaves) from which each botanical dietary ingredient in the product is derived, as required by 21 CFR 101.4(h)(1).\n\n7. Your “Yerbas Finas Leche de Alpiste con Guanabana y Omega-3” product is misbranded within the meaning of section 403(i)(2) of the Act [21 U.S.C. § 343(i)(2)] in that the label fails to declare the common or usual name of each ingredient used as required by 21 CFR 101.36 and 21 CFR 101.4(a) and (h). For example, the product’s batch product record indicates “canary seed (Phalaris canariensis).” The standardized common name for Phalaris canariensis is “canary grass”, as noted in Herbs of Commerce. Furthermore, the Supplement Facts label lists “guanabana” which is not a standardized common name listed in the reference Herbs of Commerce; soursop is the standardized common name for guanabana.” In addition, the batch record indicates “guanabana leaf powder”.\n\n8. Your “Yerbas Finas Leche de Alpiste con Guanabana y Omega-3” product is misbranded within the meaning of Section 403(r)(6) of the Act [21 U.S.C. § 343(r)(6)] because the labeling makes structure\u002Ffunction claims but fails to bear the required dietary supplement disclaimer in accordance with 21 CFR 101.93(b) and (c). Under section 403(r)(6) of the Act, a dietary supplement may bear certain claims, generally called \"structure\u002Ffunction claims,\" on its label or in its labeling provided that the firm has substantiation that the claim is truthful and not misleading; the firm has notified FDA within 30 days of marketing the product bearing the claim; and the claim includes the mandatory disclaimer.\n\nThis letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\n\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\n\nWe also offer the following comments:\n\n1. Your “Yerbas Finas Leche de Alpiste con Guanabana y Omega-3” product label’s dietary supplement statement of identity is not presented in bold type on the principal display panel and in a size reasonably related to the most prominent printed matter on the principal display panel. (see 21 CFR 101.3(d))\n\n2. Your “Yerbas Finas Leche de Alpiste con Guanabana y Omega-3” product label is not based upon the revised nutrition labeling regulation which became effective July 26, 2016. Labels were to comply with the revised labeling regulation by January 1, 2020, or January 1, 2021, depending upon the annual food sales of the manufacturer. When making revisions to your product label, you must comply with the current regulations. (see 21 CFR 101.9, 101.30, and 101.36)\n\n3. Your “Yerbas Finas Leche de Alpiste con Guanabana y Omega-3” product label declares Vitamin C at a level of 214% Daily Value (DV) per serving; however, a review of the batch production record, packing slip and certificate of analysis for this product does not appear to indicate that the product contains ingredient(s) that would provide Vitamin C at a level of 214% DV per serving.\n\nPlease notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\n\nYour written response should be directed to:\n\nSergio Chavez, Director Compliance Branch\n\nFood and Drug Administration\n\nOffice of Human and Animal Foods Division West 5\n\nLos Angeles District Office\n\n19701 Fairchild\n\nIrvine, CA 92612\n\nOr emailed to ORAHAFWEST5FirmResponses@fda.hhs.gov.\n\nRefer to the Unique Identification Number CMS 624797 when replying.\n\nIf you have questions regarding this letter, please contact Rochelle R. Blair, Compliance Officer at rochelle.blair@FDA.hhs.gov, or (949) 608-4496.\n\nSincerely,\n\n\u002FS\u002F\n\nDarla R. Bracy\n\nDistrict Director | FDA San Francisco District\n\nProgram Division Director\n\nOffice of Human and Animal Food Operations- West Division 5","Evimeria El Aztecano, Inc.","evimeria-el-aztecano-inc-624797-11162022","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fevimeria-el-aztecano-inc-624797-11162022","2026-10-26T08:08:37.621068+00:00","2023-01-24","624797","Dietary Supplements","Division of Human and Animal Food Operations West V","Michael A. Vizcarrondo","2026-08-20T01:18:07.015+00:00","VIA UNITED PARCEL SERVICE","2022-11-16",{"id":250,"raw":251,"subject":257,"body_html":258,"body_text":259,"firm_name":260,"letter_id":261,"created_at":43,"fei_number":19,"letter_url":262,"updated_at":263,"action_type":22,"case_status":23,"posted_date":264,"marcs_cms_no":265,"product_type":266,"closeout_date":19,"issuing_office":255,"recipient_name":267,"body_fetched_at":268,"delivery_method":269,"recipient_title":19,"reference_number":270,"action_taken_date":271,"medical_device_id":19,"response_letter_date":19},1077,[252,253,254,255,256,13,13,13],"\u003Ctime datetime=\"2025-01-28T05:00:00Z\">01\u002F28\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2024-12-30T05:00:00Z\">12\u002F30\u002F2024\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fevolutionary-biologics-inc-681586-12302024\">Evolutionary Biologics Inc.\u003C\u002Fa>","Center for Biologics Evaluation and Research","Deviations\u002FCFR\u002FRegulations for Human Cells, Tissues &amp; Cellular Products (HCT\u002FPs)","Deviations\u002FCFR\u002FRegulations for Human Cells, Tissues & Cellular Products (HCT\u002FPs)","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA EMAIL AND UNITED PARCEL SERVICE\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>CBER-24-681586\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Biologics                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Jim Morrison\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>CEO\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Evolutionary Biologics Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>14 Penn Plaza West 34th Street Floor 9\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>New York\u003C\u002Fspan>, \u003Cspan>NY\u003C\u002Fspan> \u003Cspan>10122\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:admin@evolutionarybiologics.com\"> admin@evolutionarybiologics.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Biologics Evaluation and Research\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>December 30, 2024\u003C\u002Fp>\u003Cp>Warning Letter #: CBER-24-681586\u003C\u002Fp>\u003Cp>Dear Mr. Morrison:\u003C\u002Fp>\u003Cp>The United States Food and Drug Administration (FDA) has reviewed your company’s website at the internet address www.evolutionarybiologics.com\u002Frx (last visited November 2024), as well as other information available to the Agency. FDA has determined that you sell the following products in the United States: EXO RNA™ (exosome product), EVO JEL™ (an umbilical cord-derived product), and EVO HYBRID™ (a cellular product derived from umbilical cord, “placental tissue,” and amniotic membrane) (collectively, “your products”). This letter is to advise you that your products are unapproved new drugs and are also unlicensed biological products. The introduction or delivery for introduction of your products into interstate commerce, or the causing thereof, is prohibited under section 301(d) of the FD&amp;C Act, 21 U.S.C. § 331(d).\u003C\u002Fp>\u003Cp>Based on information and records reviewed by FDA, including your website at www.evolutionarybiologics.com\u002Frx (last visited November 2024), your products are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease or conditions in humans and\u002For are intended to affect the structure or function of the body. For example, your website contains the following statements:\u003C\u002Fp>\u003Cp>\u003Cu>EVO JEL™\u003C\u002Fu>\u003Cbr>• “EVO JEL™ is especially effective in orthopedics because it provides cushioning and structural support for tissue and joints while addressing widespread inflammation and modulating an abnormal immune response.” • “EVO JEL™ … can be used as an alternative to assist with musculoskeletal injuries, ailments involving tissue and joints in both acute and chronic settings.”\u003Cbr>• “EVO JEL™ is ideally suited to repair, rebuild and regenerate tissue while reducing inflammation”\u003Cbr>• Under “Advantages of EVO JEL™”, you list, “Decreases Inflammation” and “Non-surgical orthopedic option for patients”\u003Cbr>• Under “Applications of EVO JEL™”, you list, “Large joints (Knee, Hip, Shoulder &amp; Ankle)”…”Chronic partial rotator cuff tears”…”Persistent partial tendon tears (Tennis Elbow)”…”Plantar fasciitis\u002FBone Spurs”…”Quadriceps and patellar tendon tears”…”Muscular tears”…”Meniscus and cartilage tears”…”Intervertebral disc and spinal facet joints”…”Radicular and Sacroiliac nerves”…”Osteoarthritis”\u003C\u002Fp>\u003Cp>\u003Cu>EVO HYBRID™\u003C\u002Fu>\u003Cbr>• “EVO HYBRID helps restore and improve your internal wellness by reducing inflammation, regenerating tissue, lengthening telomeres, stimulating neuronal growth, modulating the immune response, and other important factors contributing to homeostasis, longevity, and quality of life.”\u003Cbr>• “EVO HYBRID™ is ideally suited to repair, rebuild and regenerate tissue while reducing inflammation”\u003Cbr>• “SOME KEY GROWTH FACTORS PRESENT IN EVO HYBRID™...\u003Cbr>&nbsp; &nbsp; • “TGFß3 Transforming Growth Factor Beta 3: Most important anti-inflammatory protein; converts inflammatory T cells into anti-inflammatory regulatory T cells...\u003Cbr>&nbsp; &nbsp; • HGF Hepatocyte Growth Factor: Involved in organ regeneration and wound healing\u003Cbr>&nbsp; &nbsp; • PDGF-AA: Regulates proliferation and migration of myocytes and supports angiogenesis\u003Cbr>&nbsp; &nbsp; • VEGF Vascular Endothelial Growth Factor: A protein involved in both angiogenesis and vasculogenesis. Its most important role is to help in the creation of new blood vessels following an injury\u003Cbr>&nbsp; &nbsp; • TIMP -1 and 2 Tissue Inhibitor of Metallopeptidase 1 &amp; 2: Blocks Cartilage and Extracellular Matrix Degradation, Important for Cartilage Repair\u003Cbr>&nbsp; &nbsp; • IGF-1 Insulin-Like Growth Factor: Mediates many of the actions of GH, stimulates the growth of bones and other tissues...\u003Cbr>&nbsp; &nbsp; • B-NGF Beta Nerve Growth Factor: involved with the maintenance, growth and proliferation of target growth neurons”\u003C\u002Fp>\u003Cp>\u003Cu>EXO RNA™\u003C\u002Fu>\u003Cbr>• “Can EXO RNATM Benefit Neurodegenerative Diseases? Research has shown that MSC Exosomes can penetrate the blood-brain barrier and stimulate neuronal differentiation, neuronal growth, and suppress inflammatory processes within the brain tissue.”&nbsp;&nbsp;\u003Cbr>• “NEUROBIOLOGICS; SOME KEY GROWTH FACTORS PRESENT IN EXO RNA™ . . .\u003Cbr>&nbsp; &nbsp; • HGF Hepatocyte Growth Factor: Involved in organ regeneration and wound healing\u003Cbr>&nbsp; &nbsp; • PDGF-BB Platelet Derived Growth Factor Sub-Unit B: Growth factor used to stimulate healing in soft and hard tissues\u003Cbr>&nbsp; &nbsp; • VEGF Vascular Endothelial Growth Factor: A protein involved in both angiogenesis and vasculogenesis. Its most important role is to help in the creation of new blood vessels following an injury\u003Cbr>&nbsp; &nbsp; • GDF-15 Growth Differentiation Factor 15: Regulates inflammation, apoptosis, cell repair, and growth\u003Cbr>&nbsp; &nbsp; • TGFß3 Transforming Growth Factor Beta 3: Most important anti-inflammatory protein. Converts inflammatory T cells into anti-inflammatory regulatory T cells...\u003Cbr>&nbsp; &nbsp; • HGF Hepatocyte Growth Factor: Involved in organ regeneration and wound healing\u003Cbr>&nbsp; &nbsp; • MIP-1 Macrophage Inflammatory Protein 1: Also known as CC1-4, recruits mononuclear cells to the treatment area”\u003C\u002Fp>\u003Cp>Therefore, your products are drugs as defined in section 201(g)(1) of the FD&amp;C Act, 21 U.S.C. § 321(g)(1), and biological products as defined in section 351(i) of the Public Health Service Act (PHS Act) 42 U.S.C. § 262(i).\u003C\u002Fp>\u003Cp>Your product derived from umbilical cord (EVO JEL™) and your cellular product derived from umbilical cord, “placental tissue,” and amniotic membrane (EVO HYBRID™) are also human cells, tissues, or cellular or tissue-based products (HCT\u002FPs) as defined in 21 CFR 1271.3(d) and are subject to regulation under 21 CFR Part 1271, issued under the authority of section 361 of the PHS Act, 42 U.S.C. § 264. HCT\u002FPs that do not meet all the criteria in 21 CFR 1271.10(a), and when no exception in 21 CFR 1271.15 applies, are not regulated solely under section 361 of the PHS Act, 42 U.S.C. 264, and the regulations in 21 CFR Part 1271. Such products are regulated as drugs, devices, and\u002For biological products under the FD&amp;C Act and\u002For the PHS Act, and are subject to additional regulation, including applicable premarket review.\u003C\u002Fp>\u003Cp>Based on the review of the materials described above, your firm does not qualify for any exception in 21 CFR 1271.15, and your EVO JEL™ and EVO HYBRID™ products fail to meet all the criteria in 21 CFR 1271.10(a).\u003C\u002Fp>\u003Cp>For example, your umbilical cord derived product, EVO JEL™, fails to meet the criterion in 21 CFR 1271.10(a)(2) that the HCT\u002FP be “intended for homologous use only, as reflected by the labeling, advertising, or other indications of the manufacturer's objective intent.” This product is not intended solely to perform the same basic function or functions of the umbilical cord in the recipient as in the donor, such as serving as a conduit. Rather, using this product for the treatment of diseases or conditions, such as inflammation, joint tears, tendon tears, muscle tears, cartilage tears, osteoarthritis, plantar fasciitis, and bone spurs is not homologous use as defined in 21 CFR 1271.3(c).\u003C\u002Fp>\u003Cp>In addition, your umbilical cord derived product, EVO JEL™, fails to meet the minimal manipulation criterion set forth in 21 CFR 1271.10(a)(1) and defined for structural tissue in 21 CFR 1271.3(f)(1) because the umbilical cord undergoes processing that alters the original relevant characteristics of the umbilical cord related to its utility for reconstruction, repair, or replacement. Information available to the Agency indicates that EVO JEL is offered in a “flowable” form. The processing of the umbilical cord from the form of a tube into a flowable form is more than minimal manipulation because such processing alters the original relevant characteristics of the umbilical cord relating to the tissue’s utility to serve as a conduit by effectively altering or eliminating its physical integrity and tubular form.\u003C\u002Fp>\u003Cp>Additionally, EVO HYBRID™ fails to meet the minimal manipulation criterion set forth in 21 CFR 1271.10(a)(1) and defined for structural tissue in 21 CFR 1271.3(f)(1) because the umbilical cord and amniotic membrane undergo processing that alters the original relevant characteristics of those tissues related to their utility for reconstruction, repair, or replacement. For example, the processing of umbilical cord from the form of a tube into a flowable form is more than minimal manipulation because the processing alters the original relevant characteristics of the umbilical cord relating to the tissue’s utility to serve as a conduit by effectively altering or eliminating its physical integrity and tubular form, and the processing of amniotic membrane from the form of a sheet into a flowable form alters the original relevant characteristics of the amniotic membrane relating to its utility to serve as a barrier by effectively eliminating its physical integrity, tensile strength and elasticity.\u003Cem>\u003Cstrong>\u003Csup>1\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fp>\u003Cp>In addition, your product derived from umbilical cord, “placental tissue,” and amniotic membrane, EVO HYBRID™, fails to meet the criterion in 21 CFR 1271.10(a)(2) because this product is not intended solely to perform the same basic function or functions of umbilical cord and amniotic membrane in the recipient as in the donor, such as serving as a conduit (for umbilical cord) or serving as a selective barrier for the movement of nutrients between the external and in utero environment, protecting the fetus from the surrounding maternal environment, and serving as a covering to enclose the fetus and retain fluid in utero (for amniotic membrane). Rather, use of this product for reducing inflammation, tissue regeneration, organ regeneration, bone growth, tissue growth, cartilage repair, and wound healing, for example, is not homologous use as defined in 21 CFR 1271.3(c).\u003C\u002Fp>\u003Cp>Therefore, these products are not regulated solely under section 361 of the PHS Act, 42 U.S.C. § 264, and the regulations in 21 CFR part 1271.\u003Cem>\u003Cstrong>\u003Csup>2\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> See 21 CFR 1271.20. In addition to being regulated under section 361 of the PHS Act and 21 CFR part 1271, your EVO JEL™ and EVO HYBRID™ products are regulated as drugs as defined in section 201(g)(1) of the FD&amp;C Act, 21 U.S.C. § 321(g)(1), and biological products as defined in section 351(i) of the PHS Act, 42 U.S.C. § 262(i), as stated above.\u003C\u002Fp>\u003Cp>Your exosome product, EXO RNA™, also meets the definition of a drug and biological product under section 201(g)(1) of the FD&amp;C Act and section 351(i) of the PHS Act, as discussed above, and is subject to premarket review and approval requirements. We direct your attention to FDA’s Public Safety Notification on Exosome Products, at https:\u002F\u002Fwww.fda.gov\u002Fvaccines-blood-biologics\u002Fsafety-availability-biologics\u002Fpublic-safety-notification-exosome-products. FDA issued this public safety notification following multiple reports of serious adverse events experienced by patients who were treated with exosome products.\u003C\u002Fp>\u003Cp>To lawfully market a drug that is a biological product, a valid biologics license must be in effect under section 351(a)(1) of the PHS Act, 42 U.S.C. § 262(a)(1). Such licenses are issued only after showing that the product is safe, pure, and potent. A biological product for which a BLA has been approved under section 351(a) is not required to have an approved application under section 505 of the FD&amp;C Act. 21 U.S.C. § 355; 42 U.S.C. § 262(j). Otherwise, with certain exceptions not applicable here, a new drug may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in section 505(a) of the FD&amp;C Act. Your products are not the subject of an approved biologics license application (BLA) or an approved application under section 505 of the FD&amp;C Act. Based on our review, your products are both unapproved new drugs and unlicensed biological products, and you cause their introduction or delivery for introduction into interstate commerce in violation of section 301(d) of the FD&amp;C Act, 21 U.S.C. § 331(d).\u003C\u002Fp>\u003Cp>This letter addresses certain issues regarding the above-described products and is not intended to be an all-inclusive review. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure full compliance with the FD&amp;C Act, PHS Act, and all applicable regulations. We advise you to comprehensively review your website, product labels, and other labeling and marketing materials to ensure that you are lawfully marketing your products in full compliance with the FD&amp;C Act, the PHS Act, and their implementing regulations.\u003C\u002Fp>\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address these matters may result in action without further notice, including, without limitation, seizure and\u002For injunction.\u003C\u002Fp>\u003Cp>Please submit your response in writing within fifteen (15) working days from your receipt of this letter, outlining the specific steps you have taken or plan to take to address any violations and prevent their recurrence. Include any documentation necessary to show that the matters have been addressed. If you cannot address these matters within fifteen working days, please explain the reason for the delay and the timeframe for completion. If you believe that your products are not in violation of the FD&amp;C Act or applicable regulations, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\u003Cp>In addition, we have concerns with your products EXO RX, EXO ELIXIR™ and \u003Cstrong>EXO PERIO™\u003C\u002Fstrong>, which are other products described on your websites www.evolutionarybiologics.com\u002Frx and www.evobiologics.com. Your websites (last visited November 2024), make statements indicating these products are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease or conditions in humans and\u002For are intended to affect the structure or function of the human body, for example:\u003Cbr>• “EXO RX™ expresses 30 forms of collagen and is ideally suited to repair, rebuild and regenerate tissue while reducing inflammation”\u003Cbr>• Under “WHY EXO RX™…”, you list, “Anti-Fibrotic”… “Increases epidermal thickness and dermal collagen”…”Reduces scarring in cosmetic procedures and burns”…”Has been known to reduces [sic] acne”\u003Cbr>• “EXO ELIXIR is designed to regenerate your skin at a cellular level, with exceptional wound healing and anti-inflammatory growth factors that promote tissue engineering and regeneration.”\u003Cbr>• Under EXO ELIXIR “Advantages” you describe, “Modulating Inflammation…Promoting healing of wounds...”\u003Cbr>• “EVO PERIO™ Is a Wharton’s Jelly product rich with Mesenchymal Stem Cell exosomes. MSC exosomes induce bone, cartilage, dentin, mucosa, and pulp tissue formation while enhancing oral and craniofacial tissue engineering and regeneration.”&nbsp;\u003Cbr>• “EXO PERIO has demonstrated unique biological properties including being angiogenic, anti-inflammatory, antifibrotic, antimicrobial and immune privileged. The product has shown a strong tendency to accelerate healing and wound repair.\"\u003Cbr>• “Exo Perio can offer solutions for problems like craniofacial, osteochondral, periodontal tissue, nerve, pulp, or endodontics injuries.”\u003C\u002Fp>\u003Cp>FDA has not identified approved BLAs in effect for your EXO RX™, EXO ELIXIR™ and \u003Cstrong>EXO PERIO™\u003C\u002Fstrong> products. In your response, please explain the basis of your determination regarding whether these products require FDA premarket review. For example, if you believe these products meet the criteria in 21 CFR 1271.10(a) for regulation solely under section 361 of the PHS Act, 42 U.S.C. 264, and 21 CFR part 1271, please explain that determination.\u003C\u002Fp>\u003Cp>Your response should be emailed to CBERDCMRecommendations@fda.hhs.gov. If you have any questions regarding this letter, please contact the Division of Case Management, CBER at (240) 402-9156.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>Melissa J. Mendoza\u003Cbr>Director, Office of Compliance and Biologics Quality&nbsp;&nbsp;\u003Cbr>Center for Biologics Evaluation and Research\u003C\u002Fp>\u003Cp>______________________\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> You market EVO HYBRID as being derived from “placental tissue,” in addition to umbilical cord and amniotic membrane. It is unclear what you mean by “placental tissue” in this context, as the mature placenta is composed of multiple tissues. Regardless, your EVO HYBRID product is regulated as a drug and biological product for the reasons described in this letter.\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> Because your EVO JEL™ and EVO HYBRID™ products fail to meet at least one criterion in 21 CFR 1271.10(a), this letter does not evaluate all other criteria in 21 CFR 1271.10(a).\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA EMAIL AND UNITED PARCEL SERVICE\n\nReference #:\n\nCBER-24-681586\n\nProduct:\n\nBiologics\n\nRecipient:\n\nRecipient Name\n\nJim Morrison\n\nRecipient Title\n\nCEO\n\nEvolutionary Biologics Inc.\n\n14 Penn Plaza West 34th Street Floor 9\n\nNew York, NY 10122\n\nUnited States\n\nadmin@evolutionarybiologics.com\n\nIssuing Office:\n\nCenter for Biologics Evaluation and Research\n\nUnited States\n\nWARNING LETTER\nDecember 30, 2024\nWarning Letter #: CBER-24-681586\nDear Mr. Morrison:\nThe United States Food and Drug Administration (FDA) has reviewed your company’s website at the internet address www.evolutionarybiologics.com\u002Frx (last visited November 2024), as well as other information available to the Agency. FDA has determined that you sell the following products in the United States: EXO RNA™ (exosome product), EVO JEL™ (an umbilical cord-derived product), and EVO HYBRID™ (a cellular product derived from umbilical cord, “placental tissue,” and amniotic membrane) (collectively, “your products”). This letter is to advise you that your products are unapproved new drugs and are also unlicensed biological products. The introduction or delivery for introduction of your products into interstate commerce, or the causing thereof, is prohibited under section 301(d) of the FD&C Act, 21 U.S.C. § 331(d).\nBased on information and records reviewed by FDA, including your website at www.evolutionarybiologics.com\u002Frx (last visited November 2024), your products are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease or conditions in humans and\u002For are intended to affect the structure or function of the body. For example, your website contains the following statements:\nEVO JEL™\n• “EVO JEL™ is especially effective in orthopedics because it provides cushioning and structural support for tissue and joints while addressing widespread inflammation and modulating an abnormal immune response.” • “EVO JEL™ … can be used as an alternative to assist with musculoskeletal injuries, ailments involving tissue and joints in both acute and chronic settings.”\n• “EVO JEL™ is ideally suited to repair, rebuild and regenerate tissue while reducing inflammation”\n• Under “Advantages of EVO JEL™”, you list, “Decreases Inflammation” and “Non-surgical orthopedic option for patients”\n• Under “Applications of EVO JEL™”, you list, “Large joints (Knee, Hip, Shoulder & Ankle)”…”Chronic partial rotator cuff tears”…”Persistent partial tendon tears (Tennis Elbow)”…”Plantar fasciitis\u002FBone Spurs”…”Quadriceps and patellar tendon tears”…”Muscular tears”…”Meniscus and cartilage tears”…”Intervertebral disc and spinal facet joints”…”Radicular and Sacroiliac nerves”…”Osteoarthritis”\nEVO HYBRID™\n• “EVO HYBRID helps restore and improve your internal wellness by reducing inflammation, regenerating tissue, lengthening telomeres, stimulating neuronal growth, modulating the immune response, and other important factors contributing to homeostasis, longevity, and quality of life.”\n• “EVO HYBRID™ is ideally suited to repair, rebuild and regenerate tissue while reducing inflammation”\n• “SOME KEY GROWTH FACTORS PRESENT IN EVO HYBRID™...\n• “TGFß3 Transforming Growth Factor Beta 3: Most important anti-inflammatory protein; converts inflammatory T cells into anti-inflammatory regulatory T cells...\n• HGF Hepatocyte Growth Factor: Involved in organ regeneration and wound healing\n• PDGF-AA: Regulates proliferation and migration of myocytes and supports angiogenesis\n• VEGF Vascular Endothelial Growth Factor: A protein involved in both angiogenesis and vasculogenesis. Its most important role is to help in the creation of new blood vessels following an injury\n• TIMP -1 and 2 Tissue Inhibitor of Metallopeptidase 1 & 2: Blocks Cartilage and Extracellular Matrix Degradation, Important for Cartilage Repair\n• IGF-1 Insulin-Like Growth Factor: Mediates many of the actions of GH, stimulates the growth of bones and other tissues...\n• B-NGF Beta Nerve Growth Factor: involved with the maintenance, growth and proliferation of target growth neurons”\nEXO RNA™\n• “Can EXO RNATM Benefit Neurodegenerative Diseases? Research has shown that MSC Exosomes can penetrate the blood-brain barrier and stimulate neuronal differentiation, neuronal growth, and suppress inflammatory processes within the brain tissue.”\n• “NEUROBIOLOGICS; SOME KEY GROWTH FACTORS PRESENT IN EXO RNA™ . . .\n• HGF Hepatocyte Growth Factor: Involved in organ regeneration and wound healing\n• PDGF-BB Platelet Derived Growth Factor Sub-Unit B: Growth factor used to stimulate healing in soft and hard tissues\n• VEGF Vascular Endothelial Growth Factor: A protein involved in both angiogenesis and vasculogenesis. Its most important role is to help in the creation of new blood vessels following an injury\n• GDF-15 Growth Differentiation Factor 15: Regulates inflammation, apoptosis, cell repair, and growth\n• TGFß3 Transforming Growth Factor Beta 3: Most important anti-inflammatory protein. Converts inflammatory T cells into anti-inflammatory regulatory T cells...\n• HGF Hepatocyte Growth Factor: Involved in organ regeneration and wound healing\n• MIP-1 Macrophage Inflammatory Protein 1: Also known as CC1-4, recruits mononuclear cells to the treatment area”\nTherefore, your products are drugs as defined in section 201(g)(1) of the FD&C Act, 21 U.S.C. § 321(g)(1), and biological products as defined in section 351(i) of the Public Health Service Act (PHS Act) 42 U.S.C. § 262(i).\nYour product derived from umbilical cord (EVO JEL™) and your cellular product derived from umbilical cord, “placental tissue,” and amniotic membrane (EVO HYBRID™) are also human cells, tissues, or cellular or tissue-based products (HCT\u002FPs) as defined in 21 CFR 1271.3(d) and are subject to regulation under 21 CFR Part 1271, issued under the authority of section 361 of the PHS Act, 42 U.S.C. § 264. HCT\u002FPs that do not meet all the criteria in 21 CFR 1271.10(a), and when no exception in 21 CFR 1271.15 applies, are not regulated solely under section 361 of the PHS Act, 42 U.S.C. 264, and the regulations in 21 CFR Part 1271. Such products are regulated as drugs, devices, and\u002For biological products under the FD&C Act and\u002For the PHS Act, and are subject to additional regulation, including applicable premarket review.\nBased on the review of the materials described above, your firm does not qualify for any exception in 21 CFR 1271.15, and your EVO JEL™ and EVO HYBRID™ products fail to meet all the criteria in 21 CFR 1271.10(a).\nFor example, your umbilical cord derived product, EVO JEL™, fails to meet the criterion in 21 CFR 1271.10(a)(2) that the HCT\u002FP be “intended for homologous use only, as reflected by the labeling, advertising, or other indications of the manufacturer's objective intent.” This product is not intended solely to perform the same basic function or functions of the umbilical cord in the recipient as in the donor, such as serving as a conduit. Rather, using this product for the treatment of diseases or conditions, such as inflammation, joint tears, tendon tears, muscle tears, cartilage tears, osteoarthritis, plantar fasciitis, and bone spurs is not homologous use as defined in 21 CFR 1271.3(c).\nIn addition, your umbilical cord derived product, EVO JEL™, fails to meet the minimal manipulation criterion set forth in 21 CFR 1271.10(a)(1) and defined for structural tissue in 21 CFR 1271.3(f)(1) because the umbilical cord undergoes processing that alters the original relevant characteristics of the umbilical cord related to its utility for reconstruction, repair, or replacement. Information available to the Agency indicates that EVO JEL is offered in a “flowable” form. The processing of the umbilical cord from the form of a tube into a flowable form is more than minimal manipulation because such processing alters the original relevant characteristics of the umbilical cord relating to the tissue’s utility to serve as a conduit by effectively altering or eliminating its physical integrity and tubular form.\nAdditionally, EVO HYBRID™ fails to meet the minimal manipulation criterion set forth in 21 CFR 1271.10(a)(1) and defined for structural tissue in 21 CFR 1271.3(f)(1) because the umbilical cord and amniotic membrane undergo processing that alters the original relevant characteristics of those tissues related to their utility for reconstruction, repair, or replacement. For example, the processing of umbilical cord from the form of a tube into a flowable form is more than minimal manipulation because the processing alters the original relevant characteristics of the umbilical cord relating to the tissue’s utility to serve as a conduit by effectively altering or eliminating its physical integrity and tubular form, and the processing of amniotic membrane from the form of a sheet into a flowable form alters the original relevant characteristics of the amniotic membrane relating to its utility to serve as a barrier by effectively eliminating its physical integrity, tensile strength and elasticity.1\nIn addition, your product derived from umbilical cord, “placental tissue,” and amniotic membrane, EVO HYBRID™, fails to meet the criterion in 21 CFR 1271.10(a)(2) because this product is not intended solely to perform the same basic function or functions of umbilical cord and amniotic membrane in the recipient as in the donor, such as serving as a conduit (for umbilical cord) or serving as a selective barrier for the movement of nutrients between the external and in utero environment, protecting the fetus from the surrounding maternal environment, and serving as a covering to enclose the fetus and retain fluid in utero (for amniotic membrane). Rather, use of this product for reducing inflammation, tissue regeneration, organ regeneration, bone growth, tissue growth, cartilage repair, and wound healing, for example, is not homologous use as defined in 21 CFR 1271.3(c).\nTherefore, these products are not regulated solely under section 361 of the PHS Act, 42 U.S.C. § 264, and the regulations in 21 CFR part 1271.2 See 21 CFR 1271.20. In addition to being regulated under section 361 of the PHS Act and 21 CFR part 1271, your EVO JEL™ and EVO HYBRID™ products are regulated as drugs as defined in section 201(g)(1) of the FD&C Act, 21 U.S.C. § 321(g)(1), and biological products as defined in section 351(i) of the PHS Act, 42 U.S.C. § 262(i), as stated above.\nYour exosome product, EXO RNA™, also meets the definition of a drug and biological product under section 201(g)(1) of the FD&C Act and section 351(i) of the PHS Act, as discussed above, and is subject to premarket review and approval requirements. We direct your attention to FDA’s Public Safety Notification on Exosome Products, at https:\u002F\u002Fwww.fda.gov\u002Fvaccines-blood-biologics\u002Fsafety-availability-biologics\u002Fpublic-safety-notification-exosome-products. FDA issued this public safety notification following multiple reports of serious adverse events experienced by patients who were treated with exosome products.\nTo lawfully market a drug that is a biological product, a valid biologics license must be in effect under section 351(a)(1) of the PHS Act, 42 U.S.C. § 262(a)(1). Such licenses are issued only after showing that the product is safe, pure, and potent. A biological product for which a BLA has been approved under section 351(a) is not required to have an approved application under section 505 of the FD&C Act. 21 U.S.C. § 355; 42 U.S.C. § 262(j). Otherwise, with certain exceptions not applicable here, a new drug may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in section 505(a) of the FD&C Act. Your products are not the subject of an approved biologics license application (BLA) or an approved application under section 505 of the FD&C Act. Based on our review, your products are both unapproved new drugs and unlicensed biological products, and you cause their introduction or delivery for introduction into interstate commerce in violation of section 301(d) of the FD&C Act, 21 U.S.C. § 331(d).\nThis letter addresses certain issues regarding the above-described products and is not intended to be an all-inclusive review. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure full compliance with the FD&C Act, PHS Act, and all applicable regulations. We advise you to comprehensively review your website, product labels, and other labeling and marketing materials to ensure that you are lawfully marketing your products in full compliance with the FD&C Act, the PHS Act, and their implementing regulations.\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address these matters may result in action without further notice, including, without limitation, seizure and\u002For injunction.\nPlease submit your response in writing within fifteen (15) working days from your receipt of this letter, outlining the specific steps you have taken or plan to take to address any violations and prevent their recurrence. Include any documentation necessary to show that the matters have been addressed. If you cannot address these matters within fifteen working days, please explain the reason for the delay and the timeframe for completion. If you believe that your products are not in violation of the FD&C Act or applicable regulations, include your reasoning and any supporting information for our consideration.\nIn addition, we have concerns with your products EXO RX, EXO ELIXIR™ and EXO PERIO™, which are other products described on your websites www.evolutionarybiologics.com\u002Frx and www.evobiologics.com. Your websites (last visited November 2024), make statements indicating these products are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease or conditions in humans and\u002For are intended to affect the structure or function of the human body, for example:\n• “EXO RX™ expresses 30 forms of collagen and is ideally suited to repair, rebuild and regenerate tissue while reducing inflammation”\n• Under “WHY EXO RX™…”, you list, “Anti-Fibrotic”… “Increases epidermal thickness and dermal collagen”…”Reduces scarring in cosmetic procedures and burns”…”Has been known to reduces [sic] acne”\n• “EXO ELIXIR is designed to regenerate your skin at a cellular level, with exceptional wound healing and anti-inflammatory growth factors that promote tissue engineering and regeneration.”\n• Under EXO ELIXIR “Advantages” you describe, “Modulating Inflammation…Promoting healing of wounds...”\n• “EVO PERIO™ Is a Wharton’s Jelly product rich with Mesenchymal Stem Cell exosomes. MSC exosomes induce bone, cartilage, dentin, mucosa, and pulp tissue formation while enhancing oral and craniofacial tissue engineering and regeneration.”\n• “EXO PERIO has demonstrated unique biological properties including being angiogenic, anti-inflammatory, antifibrotic, antimicrobial and immune privileged. The product has shown a strong tendency to accelerate healing and wound repair.\"\n• “Exo Perio can offer solutions for problems like craniofacial, osteochondral, periodontal tissue, nerve, pulp, or endodontics injuries.”\nFDA has not identified approved BLAs in effect for your EXO RX™, EXO ELIXIR™ and EXO PERIO™ products. In your response, please explain the basis of your determination regarding whether these products require FDA premarket review. For example, if you believe these products meet the criteria in 21 CFR 1271.10(a) for regulation solely under section 361 of the PHS Act, 42 U.S.C. 264, and 21 CFR part 1271, please explain that determination.\nYour response should be emailed to CBERDCMRecommendations@fda.hhs.gov. If you have any questions regarding this letter, please contact the Division of Case Management, CBER at (240) 402-9156.\nSincerely,\nMelissa J. Mendoza\nDirector, Office of Compliance and Biologics Quality\nCenter for Biologics Evaluation and Research\n______________________\n1 You market EVO HYBRID as being derived from “placental tissue,” in addition to umbilical cord and amniotic membrane. It is unclear what you mean by “placental tissue” in this context, as the mature placenta is composed of multiple tissues. Regardless, your EVO HYBRID product is regulated as a drug and biological product for the reasons described in this letter.\n2 Because your EVO JEL™ and EVO HYBRID™ products fail to meet at least one criterion in 21 CFR 1271.10(a), this letter does not evaluate all other criteria in 21 CFR 1271.10(a).","Evolutionary Biologics Inc.","evolutionary-biologics-inc-681586-12302024","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fevolutionary-biologics-inc-681586-12302024","2026-10-26T08:08:37.862855+00:00","2025-01-28","681586","Biologics","Jim Morrison","2026-08-19T17:03:23.375+00:00","VIA EMAIL AND UNITED PARCEL SERVICE","CBER-24-681586","2024-12-30",{"id":273,"raw":274,"subject":58,"body_html":278,"body_text":279,"firm_name":280,"letter_id":281,"created_at":165,"fei_number":19,"letter_url":282,"updated_at":283,"action_type":22,"case_status":23,"posted_date":284,"marcs_cms_no":285,"product_type":68,"closeout_date":19,"issuing_office":57,"recipient_name":170,"body_fetched_at":286,"delivery_method":70,"recipient_title":19,"reference_number":19,"action_taken_date":284,"medical_device_id":19,"response_letter_date":19},2022,[275,276,277,57,58,13,13,13],"\u003Ctime datetime=\"2023-06-29T17:00:00Z\">06\u002F29\u002F2023\u003C\u002Ftime>\n","\u003Ctime datetime=\"2023-06-29T04:00:00Z\">06\u002F29\u002F2023\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Feverything-vapor-aztec-657971-06292023\">Everything Vapor Aztec\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS and Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Tobacco                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Tammy Garrison\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Owner\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Everything Vapor Aztec\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>1409 West Aztec Boulevard\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Aztec\u003C\u002Fspan>, \u003Cspan>NM\u003C\u002Fspan> \u003Cspan>87410\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:garrison@animas.net\"> garrison@animas.net\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Tobacco Products\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>June 29, 2023\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Dear Ms. Garrison:\u003C\u002Fp>\n\n\u003Cp>The Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) has reviewed your submissions to the FDA and our inspection records, and determined that Everything Vapor manufactures and distributes e-liquid products for commercial distribution in the United States, and that the e-liquid products are manufactured and offered for sale or distribution to customers in the United States.\u003C\u002Fp>\n\n\u003Cp>Under section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) (21 U.S.C. § 321(rr)), these products are tobacco products because they are made or derived from tobacco or contain nicotine from any source, and intended for human consumption. Certain tobacco products, including e-liquid products, are subject to FDA jurisdiction under section 901(b) of the FD&amp;C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1, and are required to be in compliance with the requirements in the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>Please be aware that, on March 15, 2022, the President signed legislation to amend the FD&amp;C Act to extend FDA’s jurisdiction to products “containing nicotine from any source,” not just nicotine derived from tobacco. See Consolidated Appropriations Act, 2022, Public Law 117-103, Division P, Title I, Subtitle B. Specifically, this legislation expanded the definition of “tobacco product” under section 201(rr) of the FD&amp;C Act (21 U.S.C. § 321(rr)) to include products containing nicotine from any source. Tobacco products, including e-liquid products, containing nicotine from any source, must be in compliance with the FD&amp;C Act and its implementing regulations. For more information, please see https:\u002F\u002Fwww.fda.gov\u002Ftobacco-products\u002Fctp-newsroom\u002Frequirements-products-made-non-tobacco-nicotine-take-effect-april-14.\u003C\u002Fp>\n\n\u003Cp>Generally, to be legally marketed in the United States, the FD&amp;C Act requires “new tobacco products” to have a premarket authorization in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&amp;C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&amp;C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&amp;C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&amp;C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&amp;C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&amp;C Act (21 U.S.C. § 387e(j)(3)).\u003Cbr>\n\u003Cbr>\n\u003Cstrong>New Tobacco Products Without Required Marketing Authorization Are Adulterated and Misbranded\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>FDA has determined that you manufacture, sell, and\u002For distribute to customers in the United States e-liquid products without a marketing authorization order, including: House Juice # 11.\u003C\u002Fp>\n\n\u003Cp>The e-liquid products listed above are new tobacco products because they were not commercially marketed in the United States as of February 15, 2007. These products do not have FDA marketing authorization orders in effect under section 910(c)(1)(A)(i) of the FD&amp;C Act and are not otherwise exempt from the marketing authorization requirement. Therefore, these products are adulterated under section 902(6)(A) of the FD&amp;C Act (21 U.S.C. § 387b(6)(A)). In addition, they are misbranded under section 903(a)(6) of the FD&amp;C Act (21 U.S.C. § 387c(a)(6)) because a notice or other information respecting these products was not provided as required by section 905(j) of the FD&amp;C Act. The doing of any act with respect to a tobacco product while such article is held for sale after shipment in interstate commerce which results in such product being adulterated or misbranded is a prohibited act under section 301(k) of the FD&amp;C Act (21 U.S.C. § 331(k)). Additionally, to the extent that a report was required under section 905(j) of the FD&amp;C Act, the failure to provide such report is a prohibited act under section 301(p) of the FD&amp;C Act (21 U.S.C. § 331(p)).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion and Requested Actions\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>FDA has determined that your firm markets new tobacco products lacking premarket authorization in the United States. All new tobacco products on the market without the statutorily required premarket authorization are marketed unlawfully and are subject to enforcement action at FDA’s discretion.\u003C\u002Fp>\n\n\u003Cp>It is your responsibility to ensure that all of your tobacco products comply with each applicable provision of the FD&amp;C Act and FDA’s implementing regulations. Failure to address any violations of the FD&amp;C Act, 21 U.S.C. § 301 et seq., Chapter IX, relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, and 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&amp;C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated and\u002For misbranded may be detained or refused admission.\u003C\u002Fp>\n\n\u003Cp>The violations discussed in this letter do not necessarily constitute an exhaustive list. You should take prompt action to address any violations that are referenced above, as well as violations that are the same as or similar to the ones stated above, and take any necessary actions to bring your tobacco products into compliance with the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>Please submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring your products into compliance, including the dates on which you discontinued the violative sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&amp;C Act. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&amp;C Act through links on FDA’s homepage at http:\u002F\u002Fwww.fda.gov.\u003C\u002Fp>\n\n\u003Cp>Please note your reference number, ER2300840, in your response and direct your response to the following address:\u003C\u002Fp>\n\n\u003Cp>DEM-WL Response, Office of Compliance and Enforcement\u003Cbr>\nFDA Center for Tobacco Products\u003Cbr>\nc\u002Fo Document Control Center\u003Cbr>\nBuilding 71, Room G335\u003Cbr>\n10903 New Hampshire Avenue\u003Cbr>\nSilver Spring, MD 20993-0002\u003C\u002Fp>\n\n\u003Cp>If you have any questions about the content of this letter, please contact CTPCompliance@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Ann Simoneau, J.D.\u003Cbr>\nDirector\u003Cbr>\nOffice of Compliance and Enforcement\u003Cbr>\nCenter for Tobacco Products\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS and Electronic Mail\n\nProduct:\n\nTobacco\n\nRecipient:\n\nRecipient Name\n\nTammy Garrison\n\nRecipient Title\n\nOwner\n\nEverything Vapor Aztec\n\n1409 West Aztec Boulevard\n\nAztec, NM 87410\n\nUnited States\n\ngarrison@animas.net\n\nIssuing Office:\n\nCenter for Tobacco Products\n\nUnited States\n\nJune 29, 2023\n\nWARNING LETTER\n\nDear Ms. Garrison:\n\nThe Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) has reviewed your submissions to the FDA and our inspection records, and determined that Everything Vapor manufactures and distributes e-liquid products for commercial distribution in the United States, and that the e-liquid products are manufactured and offered for sale or distribution to customers in the United States.\n\nUnder section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. § 321(rr)), these products are tobacco products because they are made or derived from tobacco or contain nicotine from any source, and intended for human consumption. Certain tobacco products, including e-liquid products, are subject to FDA jurisdiction under section 901(b) of the FD&C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1, and are required to be in compliance with the requirements in the FD&C Act.\n\nPlease be aware that, on March 15, 2022, the President signed legislation to amend the FD&C Act to extend FDA’s jurisdiction to products “containing nicotine from any source,” not just nicotine derived from tobacco. See Consolidated Appropriations Act, 2022, Public Law 117-103, Division P, Title I, Subtitle B. Specifically, this legislation expanded the definition of “tobacco product” under section 201(rr) of the FD&C Act (21 U.S.C. § 321(rr)) to include products containing nicotine from any source. Tobacco products, including e-liquid products, containing nicotine from any source, must be in compliance with the FD&C Act and its implementing regulations. For more information, please see https:\u002F\u002Fwww.fda.gov\u002Ftobacco-products\u002Fctp-newsroom\u002Frequirements-products-made-non-tobacco-nicotine-take-effect-april-14.\n\nGenerally, to be legally marketed in the United States, the FD&C Act requires “new tobacco products” to have a premarket authorization in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&C Act (21 U.S.C. § 387e(j)(3)).\n\nNew Tobacco Products Without Required Marketing Authorization Are Adulterated and Misbranded\n\nFDA has determined that you manufacture, sell, and\u002For distribute to customers in the United States e-liquid products without a marketing authorization order, including: House Juice # 11.\n\nThe e-liquid products listed above are new tobacco products because they were not commercially marketed in the United States as of February 15, 2007. These products do not have FDA marketing authorization orders in effect under section 910(c)(1)(A)(i) of the FD&C Act and are not otherwise exempt from the marketing authorization requirement. Therefore, these products are adulterated under section 902(6)(A) of the FD&C Act (21 U.S.C. § 387b(6)(A)). In addition, they are misbranded under section 903(a)(6) of the FD&C Act (21 U.S.C. § 387c(a)(6)) because a notice or other information respecting these products was not provided as required by section 905(j) of the FD&C Act. The doing of any act with respect to a tobacco product while such article is held for sale after shipment in interstate commerce which results in such product being adulterated or misbranded is a prohibited act under section 301(k) of the FD&C Act (21 U.S.C. § 331(k)). Additionally, to the extent that a report was required under section 905(j) of the FD&C Act, the failure to provide such report is a prohibited act under section 301(p) of the FD&C Act (21 U.S.C. § 331(p)).\n\nConclusion and Requested Actions\n\nFDA has determined that your firm markets new tobacco products lacking premarket authorization in the United States. All new tobacco products on the market without the statutorily required premarket authorization are marketed unlawfully and are subject to enforcement action at FDA’s discretion.\n\nIt is your responsibility to ensure that all of your tobacco products comply with each applicable provision of the FD&C Act and FDA’s implementing regulations. Failure to address any violations of the FD&C Act, 21 U.S.C. § 301 et seq., Chapter IX, relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, and 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated and\u002For misbranded may be detained or refused admission.\n\nThe violations discussed in this letter do not necessarily constitute an exhaustive list. You should take prompt action to address any violations that are referenced above, as well as violations that are the same as or similar to the ones stated above, and take any necessary actions to bring your tobacco products into compliance with the FD&C Act.\n\nPlease submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring your products into compliance, including the dates on which you discontinued the violative sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&C Act. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&C Act through links on FDA’s homepage at http:\u002F\u002Fwww.fda.gov.\n\nPlease note your reference number, ER2300840, in your response and direct your response to the following address:\n\nDEM-WL Response, Office of Compliance and Enforcement\n\nFDA Center for Tobacco Products\n\nc\u002Fo Document Control Center\n\nBuilding 71, Room G335\n\n10903 New Hampshire Avenue\n\nSilver Spring, MD 20993-0002\n\nIf you have any questions about the content of this letter, please contact CTPCompliance@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nAnn Simoneau, J.D.\n\nDirector\n\nOffice of Compliance and Enforcement\n\nCenter for Tobacco Products","Everything Vapor Aztec","everything-vapor-aztec-657971-06292023","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Feverything-vapor-aztec-657971-06292023","2026-10-26T08:08:37.460608+00:00","2023-06-29","657971","2026-08-20T00:59:38.614+00:00",{"id":288,"raw":289,"subject":293,"body_html":294,"body_text":295,"firm_name":296,"letter_id":297,"created_at":18,"fei_number":19,"letter_url":298,"updated_at":299,"action_type":22,"case_status":23,"posted_date":300,"marcs_cms_no":301,"product_type":302,"closeout_date":19,"issuing_office":11,"recipient_name":303,"body_fetched_at":304,"delivery_method":29,"recipient_title":19,"reference_number":305,"action_taken_date":306,"medical_device_id":19,"response_letter_date":19},715,[290,291,292,11,293,13,13,13],"\u003Ctime datetime=\"2025-08-19T04:00:00Z\">08\u002F19\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-08-11T04:00:00Z\">08\u002F11\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Feverlaan-organics-inc-dba-maple-organics-707956-08112025\">Everlaan Organics, Inc. dba Maple Organics\u003C\u002Fa>","Nonprescription\u002FOTC","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>320-25-99\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n                          \u003Cbr>Over-the-Counter Drugs\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Ms. Rosy Atwal\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Founder and CEO \u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Everlaan Organics, Inc. dba Maple Organics\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>17220 Heather Dr, Unit 106\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Surrey\u003C\u002Fspan> \u003Cspan>BC\u003C\u002Fspan> \u003Cspan>V3S 8G6\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Canada\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>Warning Letter\u003C\u002Fstrong> 320-25-99\u003C\u002Fp>\u003Cp>August 11, 2025\u003C\u002Fp>\u003Cp>Dear Ms. Atwal:\u003C\u002Fp>\u003Cp>Your facility was registered with the United States Food and Drug Administration (FDA) as a manufacturer of over-the-counter (OTC) drug products. FDA has reviewed the records you submitted in response to our September 4, 2024 request and subsequent correspondence, for records and other information pursuant to section 704(a)(4) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) for your facility, Everlaan Organics, Inc., dba Maple Organics, FEI 3025798567, 17220 Heather Dr, Unit 106, Surrey, British Columbia, Canada.\u003C\u002Fp>\u003Cp>This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations, parts 210 and 211 (21 CFR, parts 210 and 211).\u003C\u002Fp>\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding of drugs as described in your response to our 704(a)(4) request do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the FD&amp;C Act (21 U.S.C. 351(a)(2)(B)).\u003C\u002Fp>\u003Cp>In addition, “maple organics Joint Pain Relief” and “maple organics Muscle Pain Relief” are unapproved new drugs introduced or delivered for introduction into interstate commerce in violation of section 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 355(a). Furthermore, “maple organics Joint Pain Relief,” “maple organics Muscle Pain Relief,” “maple organics Cough &amp; Cold Relief for Kids,” and “maple organics Cough &amp; Cold Relief” are misbranded under 502(a) of the FD&amp;C Act, 21 U.S.C. 352(a). Additionally, “maple organics Cough &amp; Cold Relief” is further misbranded under 502(f)(1) of the FD&amp;C Act, 21 U.S.C. 352(f)(1) and “maple organics Joint Pain Relief,” “maple organics Muscle Pain Relief,” and “maple organics Cough &amp; Cold Relief” are misbranded under section 502(ee) of the FD&amp;C Act, 21 U.S.C. 352(ee). Introduction or delivery for introduction of a misbranded product into interstate commerce is prohibited under section 301(a) of the FD&amp;C Act, 21 U.S.C. 331(a). These violations are described in more detail below.\u003C\u002Fp>\u003Cp>Following review of records and other information provided pursuant to section 704(a)(4) of the FD&amp;C Act, significant violations were observed including, but not limited to, the following:\u003C\u002Fp>\u003Cp>\u003Cstrong>CGMP Violations\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cstrong>1. Your firm failed to have, for each batch of drug product, appropriate laboratory determination of satisfactory conformance to final specifications for the drug product, including the identity and strength of each active ingredient, prior to release (21 CFR 211.165(a)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>You manufacture OTC drug products, including \u003Cstrong>(b)(4)\u003C\u002Fstrong> products for \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Based on the records and information you provided, you did not demonstrate that you adequately test your OTC finished drug products prior to release for distribution to the United States.\u003C\u002Fp>\u003Cp>In your initial response, you state that you test each batch of your finished drug products before release. However, when FDA requested you to provide the test data, you failed to provide any records demonstrating that you tested your finished products prior to release. You do not appear to be performing release testing on finished products.\u003C\u002Fp>\u003Cp>Full release testing, including for identity, strength, and impurities, must be performed prior to drug release and distribution. Without adequate testing, there is no scientific evidence to assure that your drug products conform to appropriate specifications before release.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A list of chemical and microbial specifications, including adequate test methods, used to analyze each batch of your drug products before a batch disposition decision.\u003Cbr>o An action plan and timelines for conducting full chemical and microbiological testing of retain samples to determine the quality of all batches of drug product distributed to the United States that are within expiry as of the date of this letter.\u003Cbr>o A summary of all results obtained from testing retain samples from each batch. If such testing reveals substandard quality drug products, take rapid corrective actions, such as notifying customers and product recalls.\u003C\u002Fli>\u003Cli>A comprehensive, independent assessment of your laboratory practices, procedures, methods, equipment, documentation, and analyst competencies. Based on this review, provide a detailed plan to remediate and evaluate the effectiveness of your laboratory system.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>2. Your firm failed to conduct at least one test to verify the identity of each component of a drug product (21 CFR 211.84(d)(1)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Based on the records and information you provided about the manufacture of your OTC drug products, you did not demonstrate that you are adequately testing each shipment of each lot of incoming components.\u003C\u002Fp>\u003Cp>In response to our initial request, you state that you “identify all items via receiving practices” and provided a receiving procedure. However, the procedure did not specify chemical identity testing for incoming components. You also did not provide your incoming component testing data for the most recent batches shipped to the United States when asked by FDA subsequently.\u003C\u002Fp>\u003Cp>Without adequate testing, you do not have scientific evidence that incoming materials conform to appropriate specifications prior to use in the manufacture of your drugs. As a manufacturer, you have a responsibility to sample, test, and examine incoming materials before use in production to assure adequate quality.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A comprehensive, independent review of your material system to determine whether all suppliers of incoming materials are each qualified and the materials are assigned appropriate expiration or retest dates. The review should also determine whether incoming material controls are adequate to prevent use of unsuitable materials.\u003C\u002Fli>\u003Cli>The chemical and microbiological quality control specifications you use to test and release each incoming lot of components for use in manufacturing.\u003C\u002Fli>\u003Cli>A description of how you will test each incoming material lot for conformity with all appropriate specifications for identity. If you intend to accept any results from your supplier’s certificate of analysis (COA) instead of testing each incoming material lot for other tests, specify how you will ensure that you have adequate evidence to establish that the supplier consistently provides material meeting specifications. In addition, include a commitment to always conduct at least one specific identity test for each incoming material lot.\u003C\u002Fli>\u003Cli>A summary of results obtained from testing all incoming materials to evaluate the reliability of the COA from each incoming materials manufacturer. Include your standard operating procedure that describes this COA validation program.\u003C\u002Fli>\u003Cli>A summary of your program for qualifying and overseeing contract facilities that test the drugs you manufacture.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>3. Your firm failed to establish and follow an adequate written testing program designed to assess the stability characteristics of drug products (21 CFR 211.166(a)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The records and information you provided did not demonstrate that you have an adequate stability program for the OTC drug products you manufacture. You provided a stability test procedure that only discussed accelerated stability testing but did not include long-term stability testing. In lieu of stability data, you provided a cost estimate from a contract testing laboratory outlining the various stability tests to be performed. We note that one of your microbiological test references USP &lt;2021&gt;, which is intended for evaluating nutritional supplements, and not drug products.\u003C\u002Fp>\u003Cp>Without appropriate stability studies, you do not have scientific evidence to support whether your drug products meet established specifications and retain their quality attributes through their labeled expiry.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A comprehensive, independent assessment and CAPA plan to ensure the adequacy of your stability program. Your remediated program should include, but not be limited to:\u003Cbr>o Stability indicating methods.\u003Cbr>o Stability studies for each drug product in its marketed container-closure system before distribution is permitted.\u003Cbr>o An ongoing program in which representative batches of each product are added each year to the program to determine if the shelf-life claim remains valid.\u003Cbr>o Detailed definition of the specific attributes to be tested at each station (timepoint).\u003C\u002Fli>\u003Cli>All procedures that describe these and other elements of your remediated stability program.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>4. Your firm failed to prepare batch production and control records that include documentation of the accomplishment of each significant step in the manufacture, processing, packing, or holding of the batch, for each batch of drug product (21 CFR 211.188(b)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The batch records you provided in response to our request for records lacked adequate production details regarding significant manufacturing steps, including, but not limited to, identity of major equipment and lines, in-process controls, yield, and container closures. This documentation is necessary to establish that manufacturing processes were consistently followed and are reproducible. Having incomplete records deprives you of traceability of actions necessary for investigational purposes.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cp>• Your master production and control records for your drug products, to demonstrate that they fully document each significant and validated manufacturing step.\u003C\u002Fp>\u003Cp>• A complete assessment of documentation systems used throughout your manufacturing operations, to determine where documentation practices are insufficient. Include a detailed corrective action and preventive action (CAPA) plan that comprehensively remediates your firm’s documentation practices, to ensure you retain attributable, legible, complete, original, accurate, and contemporaneous records throughout your operation.\u003C\u002Fp>\u003Cp>\u003Cstrong>5. Your firm failed to establish an adequate quality control unit with the responsibility and authority to approve or reject all components, drug product containers, closures, in-process materials, packaging materials, labeling, and drug products (21 CFR 211.22(a)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The records and information you provided demonstrate that your quality unit (QU) did not effectively exercise its responsibilities to oversee the quality of your drug manufacturing operations. Specifically, your QU did not adequately exercise its authority in the approval or rejection of components, approval or rejection of finished drug products, batch record review, establishment and implementation of an adequate stability study program, and performance of adequate process validation.\u003C\u002Fp>\u003Cp>Your procedures did not define your QU structure and delineation of QU roles and responsibilities. We acknowledge that you plan to cease production and seek a contract manufacturing organization (CMO), \u003Cstrong>(b)(4)\u003C\u002Fstrong>, to manufacture your drug products.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\u003Cbr>o A determination of whether procedures used by your firm are robust and appropriate.\u003Cbr>o Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices.\u003Cbr>o A complete and final review of each batch and its related information before the QU disposition decision.\u003Cbr>o Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>Use of Contract Manufacturers\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>We note that your prospective contract manufacturing facility, \u003Cstrong>(b)(4)\u003C\u002Fstrong>, was placed on Import Alert 66-40 on \u003Cstrong>(b)(4)\u003C\u002Fstrong> for failure to comply with CGMP requirements. Drugs manufactured at your prospective CMO are considered adulterated and thus should not be used for the manufacture of drugs for the United States market. It is your responsibility to perform adequate due diligence to ensure that your CMO is in full compliance with CGMPs, the applicable requirements in the FD&amp;C Act, PHS Act, and all applicable regulations.\u003C\u002Fp>\u003Cp>Drugs must be manufactured in conformance with CGMP. FDA is aware that many drug manufacturers use independent contractors, such as production facilities, testing laboratories, packagers, and labelers. FDA regards contractors as extensions of the manufacturer.\u003C\u002Fp>\u003Cp>You are responsible for the quality of your drugs regardless of agreements in place with your contract facilities. You are required to ensure that drugs are made in accordance with section 501(a)(2)(B) of the FD&amp;C Act to ensure safety, identity, strength, quality, and purity. See FDA’s guidance document \u003Cem>Contract Manufacturing Arrangements for Drugs: Quality Agreements\u003C\u002Fem> at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F86193\u002Fdownload.\u003C\u002Fp>\u003Cp>\u003Cstrong>Quality Systems\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your firm’s quality systems are inadequate. See FDA’s guidance document \u003Cem>Quality Systems Approach to Pharmaceutical CGMP Regulations\u003C\u002Fem> for help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR, parts 210 and 211 at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload.\u003C\u002Fp>\u003Cp>\u003Cstrong>CGMP Consultant Recommended\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Based upon the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34 to evaluate your operations and to assist your firm in meeting CGMP requirements if your firm intends to resume manufacturing drugs for the U.S. market. The qualified consultant should also perform a comprehensive six-system audit\u003Cem>\u003Cstrong>\u003Csup>1\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> of your entire operation for CGMP compliance and evaluate the completion and efficacy of your CAPA before you pursue resolution of your firm’s compliance status with FDA.\u003C\u002Fp>\u003Cp>Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\u003C\u002Fp>\u003Cp>\u003Cstrong>Unapproved New Drug and Misbranding Violations\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>“maple organics Joint Pain Relief,” “maple organics Muscle Pain Relief,” “maple organics Cough &amp; Cold Relief for Kids,” and “maple organics Cough &amp; Cold Relief” are drugs as defined by section 201(g)(1)(B) of the FD&amp;C Act, 21 U.S.C. 321(g)(1)(B) because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and\u002For under section 201(g)(1)(C) of the FD&amp;C Act, 21 U.S.C. 321(g)(1)(C) because they are intended to affect the structure or any function of the body.\u003C\u002Fp>\u003Cp>Examples of claims observed on the product labels and labeling from your website listed above that provide evidence of the intended uses (as defined in 21 CFR 201.128) of the products include, but may not be limited to, the following:\u003C\u002Fp>\u003Cp>“\u003Cu>maple organics Joint Pain Relief\u003C\u002Fu>”\u003Cbr>• “\u003Cstrong>DRUG FACTS . . . Uses:\u003C\u002Fstrong> Temporarily relieves joint pain.” [from the product label]\u003Cbr>• “Maple Organics Joint Therapy is an FDA-approved, all-natural formula designed to relieve pain, stiffness, and inflammation.” [from the product website www.mapleorganics.com]\u003Cbr>• “Made with organic Arnica Montana, known for its anti-inflammatory and analgesic properties, this balm provides fast-acting, long-lasting relief from discomfort caused by osteoarthritis, tendonitis, and rheumatoid arthritis.” [from the product website www.mapleorganics.com]\u003C\u002Fp>\u003Cp>• “Unlike conventional ointments, our steroid-free formula helps reduce muscle damage, so you can feel better without the harsh side effects.” [from the product website www.mapleorganics.com]\u003Cbr>• “A remedy for pain and inflammation due to osteoarthritis, tendonitis and rheumatoid arthritis.” [from the product website www.mapleorganics.com]\u003C\u002Fp>\u003Cp>“\u003Cu>maple organics Muscle Pain Relief\u003C\u002Fu>”\u003Cbr>• “\u003Cstrong>DRUG FACTS . . . Uses:\u003C\u002Fstrong> Temporarily relieves minor aches and pains of muscles and joints associated with simple backache, strains and bruises.” [from the product label]\u003Cbr>• “This is not an icy hot product but will increase circulation to remove lapsed blood while giving a numbness in your muscles to help reduce pain.” [from the product website www.mapleorganics.com]\u003C\u002Fp>\u003Cp>“\u003Cu>maple organics Cough &amp; Cold Relief for Kids\u003C\u002Fu>”\u003Cbr>• “\u003Cstrong>DRUG FACTS . . . Uses:\u003C\u002Fstrong> Temporarily relieves cough associated with the common cold.” [from the product label]\u003C\u002Fp>\u003Cp>\u003Cu>“maple organics Cough &amp; Cold Relief\u003C\u002Fu>”\u003Cbr>• “\u003Cstrong>DRUG FACTS…Uses:\u003C\u002Fstrong> Temporarily relieves cough associated with the common cold.” [from the product label]\u003C\u002Fp>\u003Cp>\u003Cstrong>Unapproved New Drug Violations\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Based on the above labeling evidence, “maple organics Joint Pain Relief” and “maple organics Muscle Pain Relief” are intended for use as external analgesic drug products. As described below, these drug products are unapproved new drugs marketed in violation of sections 505(a) and 301(d) of the FD&amp;C Act, 21 U.S.C 355(a) and 331(d).\u003C\u002Fp>\u003Cp>A drug product is a “new drug” within the meaning of section 201(p) of the FD&amp;C Act, 21 U.S.C. 321(p), if it is not generally recognized as safe and effective (GRASE) for use under the conditions prescribed, recommended, or suggested in its labeling. With certain exceptions not applicable here, a new drug may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in section 505(a) of the FD&amp;C Act, 21 U.S.C. 355(a). No FDA-approved applications pursuant to section 505 of the FD&amp;C Act, 21 U.S.C. 355, are in effect for these drug products identified above.\u003C\u002Fp>\u003Cp>Under section 505G of the FD&amp;C Act, certain nonprescription drugs marketed without an approved application —commonly referred to as \"OTC monograph drugs\"—may be legally marketed if they meet applicable requirements. With respect to external analgesic drug products, such as your “maple organics Joint Pain Relief” and “maple organics Muscle Pain Relief,” in order to be GRASE and not new drugs, the products must, among other things, conform to the conditions in the applicable OTC monograph, here the External Analgesic Drug Products for Over-the-Counter Human Use (M017).\u003Cem>\u003Cstrong>\u003Csup>2\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> However, “maple organics Joint Pain Relief” and “maple organics Muscle Pain Relief” do not conform to the conditions specified in M017 for the reasons described below\u003C\u002Fp>\u003Cp>Specifically, “maple organics Joint Pain Relief” contains the active ingredient arnica, which is not a permitted active ingredient under M017. 21 CFR 201.66(b)(2) defines “active ingredient” to mean “any component that is intended to furnish pharmacological activity or other direct effect in the diagnosis, cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body of humans.” Although your firm does not specifically list arnica as an active ingredient, your labeling of “maple organics Joint Pain Relief,” such as your website, includes statements that claim arnica is intended as an anti-inflammatory and analgesic, and “…provides fast-acting, long-lasting relief from discomfort caused by osteoarthritis, tendonitis, and rheumatoid arthritis.” Such statements demonstrate that arnica is an “active ingredient” in your “maple organics Joint Pain Relief” because it is intended to furnish pharmacological activity or other direct effect to affect the structure or any function of the body of humans. Because arnica is not an active ingredient permitted under M017, your “maple organics Joint Pain Relief” does not conform with the conditions set forth in M017.\u003C\u002Fp>\u003Cp>Furthermore, the labeling for “maple organics Joint Pain Relief” and “maple organics Muscle Pain Relief” include intended uses that are not permitted in M017. For example, you claim that “maple organic Joint Pain Relief” will “help reduce muscle damage” and it can be used as “a remedy for pain and inflammation due to osteoarthritis, tendonitis and rheumatoid arthritis.” In addition, you claim that “maple organic Muscle Pain Relief” “…will increase circulation to remove lapsed blood while giving a numbness in your muscles to help reduce pain.” Such intended uses do not conform with M017.50(b).\u003C\u002Fp>\u003Cp>Thus, as formulated and labeled, your “maple organics Joint Pain Relief” and “maple organics Muscle Pain Relief” products do not comply with the applicable final administrative order described above or any other final order.\u003Cem>\u003Cstrong>\u003Csup>3\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> Moreover, there is no evident basis under the FD&amp;C Act under which these products would be legally marketed without an approved application. Thus, these products are new drugs within the meaning of section 201(p) of the FD&amp;C Act, 21 U.S.C. 321(p). Accordingly, these products are unapproved new drugs marketed in violation of section 505(a) of the FD&amp;C Act, 21 U.S.C. 355(a).\u003C\u002Fp>\u003Cp>The introduction or delivery for introduction of these unapproved new drug products into interstate commerce violates sections 505(a) and 301(d) of the FD&amp;C Act, 21 U.S.C. 355(a) and 331(d).\u003C\u002Fp>\u003Cp>\u003Cstrong>Misbranded Drug Violations\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your “maple organics Joint Pain Relief” product is misbranded under section 502(a) because the website labeling claims the product is “…an FDA-approved, all-natural formula….” This claim suggests that the drug is approved or legally marketable (see 21 CFR 207.77(b)). However, your product is not subject to an FDA-approved application. Therefore, your labeling representation suggesting that your product is FDA-approved is false or misleading.\u003C\u002Fp>\u003Cp>Further, “maple organics Joint Pain Relief,” “maple organics Muscle Pain Relief,” “maple organics Cough &amp; Cold Relief for Kids,” and “maple organics Cough &amp; Cold Relief” are misbranded under 502(a) because your products’ labels claim ”At Maple Organics, we scientifically validate natural remedies to FDA standards, ensuring their efficacy….” This claim misleadingly suggests that your products are validated to FDA-standards when such is not the case.\u003C\u002Fp>\u003Cp>We note that, based on the labeling evidence described above, “maple organics Cough &amp; Cold Relief” is intended for use as topical antitussives under M012 (Cold, Cough Allergy, Bronchodilator, and Antiasthmatic Drug Products for Over-the-Counter Human Use). Your “maple organics Cough &amp; Cold Relief” product is misbranded under section 502(f)(1) because the product label is missing adequate directions for use specified in M012.74(d)(2)(i) and M012.74(d)(2)(ii). Specifically, the directions on the product label are missing the following statement, “Children under 2 years of age: Ask a doctor.”\u003C\u002Fp>\u003Cp>Additionally, “maple organics Joint Pain Relief,” “maple organics Muscle Pain Relief,” and “maple organics Cough &amp; Cold Relief” are misbranded under section 502(ee) of the FD&amp;C Act, 21 U.S.C. 352(ee), because these products are nonprescription drugs subject to section 505G of the FD&amp;C Act, 21 U.S.C. 355h, but do not comply with the requirements for marketing under that section and are not the subject of an application approved under section 505 of the FD&amp;C Act, 21 U.S.C. 355.\u003C\u002Fp>\u003Cp>The introduction or delivery for introduction of a misbranded drug into interstate commerce violates section 301(a) of the FD&amp;C Act, 21 U.S.C. 331(a).\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\u003Cp>FDA placed all drugs and drug products offered for import into the United States from your firm on Import Alert 66-40 on May 23, 2025. Additionally, FDA placed your “maple organics Joint Pain Relief” and “maple organics Muscle Pain Relief” drug products on Import Alert 66-41 on June 30, 2025.\u003C\u002Fp>\u003Cp>Correct any violations promptly. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to any violations.\u003C\u002Fp>\u003Cp>Failure to address any violations may also result in the FDA continuing to refuse admission of articles manufactured at Everlaan Organics, Inc., dba Maple Organics, 17220 Heather Dr, Unit 106 Surrey, British Columbia, Canada, into the United States under section 801(a)(3) of the FD&amp;C Act, 21 U.S.C. 381(a)(3). Articles under this authority that appear to be adulterated or misbranded may be detained or refused admission, in that the methods and controls used in their manufacture do not appear to conform to CGMP within the meaning of section 501(a)(2)(B) of the FD&amp;C Act, 21 U.S.C. 351(a)(2)(B) and are misbranded under section 502 of the FD&amp;C Act, respectively.\u003C\u002Fp>\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\u003Cp>Send your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3025798567 and ATTN: William Yang.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Francis Godwin\u003Cbr>Director\u003Cbr>Office of Manufacturing Quality\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003C\u002Fp>\u003Cp>\u002FS\u002F\u003C\u002Fp>\u003Cp>Tina Smith\u003Cbr>Captain, U.S. Public Health Service\u003Cbr>Director\u003Cbr>Office of Unapproved Drugs &amp; Labeling Compliance\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003C\u002Fp>\u003Cp>_____________________\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> i.e., Quality System, Facilities &amp; Equipment System, Materials System, Production System, Packaging &amp; Labeling System, and Laboratory Control System per FDA’s guidance document Quality Systems Approach to Pharmaceutical CGMP Regulations.\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> M017 reflects the conditions in the relevant final order established and in effect under Section 505G of the FD&amp;C Act; see Order ID OTC000033, available at FDA’s website OTC Monographs@FDA, https:\u002F\u002Fdps.fda.gov\u002Fomuf\u002Fordersearch\u002Forder_otc000033.\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem> FDA is not aware of any adequate and well-controlled clinical trials in the published literature that support a determination that “maple organics Joint Pain Relief” and “maple organics Muscle Pain Relief” are GRASE for use under the conditions prescribed, recommended, or suggested in their labeling, nor has FDA determined these drug products to be GRASE pursuant to an order issued under section 505G(b).\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS\n\nReference #:\n\n320-25-99\n\nProduct:\n\nDrugs\n\nOver-the-Counter Drugs\n\nRecipient:\n\nRecipient Name\n\nMs. Rosy Atwal\n\nRecipient Title\n\nFounder and CEO\n\nEverlaan Organics, Inc. dba Maple Organics\n\n17220 Heather Dr, Unit 106\n\nSurrey BC V3S 8G6\n\nCanada\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nWarning Letter 320-25-99\nAugust 11, 2025\nDear Ms. Atwal:\nYour facility was registered with the United States Food and Drug Administration (FDA) as a manufacturer of over-the-counter (OTC) drug products. FDA has reviewed the records you submitted in response to our September 4, 2024 request and subsequent correspondence, for records and other information pursuant to section 704(a)(4) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) for your facility, Everlaan Organics, Inc., dba Maple Organics, FEI 3025798567, 17220 Heather Dr, Unit 106, Surrey, British Columbia, Canada.\nThis warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations, parts 210 and 211 (21 CFR, parts 210 and 211).\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding of drugs as described in your response to our 704(a)(4) request do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the FD&C Act (21 U.S.C. 351(a)(2)(B)).\nIn addition, “maple organics Joint Pain Relief” and “maple organics Muscle Pain Relief” are unapproved new drugs introduced or delivered for introduction into interstate commerce in violation of section 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 355(a). Furthermore, “maple organics Joint Pain Relief,” “maple organics Muscle Pain Relief,” “maple organics Cough & Cold Relief for Kids,” and “maple organics Cough & Cold Relief” are misbranded under 502(a) of the FD&C Act, 21 U.S.C. 352(a). Additionally, “maple organics Cough & Cold Relief” is further misbranded under 502(f)(1) of the FD&C Act, 21 U.S.C. 352(f)(1) and “maple organics Joint Pain Relief,” “maple organics Muscle Pain Relief,” and “maple organics Cough & Cold Relief” are misbranded under section 502(ee) of the FD&C Act, 21 U.S.C. 352(ee). Introduction or delivery for introduction of a misbranded product into interstate commerce is prohibited under section 301(a) of the FD&C Act, 21 U.S.C. 331(a). These violations are described in more detail below.\nFollowing review of records and other information provided pursuant to section 704(a)(4) of the FD&C Act, significant violations were observed including, but not limited to, the following:\nCGMP Violations\n1. Your firm failed to have, for each batch of drug product, appropriate laboratory determination of satisfactory conformance to final specifications for the drug product, including the identity and strength of each active ingredient, prior to release (21 CFR 211.165(a)).\nYou manufacture OTC drug products, including (b)(4) products for (b)(4). Based on the records and information you provided, you did not demonstrate that you adequately test your OTC finished drug products prior to release for distribution to the United States.\nIn your initial response, you state that you test each batch of your finished drug products before release. However, when FDA requested you to provide the test data, you failed to provide any records demonstrating that you tested your finished products prior to release. You do not appear to be performing release testing on finished products.\nFull release testing, including for identity, strength, and impurities, must be performed prior to drug release and distribution. Without adequate testing, there is no scientific evidence to assure that your drug products conform to appropriate specifications before release.\nIn response to this letter, provide:\nA list of chemical and microbial specifications, including adequate test methods, used to analyze each batch of your drug products before a batch disposition decision.\no An action plan and timelines for conducting full chemical and microbiological testing of retain samples to determine the quality of all batches of drug product distributed to the United States that are within expiry as of the date of this letter.\no A summary of all results obtained from testing retain samples from each batch. If such testing reveals substandard quality drug products, take rapid corrective actions, such as notifying customers and product recalls.\nA comprehensive, independent assessment of your laboratory practices, procedures, methods, equipment, documentation, and analyst competencies. Based on this review, provide a detailed plan to remediate and evaluate the effectiveness of your laboratory system.\n2. Your firm failed to conduct at least one test to verify the identity of each component of a drug product (21 CFR 211.84(d)(1)).\nBased on the records and information you provided about the manufacture of your OTC drug products, you did not demonstrate that you are adequately testing each shipment of each lot of incoming components.\nIn response to our initial request, you state that you “identify all items via receiving practices” and provided a receiving procedure. However, the procedure did not specify chemical identity testing for incoming components. You also did not provide your incoming component testing data for the most recent batches shipped to the United States when asked by FDA subsequently.\nWithout adequate testing, you do not have scientific evidence that incoming materials conform to appropriate specifications prior to use in the manufacture of your drugs. As a manufacturer, you have a responsibility to sample, test, and examine incoming materials before use in production to assure adequate quality.\nIn response to this letter, provide:\nA comprehensive, independent review of your material system to determine whether all suppliers of incoming materials are each qualified and the materials are assigned appropriate expiration or retest dates. The review should also determine whether incoming material controls are adequate to prevent use of unsuitable materials.\nThe chemical and microbiological quality control specifications you use to test and release each incoming lot of components for use in manufacturing.\nA description of how you will test each incoming material lot for conformity with all appropriate specifications for identity. If you intend to accept any results from your supplier’s certificate of analysis (COA) instead of testing each incoming material lot for other tests, specify how you will ensure that you have adequate evidence to establish that the supplier consistently provides material meeting specifications. In addition, include a commitment to always conduct at least one specific identity test for each incoming material lot.\nA summary of results obtained from testing all incoming materials to evaluate the reliability of the COA from each incoming materials manufacturer. Include your standard operating procedure that describes this COA validation program.\nA summary of your program for qualifying and overseeing contract facilities that test the drugs you manufacture.\n3. Your firm failed to establish and follow an adequate written testing program designed to assess the stability characteristics of drug products (21 CFR 211.166(a)).\nThe records and information you provided did not demonstrate that you have an adequate stability program for the OTC drug products you manufacture. You provided a stability test procedure that only discussed accelerated stability testing but did not include long-term stability testing. In lieu of stability data, you provided a cost estimate from a contract testing laboratory outlining the various stability tests to be performed. We note that one of your microbiological test references USP \u003C2021>, which is intended for evaluating nutritional supplements, and not drug products.\nWithout appropriate stability studies, you do not have scientific evidence to support whether your drug products meet established specifications and retain their quality attributes through their labeled expiry.\nIn response to this letter, provide:\nA comprehensive, independent assessment and CAPA plan to ensure the adequacy of your stability program. Your remediated program should include, but not be limited to:\no Stability indicating methods.\no Stability studies for each drug product in its marketed container-closure system before distribution is permitted.\no An ongoing program in which representative batches of each product are added each year to the program to determine if the shelf-life claim remains valid.\no Detailed definition of the specific attributes to be tested at each station (timepoint).\nAll procedures that describe these and other elements of your remediated stability program.\n4. Your firm failed to prepare batch production and control records that include documentation of the accomplishment of each significant step in the manufacture, processing, packing, or holding of the batch, for each batch of drug product (21 CFR 211.188(b)).\nThe batch records you provided in response to our request for records lacked adequate production details regarding significant manufacturing steps, including, but not limited to, identity of major equipment and lines, in-process controls, yield, and container closures. This documentation is necessary to establish that manufacturing processes were consistently followed and are reproducible. Having incomplete records deprives you of traceability of actions necessary for investigational purposes.\nIn response to this letter, provide:\n• Your master production and control records for your drug products, to demonstrate that they fully document each significant and validated manufacturing step.\n• A complete assessment of documentation systems used throughout your manufacturing operations, to determine where documentation practices are insufficient. Include a detailed corrective action and preventive action (CAPA) plan that comprehensively remediates your firm’s documentation practices, to ensure you retain attributable, legible, complete, original, accurate, and contemporaneous records throughout your operation.\n5. Your firm failed to establish an adequate quality control unit with the responsibility and authority to approve or reject all components, drug product containers, closures, in-process materials, packaging materials, labeling, and drug products (21 CFR 211.22(a)).\nThe records and information you provided demonstrate that your quality unit (QU) did not effectively exercise its responsibilities to oversee the quality of your drug manufacturing operations. Specifically, your QU did not adequately exercise its authority in the approval or rejection of components, approval or rejection of finished drug products, batch record review, establishment and implementation of an adequate stability study program, and performance of adequate process validation.\nYour procedures did not define your QU structure and delineation of QU roles and responsibilities. We acknowledge that you plan to cease production and seek a contract manufacturing organization (CMO), (b)(4), to manufacture your drug products.\nIn response to this letter, provide:\nA comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\no A determination of whether procedures used by your firm are robust and appropriate.\no Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices.\no A complete and final review of each batch and its related information before the QU disposition decision.\no Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products.\nUse of Contract Manufacturers\nWe note that your prospective contract manufacturing facility, (b)(4), was placed on Import Alert 66-40 on (b)(4) for failure to comply with CGMP requirements. Drugs manufactured at your prospective CMO are considered adulterated and thus should not be used for the manufacture of drugs for the United States market. It is your responsibility to perform adequate due diligence to ensure that your CMO is in full compliance with CGMPs, the applicable requirements in the FD&C Act, PHS Act, and all applicable regulations.\nDrugs must be manufactured in conformance with CGMP. FDA is aware that many drug manufacturers use independent contractors, such as production facilities, testing laboratories, packagers, and labelers. FDA regards contractors as extensions of the manufacturer.\nYou are responsible for the quality of your drugs regardless of agreements in place with your contract facilities. You are required to ensure that drugs are made in accordance with section 501(a)(2)(B) of the FD&C Act to ensure safety, identity, strength, quality, and purity. See FDA’s guidance document Contract Manufacturing Arrangements for Drugs: Quality Agreements at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F86193\u002Fdownload.\nQuality Systems\nYour firm’s quality systems are inadequate. See FDA’s guidance document Quality Systems Approach to Pharmaceutical CGMP Regulations for help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR, parts 210 and 211 at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload.\nCGMP Consultant Recommended\nBased upon the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34 to evaluate your operations and to assist your firm in meeting CGMP requirements if your firm intends to resume manufacturing drugs for the U.S. market. The qualified consultant should also perform a comprehensive six-system audit1 of your entire operation for CGMP compliance and evaluate the completion and efficacy of your CAPA before you pursue resolution of your firm’s compliance status with FDA.\nYour use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\nUnapproved New Drug and Misbranding Violations\n“maple organics Joint Pain Relief,” “maple organics Muscle Pain Relief,” “maple organics Cough & Cold Relief for Kids,” and “maple organics Cough & Cold Relief” are drugs as defined by section 201(g)(1)(B) of the FD&C Act, 21 U.S.C. 321(g)(1)(B) because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and\u002For under section 201(g)(1)(C) of the FD&C Act, 21 U.S.C. 321(g)(1)(C) because they are intended to affect the structure or any function of the body.\nExamples of claims observed on the product labels and labeling from your website listed above that provide evidence of the intended uses (as defined in 21 CFR 201.128) of the products include, but may not be limited to, the following:\n“maple organics Joint Pain Relief”\n• “DRUG FACTS . . . Uses: Temporarily relieves joint pain.” [from the product label]\n• “Maple Organics Joint Therapy is an FDA-approved, all-natural formula designed to relieve pain, stiffness, and inflammation.” [from the product website www.mapleorganics.com]\n• “Made with organic Arnica Montana, known for its anti-inflammatory and analgesic properties, this balm provides fast-acting, long-lasting relief from discomfort caused by osteoarthritis, tendonitis, and rheumatoid arthritis.” [from the product website www.mapleorganics.com]\n• “Unlike conventional ointments, our steroid-free formula helps reduce muscle damage, so you can feel better without the harsh side effects.” [from the product website www.mapleorganics.com]\n• “A remedy for pain and inflammation due to osteoarthritis, tendonitis and rheumatoid arthritis.” [from the product website www.mapleorganics.com]\n“maple organics Muscle Pain Relief”\n• “DRUG FACTS . . . Uses: Temporarily relieves minor aches and pains of muscles and joints associated with simple backache, strains and bruises.” [from the product label]\n• “This is not an icy hot product but will increase circulation to remove lapsed blood while giving a numbness in your muscles to help reduce pain.” [from the product website www.mapleorganics.com]\n“maple organics Cough & Cold Relief for Kids”\n• “DRUG FACTS . . . Uses: Temporarily relieves cough associated with the common cold.” [from the product label]\n“maple organics Cough & Cold Relief”\n• “DRUG FACTS…Uses: Temporarily relieves cough associated with the common cold.” [from the product label]\nUnapproved New Drug Violations\nBased on the above labeling evidence, “maple organics Joint Pain Relief” and “maple organics Muscle Pain Relief” are intended for use as external analgesic drug products. As described below, these drug products are unapproved new drugs marketed in violation of sections 505(a) and 301(d) of the FD&C Act, 21 U.S.C 355(a) and 331(d).\nA drug product is a “new drug” within the meaning of section 201(p) of the FD&C Act, 21 U.S.C. 321(p), if it is not generally recognized as safe and effective (GRASE) for use under the conditions prescribed, recommended, or suggested in its labeling. With certain exceptions not applicable here, a new drug may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in section 505(a) of the FD&C Act, 21 U.S.C. 355(a). No FDA-approved applications pursuant to section 505 of the FD&C Act, 21 U.S.C. 355, are in effect for these drug products identified above.\nUnder section 505G of the FD&C Act, certain nonprescription drugs marketed without an approved application —commonly referred to as \"OTC monograph drugs\"—may be legally marketed if they meet applicable requirements. With respect to external analgesic drug products, such as your “maple organics Joint Pain Relief” and “maple organics Muscle Pain Relief,” in order to be GRASE and not new drugs, the products must, among other things, conform to the conditions in the applicable OTC monograph, here the External Analgesic Drug Products for Over-the-Counter Human Use (M017).2 However, “maple organics Joint Pain Relief” and “maple organics Muscle Pain Relief” do not conform to the conditions specified in M017 for the reasons described below\nSpecifically, “maple organics Joint Pain Relief” contains the active ingredient arnica, which is not a permitted active ingredient under M017. 21 CFR 201.66(b)(2) defines “active ingredient” to mean “any component that is intended to furnish pharmacological activity or other direct effect in the diagnosis, cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body of humans.” Although your firm does not specifically list arnica as an active ingredient, your labeling of “maple organics Joint Pain Relief,” such as your website, includes statements that claim arnica is intended as an anti-inflammatory and analgesic, and “…provides fast-acting, long-lasting relief from discomfort caused by osteoarthritis, tendonitis, and rheumatoid arthritis.” Such statements demonstrate that arnica is an “active ingredient” in your “maple organics Joint Pain Relief” because it is intended to furnish pharmacological activity or other direct effect to affect the structure or any function of the body of humans. Because arnica is not an active ingredient permitted under M017, your “maple organics Joint Pain Relief” does not conform with the conditions set forth in M017.\nFurthermore, the labeling for “maple organics Joint Pain Relief” and “maple organics Muscle Pain Relief” include intended uses that are not permitted in M017. For example, you claim that “maple organic Joint Pain Relief” will “help reduce muscle damage” and it can be used as “a remedy for pain and inflammation due to osteoarthritis, tendonitis and rheumatoid arthritis.” In addition, you claim that “maple organic Muscle Pain Relief” “…will increase circulation to remove lapsed blood while giving a numbness in your muscles to help reduce pain.” Such intended uses do not conform with M017.50(b).\nThus, as formulated and labeled, your “maple organics Joint Pain Relief” and “maple organics Muscle Pain Relief” products do not comply with the applicable final administrative order described above or any other final order.3 Moreover, there is no evident basis under the FD&C Act under which these products would be legally marketed without an approved application. Thus, these products are new drugs within the meaning of section 201(p) of the FD&C Act, 21 U.S.C. 321(p). Accordingly, these products are unapproved new drugs marketed in violation of section 505(a) of the FD&C Act, 21 U.S.C. 355(a).\nThe introduction or delivery for introduction of these unapproved new drug products into interstate commerce violates sections 505(a) and 301(d) of the FD&C Act, 21 U.S.C. 355(a) and 331(d).\nMisbranded Drug Violations\nYour “maple organics Joint Pain Relief” product is misbranded under section 502(a) because the website labeling claims the product is “…an FDA-approved, all-natural formula….” This claim suggests that the drug is approved or legally marketable (see 21 CFR 207.77(b)). However, your product is not subject to an FDA-approved application. Therefore, your labeling representation suggesting that your product is FDA-approved is false or misleading.\nFurther, “maple organics Joint Pain Relief,” “maple organics Muscle Pain Relief,” “maple organics Cough & Cold Relief for Kids,” and “maple organics Cough & Cold Relief” are misbranded under 502(a) because your products’ labels claim ”At Maple Organics, we scientifically validate natural remedies to FDA standards, ensuring their efficacy….” This claim misleadingly suggests that your products are validated to FDA-standards when such is not the case.\nWe note that, based on the labeling evidence described above, “maple organics Cough & Cold Relief” is intended for use as topical antitussives under M012 (Cold, Cough Allergy, Bronchodilator, and Antiasthmatic Drug Products for Over-the-Counter Human Use). Your “maple organics Cough & Cold Relief” product is misbranded under section 502(f)(1) because the product label is missing adequate directions for use specified in M012.74(d)(2)(i) and M012.74(d)(2)(ii). Specifically, the directions on the product label are missing the following statement, “Children under 2 years of age: Ask a doctor.”\nAdditionally, “maple organics Joint Pain Relief,” “maple organics Muscle Pain Relief,” and “maple organics Cough & Cold Relief” are misbranded under section 502(ee) of the FD&C Act, 21 U.S.C. 352(ee), because these products are nonprescription drugs subject to section 505G of the FD&C Act, 21 U.S.C. 355h, but do not comply with the requirements for marketing under that section and are not the subject of an application approved under section 505 of the FD&C Act, 21 U.S.C. 355.\nThe introduction or delivery for introduction of a misbranded drug into interstate commerce violates section 301(a) of the FD&C Act, 21 U.S.C. 331(a).\nConclusion\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\nFDA placed all drugs and drug products offered for import into the United States from your firm on Import Alert 66-40 on May 23, 2025. Additionally, FDA placed your “maple organics Joint Pain Relief” and “maple organics Muscle Pain Relief” drug products on Import Alert 66-41 on June 30, 2025.\nCorrect any violations promptly. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to any violations.\nFailure to address any violations may also result in the FDA continuing to refuse admission of articles manufactured at Everlaan Organics, Inc., dba Maple Organics, 17220 Heather Dr, Unit 106 Surrey, British Columbia, Canada, into the United States under section 801(a)(3) of the FD&C Act, 21 U.S.C. 381(a)(3). Articles under this authority that appear to be adulterated or misbranded may be detained or refused admission, in that the methods and controls used in their manufacture do not appear to conform to CGMP within the meaning of section 501(a)(2)(B) of the FD&C Act, 21 U.S.C. 351(a)(2)(B) and are misbranded under section 502 of the FD&C Act, respectively.\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\nSend your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3025798567 and ATTN: William Yang.\nSincerely,\n\u002FS\u002F\nFrancis Godwin\nDirector\nOffice of Manufacturing Quality\nOffice of Compliance\nCenter for Drug Evaluation and Research\n\u002FS\u002F\nTina Smith\nCaptain, U.S. Public Health Service\nDirector\nOffice of Unapproved Drugs & Labeling Compliance\nOffice of Compliance\nCenter for Drug Evaluation and Research\n_____________________\n1 i.e., Quality System, Facilities & Equipment System, Materials System, Production System, Packaging & Labeling System, and Laboratory Control System per FDA’s guidance document Quality Systems Approach to Pharmaceutical CGMP Regulations.\n2 M017 reflects the conditions in the relevant final order established and in effect under Section 505G of the FD&C Act; see Order ID OTC000033, available at FDA’s website OTC Monographs@FDA, https:\u002F\u002Fdps.fda.gov\u002Fomuf\u002Fordersearch\u002Forder_otc000033.\n3 FDA is not aware of any adequate and well-controlled clinical trials in the published literature that support a determination that “maple organics Joint Pain Relief” and “maple organics Muscle Pain Relief” are GRASE for use under the conditions prescribed, recommended, or suggested in their labeling, nor has FDA determined these drug products to be GRASE pursuant to an order issued under section 505G(b).","Everlaan Organics, Inc. dba Maple Organics","everlaan-organics-inc-dba-maple-organics-707956-08112025","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Feverlaan-organics-inc-dba-maple-organics-707956-08112025","2026-10-26T08:08:37.155625+00:00","2025-08-19","707956","Drugs Over-the-Counter Drugs","Ms. Rosy Atwal","2026-08-19T16:29:48.848+00:00","320-25-99","2025-08-11",{"id":308,"raw":309,"subject":101,"body_html":313,"body_text":314,"firm_name":315,"letter_id":316,"created_at":127,"fei_number":19,"letter_url":317,"updated_at":318,"action_type":22,"case_status":23,"posted_date":319,"marcs_cms_no":320,"product_type":110,"closeout_date":19,"issuing_office":100,"recipient_name":321,"body_fetched_at":322,"delivery_method":269,"recipient_title":19,"reference_number":19,"action_taken_date":323,"medical_device_id":19,"response_letter_date":19},2555,[310,311,312,100,101,13,13,13],"\u003Ctime datetime=\"2022-07-26T13:20:00Z\">07\u002F26\u002F2022\u003C\u002Ftime>\n","\u003Ctime datetime=\"2022-05-26T04:00:00Z\">05\u002F26\u002F2022\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Feveryday-import-export-inc-dba-everyday-group-llc-628633-05262022\">Everyday Import &amp; Export, Inc. dba Everyday Group LLC\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA EMAIL AND UNITED PARCEL SERVICE\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Food &amp; Beverages                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Ms. Lisa Xiu Qing Su\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>CEO\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Everyday Import &amp; Export, Inc. dba Everyday Group LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>63 Flushing Avenue\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Building 3, Suite 308\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Brooklyn\u003C\u002Fspan>, \u003Cspan>NY\u003C\u002Fspan> \u003Cspan>11205-1070\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Division of Northeast Imports\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>05\u002F26\u002F2022\u003C\u002Fp>\n\n\u003Cp>Re: CMS# 628633\u003C\u002Fp>\n\n\u003Cp>Dear Ms. Lisa Xiu Qing Su:\u003C\u002Fp>\n\n\u003Cp>On January 13 through January 18, 2022, the Food and Drug Administration (FDA) conducted a Foreign Supplier Verification Program (FSVP) inspection of Everyday Import &amp; Export, Inc. dba Everyday Group LLC, located at Brooklyn Navy Yard, 63 Flushing Avenue, Building 3, Suite 308, Brooklyn, NY 11205-1070. We also conducted inspections on December 18, 2017, through January 24, 2018; September 1 through September 25, 2020; and March 9 through March 29, 2021. These inspections were conducted to determine compliance with the requirements of section 805 of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) (21 U.S.C. 384a) and the implementing FSVP regulation in 21 CFR part 1, subpart L.\u003C\u002Fp>\n\n\u003Cp>The FSVP regulation requires that importers perform certain risk-based activities to verify that human and\u002For animal food they import into the United States has been produced in a manner that meets applicable U.S. food safety standards. You may find information relating to the FSVP regulation and your responsibilities to comply with the regulation through links in FDA’s FSVP web page at \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Ffood\u002Ffood-safety-modernization-act-fsma\u002Ffsma-final-rule-foreign-supplier-verification-programs-fsvp-importers-food-humans-and-animals\">https:\u002F\u002Fwww.fda.gov\u002Ffood\u002Ffood-safety-modernization-act-fsma\u002Ffsma-final-rule-foreign-supplier-verification-programs-fsvp-importers-food-humans-and-animals\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>During the most recent inspection, we found that you are not in compliance with the requirements of 21 CFR part 1 subpart L for the foods you import. Because of these significant violations, you are not in compliance with section 805 of the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>At the conclusion of the most recent inspection, our investigator provided you with a Form FDA 483a FSVP Observations. We have not received your response to the Form FDA 483a issued on January 18, 2022.\u003C\u002Fp>\n\n\u003Cp>Your significant violation of the FSVP regulation is as follows:\u003C\u002Fp>\n\n\u003Cp>1. You did not develop, maintain, and follow an FSVP as required by section 805 of the FD&amp;C Act and 21 CFR 1.502(a). Specifically, you did not develop an FSVP for any of the food products you import, including each of the following foods:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>\u003Cstrong>(b)(4)\u003C\u002Fstrong> imported from \u003Cstrong>(b)(4)\u003C\u002Fstrong> located in&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fli>\n\t\u003Cli>\u003Cstrong>(b)(4)\u003C\u002Fstrong> imported from \u003Cstrong>(b)(4)\u003C\u002Fstrong> located in&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fli>\n\t\u003Cli>\u003Cstrong>(b)(4)\u003C\u002Fstrong> Chocolate Strawberry Flavor imported from \u003Cstrong>(b)(4)\u003C\u002Fstrong> located in \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>The above violations are not intended to be an all-inclusive list of violations of the FSVP requirements. It is your responsibility to ensure that you are in compliance with section 805 of the FD&amp;C Act and the implementing regulation in 21 CFR part 1 subpart, L.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. If you do not adequately address this matter, we may take further action. For instance, we may take action under section 801(a)(3) of the FD&amp;C Act (21 U.S.C. 381(a)(3)) to refuse admission of the food you import for which you appear to be in violation of section 805. We may place the foods you import into the United States on detention without physical examination (DWPE) when you import the foods. You can find DWPE information relating to FSVP in Import Alert # 99-41 at \u003Ca href=\"http:\u002F\u002Fwww.accessdata.fda.gov\u002Fcms_ia\u002Fialist.html\">http:\u002F\u002Fwww.accessdata.fda.gov\u002Fcms_ia\u002Fialist.html\u003C\u002Fa>. In addition, the importation or offering for importation into the United States of an article of food without the importer having an FSVP that meets the requirements of section 805 of the FD&amp;C Act or the FSVP regulation is prohibited under section 301(zz) of the FD&amp;C Act (21 U.S.C. 331(zz)).\u003C\u002Fp>\n\n\u003Cp>Additionally, we offer the following comment:\u003C\u002Fp>\n\n\u003Cp>We note that, based on your sales volume, you may meet the definition of a very small importer under 21 CFR 1.500. If you meet the definition of a very small importer and you choose to comply with the modified requirements in 21 CFR 1.512, you must document that you meet the definition of a very small importer as required per 21 CFR 1.512(b)(1)(i). If this section applies and you choose to comply with the requirements in paragraph (b) of this section, you also are required to comply with the requirements in sections 1.502, 1.503, and 1.509, but you are not required to comply with the requirements in sections 1.504 through 1.508 or 1.510 (see 21 CFR 1.512(b)(2)). In addition, for each food you import, you must obtain written assurance, before importing the food and at least every two years thereafter, that your foreign supplier is producing the food in compliance with processes and procedures that provide at least the same level of public health protection as those required under section 418 or 419 of the FD&amp;C Act, if either is applicable, and the implementing regulations, and is producing the food in compliance with sections 402 and 403(w) (if applicable) of the FD&amp;C Act (see 21 CFR 1.512(b)(3)(i)).\u003C\u002Fp>\n\n\u003Cp>You should respond in writing within fifteen (15) working days from your receipt of this letter. Your response should address the specific things you are doing to correct any violations. You should include in your response documentation and information that would assist us in evaluating your corrections (e.g., documentation of changes you made, such as a copy of your FSVP, records to demonstrate implementation of your FSVP), and any additional information that you wish to supply relevant to your compliance with the FSVP regulation. If you believe that you are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. If you cannot complete all corrections within 15 working days, you should explain the reason for your delay and state when you will correct any remaining violations.\u003C\u002Fp>\n\n\u003Cp>Please send your reply to Food and Drug Administration, Attention: Feryal Ahmad, Compliance Officer, Division of Northeast Imports, ORAOEIONEIMPORTSWLResponses@fda.hhs.gov. Please also cc (carbon copy) Feryal.Ahmad@fda.hhs.gov. If you have any questions regarding this letter, you may contact Compliance Officer Ahmad via email at Feryal.Ahmad@fda.hhs.gov. Please reference CMS# 628633 on any documents or records you provide to us and\u002For within the subject line of any email correspondence you send to us.\u003C\u002Fp>\n\n\u003Cp>\u003Cbr>\nSincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>CAPT Nazmul Hassan\u003Cbr>\nProgram Division Director\u003Cbr>\nDivision of Northeast Imports\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA EMAIL AND UNITED PARCEL SERVICE\n\nProduct:\n\nFood & Beverages\n\nRecipient:\n\nRecipient Name\n\nMs. Lisa Xiu Qing Su\n\nRecipient Title\n\nCEO\n\nEveryday Import & Export, Inc. dba Everyday Group LLC\n\n63 Flushing Avenue\n\nBuilding 3, Suite 308\n\nBrooklyn, NY 11205-1070\n\nUnited States\n\nIssuing Office:\n\nDivision of Northeast Imports\n\nUnited States\n\nWARNING LETTER\n\n05\u002F26\u002F2022\n\nRe: CMS# 628633\n\nDear Ms. Lisa Xiu Qing Su:\n\nOn January 13 through January 18, 2022, the Food and Drug Administration (FDA) conducted a Foreign Supplier Verification Program (FSVP) inspection of Everyday Import & Export, Inc. dba Everyday Group LLC, located at Brooklyn Navy Yard, 63 Flushing Avenue, Building 3, Suite 308, Brooklyn, NY 11205-1070. We also conducted inspections on December 18, 2017, through January 24, 2018; September 1 through September 25, 2020; and March 9 through March 29, 2021. These inspections were conducted to determine compliance with the requirements of section 805 of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. 384a) and the implementing FSVP regulation in 21 CFR part 1, subpart L.\n\nThe FSVP regulation requires that importers perform certain risk-based activities to verify that human and\u002For animal food they import into the United States has been produced in a manner that meets applicable U.S. food safety standards. You may find information relating to the FSVP regulation and your responsibilities to comply with the regulation through links in FDA’s FSVP web page at https:\u002F\u002Fwww.fda.gov\u002Ffood\u002Ffood-safety-modernization-act-fsma\u002Ffsma-final-rule-foreign-supplier-verification-programs-fsvp-importers-food-humans-and-animals.\n\nDuring the most recent inspection, we found that you are not in compliance with the requirements of 21 CFR part 1 subpart L for the foods you import. Because of these significant violations, you are not in compliance with section 805 of the FD&C Act.\n\nAt the conclusion of the most recent inspection, our investigator provided you with a Form FDA 483a FSVP Observations. We have not received your response to the Form FDA 483a issued on January 18, 2022.\n\nYour significant violation of the FSVP regulation is as follows:\n\n1. You did not develop, maintain, and follow an FSVP as required by section 805 of the FD&C Act and 21 CFR 1.502(a). Specifically, you did not develop an FSVP for any of the food products you import, including each of the following foods:\n\n(b)(4) imported from (b)(4) located in (b)(4)\n\n(b)(4) imported from (b)(4) located in (b)(4)\n\n(b)(4) Chocolate Strawberry Flavor imported from (b)(4) located in (b)(4)\n\nThe above violations are not intended to be an all-inclusive list of violations of the FSVP requirements. It is your responsibility to ensure that you are in compliance with section 805 of the FD&C Act and the implementing regulation in 21 CFR part 1 subpart, L.\n\nThis letter notifies you of our concerns and provides you an opportunity to address them. If you do not adequately address this matter, we may take further action. For instance, we may take action under section 801(a)(3) of the FD&C Act (21 U.S.C. 381(a)(3)) to refuse admission of the food you import for which you appear to be in violation of section 805. We may place the foods you import into the United States on detention without physical examination (DWPE) when you import the foods. You can find DWPE information relating to FSVP in Import Alert # 99-41 at http:\u002F\u002Fwww.accessdata.fda.gov\u002Fcms_ia\u002Fialist.html. In addition, the importation or offering for importation into the United States of an article of food without the importer having an FSVP that meets the requirements of section 805 of the FD&C Act or the FSVP regulation is prohibited under section 301(zz) of the FD&C Act (21 U.S.C. 331(zz)).\n\nAdditionally, we offer the following comment:\n\nWe note that, based on your sales volume, you may meet the definition of a very small importer under 21 CFR 1.500. If you meet the definition of a very small importer and you choose to comply with the modified requirements in 21 CFR 1.512, you must document that you meet the definition of a very small importer as required per 21 CFR 1.512(b)(1)(i). If this section applies and you choose to comply with the requirements in paragraph (b) of this section, you also are required to comply with the requirements in sections 1.502, 1.503, and 1.509, but you are not required to comply with the requirements in sections 1.504 through 1.508 or 1.510 (see 21 CFR 1.512(b)(2)). In addition, for each food you import, you must obtain written assurance, before importing the food and at least every two years thereafter, that your foreign supplier is producing the food in compliance with processes and procedures that provide at least the same level of public health protection as those required under section 418 or 419 of the FD&C Act, if either is applicable, and the implementing regulations, and is producing the food in compliance with sections 402 and 403(w) (if applicable) of the FD&C Act (see 21 CFR 1.512(b)(3)(i)).\n\nYou should respond in writing within fifteen (15) working days from your receipt of this letter. Your response should address the specific things you are doing to correct any violations. You should include in your response documentation and information that would assist us in evaluating your corrections (e.g., documentation of changes you made, such as a copy of your FSVP, records to demonstrate implementation of your FSVP), and any additional information that you wish to supply relevant to your compliance with the FSVP regulation. If you believe that you are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. If you cannot complete all corrections within 15 working days, you should explain the reason for your delay and state when you will correct any remaining violations.\n\nPlease send your reply to Food and Drug Administration, Attention: Feryal Ahmad, Compliance Officer, Division of Northeast Imports, ORAOEIONEIMPORTSWLResponses@fda.hhs.gov. Please also cc (carbon copy) Feryal.Ahmad@fda.hhs.gov. If you have any questions regarding this letter, you may contact Compliance Officer Ahmad via email at Feryal.Ahmad@fda.hhs.gov. Please reference CMS# 628633 on any documents or records you provide to us and\u002For within the subject line of any email correspondence you send to us.\n\nSincerely,\n\n\u002FS\u002F\n\nCAPT Nazmul Hassan\n\nProgram Division Director\n\nDivision of Northeast Imports","Everyday Import & Export, Inc. dba Everyday Group LLC","everyday-import-export-inc-dba-everyday-group-llc-628633-05262022","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Feveryday-import-export-inc-dba-everyday-group-llc-628633-05262022","2026-10-26T08:08:37.193935+00:00","2022-07-26","628633","Ms. Lisa Xiu Qing Su","2026-08-20T01:44:00.413+00:00","2022-05-26",{"id":325,"raw":326,"subject":58,"body_html":330,"body_text":331,"firm_name":332,"letter_id":333,"created_at":165,"fei_number":19,"letter_url":334,"updated_at":335,"action_type":22,"case_status":23,"posted_date":336,"marcs_cms_no":337,"product_type":68,"closeout_date":19,"issuing_office":57,"recipient_name":338,"body_fetched_at":339,"delivery_method":70,"recipient_title":19,"reference_number":19,"action_taken_date":336,"medical_device_id":19,"response_letter_date":19},2409,[327,328,329,57,58,13,13,13],"\u003Ctime datetime=\"2022-10-06T17:00:00Z\">10\u002F06\u002F2022\u003C\u002Ftime>\n","\u003Ctime datetime=\"2022-10-06T04:00:00Z\">10\u002F06\u002F2022\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fevo-brands-llc-and-pvg2-llc-dba-puff-bar-643091-10062022\">EVO Brands, LLC and PVG2, LLC d\u002Fb\u002Fa Puff Bar\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS and Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Tobacco                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Nicholas Minas Alfaro and Patrick Beltran\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                    \n            \u003Cdd>EVO Brands, LLC and PVG2, LLC d\u002Fb\u002Fa Puff Bar\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>251 Little Falls Drive\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Wilmington\u003C\u002Fspan>, \u003Cspan>DE\u003C\u002Fspan> \u003Cspan>19807\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:info@puffbar.com\"> info@puffbar.com\u003C\u002Fa>\u003C\u002Fdd>\n    \u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:media@puffbar.com\"> media@puffbar.com\u003C\u002Fa>\u003C\u002Fdd>\n    \u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:nick@puffbar.com\"> nick@puffbar.com\u003C\u002Fa>\u003C\u002Fdd>\n    \u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:support@puffbar.com\"> support@puffbar.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Tobacco Products\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>October 6, 2022\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Dear Nicholas Minas Alfaro and Patrick Beltran:\u003C\u002Fp>\n\n\u003Cp>The Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) recently reviewed the website https:\u002F\u002Fpuffbar.com, and additional information, and determined that electronic nicotine delivery system (ENDS) products listed there are received and delivered in the United States without a marketing authorization order.\u003C\u002Fp>\n\n\u003Cp>Under section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) (21 U.S.C. § 321(rr)), these products are tobacco products because they are made or derived from tobacco or contain nicotine from any source, and are intended for human consumption. Certain tobacco products, including ENDS products, are subject to FDA jurisdiction under section 901(b) of the FD&amp;C Act (21 U.S.C. § 387a(b)), and are required to be in compliance with the requirements in the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>Please be aware that, on March 15, 2022, the President signed legislation to amend the FD&amp;C Act to extend FDA’s jurisdiction to products “containing nicotine from any source,” not just nicotine derived from tobacco. See Consolidated Appropriations Act, 2022, Public Law 117-103, Division P, Title I, Subtitle B. Specifically, this legislation expanded the definition of “tobacco product” under section 201(rr) of the FD&amp;C Act (21 U.S.C. § 321(rr)) to include products containing nicotine from any source. Tobacco products, including ENDS products containing nicotine from any source, must be in compliance with the FD&amp;C Act and its implementing regulations. For more information, please see \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Ftobacco-products\u002Fctp-newsroom\u002Frequirements-products-made-non-tobacco-nicotine-take-effect-april-14\">https:\u002F\u002Fwww.fda.gov\u002Ftobacco-products\u002Fctp-newsroom\u002Frequirements-products-made-non-tobacco-nicotine-take-effect-april-14\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>Generally, to be legally marketed in the United States, the FD&amp;C Act requires “new tobacco products” to have a premarket authorization order in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&amp;C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&amp;C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&amp;C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&amp;C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&amp;C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&amp;C Act (21 U.S.C. § 387e(j)(3)).\u003Cbr>\n\u003Cbr>\n\u003Cstrong>New Tobacco Products Without Required Marketing Authorization are Adulterated and Misbranded\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Our review of the website https:\u002F\u002Fpuffbar.com, and additional information, revealed that EVO Brands, LLC and PVG2, LLC receive and deliver ENDS products without a marketing authorization order. Specifically, PVG2, LLC receives the products, including those listed below, from a foreign manufacturer and distributes those products in the United States to some or all of the retailers listed on https:\u002F\u002Fpuffbar.com. EVO Brands, LLC and\u002For PVG2, LLC owns and operates the website https:\u002F\u002Fpuffbar.com, which lists the products below for sale, identifies retailers that sell those products, and directs consumers to those retailers. Such retailers, which are found in the “Store Locator” tab of https:\u002F\u002Fpuffbar.com, include Puffin Vape Shop (https:\u002F\u002Fwww.puffinvapeshop.com) and The Disposable World LLC (https:\u002F\u002Fthedisposableworld.com). ENDS products offered for sale or distribution within the United States on https:\u002F\u002Fwww.puffinvapeshop.com include: Puff Max - Clear and Puff Max - Mystery. ENDS products offered for sale or distribution within the United States on https:\u002F\u002Fthedisposableworld.com include: Puff Flow - Lemon Ice.\u003C\u002Fp>\n\n\u003Cp>The ENDS products listed above are new tobacco products because they were not commercially marketed in the United States as of February 15, 2007. These products do not have an FDA marketing authorization order in effect under section 910(c)(1)(A)(i) of the FD&amp;C Act and are not otherwise exempt from the marketing authorization requirement. Therefore, these products are adulterated under section 902(6)(A) of the FD&amp;C Act (21 U.S.C. § 387b(6)(A)). In addition, these products are misbranded under section 903(a)(6) of the FD&amp;C Act (21 U.S.C. § 387c(a)(6)) because a notice or other information respecting these products were not provided as required by section 905(j) of the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion and Requested Actions\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>FDA has determined that your firms receive and deliver new tobacco products lacking premarket authorization in the United States. All new tobacco products on the market without the statutorily required premarket authorization are marketed unlawfully and are subject to enforcement action at FDA’s discretion.\u003C\u002Fp>\n\n\u003Cp>The violations discussed in this letter do not necessarily constitute an exhaustive list. You should address any violations that are referenced above, as well as violations that are the same as or similar to those stated above, and promptly take any necessary actions to bring your tobacco products into compliance with the FD&amp;C Act. It is your responsibility to ensure that your tobacco products and all related labeling and\u002For advertising on this website, on any other websites (including e-commerce, social networking, or search engine websites), in any other media in which you advertise, and in any retail establishments comply with each applicable provision of the FD&amp;C Act and FDA’s implementing regulations. Failure to address any violations of the FD&amp;C Act, 21 U.S.C. § 301 et seq., and implementing regulations relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, and 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&amp;C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated or misbranded may be detained or refused admission.\u003C\u002Fp>\n\n\u003Cp>Please submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring your products into compliance, including the dates on which you discontinued the violative labeling, advertising, sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&amp;C Act. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&amp;C Act through links on FDA’s homepage at http:\u002F\u002Fwww.fda.gov.\u003C\u002Fp>\n\n\u003Cp>Please note your reference number, RW2201866, in your response and direct your response via email at CTPCompliance@fda.hhs.gov and to the following address:\u003C\u002Fp>\n\n\u003Cp>DPAL-WL Response, Office of Compliance and Enforcement\u003Cbr>\nFDA Center for Tobacco Products\u003Cbr>\nc\u002Fo Document Control Center\u003Cbr>\nBuilding 71, Room G335\u003Cbr>\n10903 New Hampshire Avenue\u003Cbr>\nSilver Spring, MD 20993-0002\u003C\u002Fp>\n\n\u003Cp>If you have any questions about the content of this letter, please contact Bryan Hills at (301) 796-9367 or via email at CTPCompliance@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Ann Simoneau, J.D.\u003Cbr>\nDirector\u003Cbr>\nOffice of Compliance and Enforcement\u003Cbr>\nCenter for Tobacco Products\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>VIA UPS and Electronic Mail\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>cc:\u003C\u002Fp>\n\n\u003Cp>EVO Brands LLC\u003Cbr>\nAttn: Nicholas Minas Alfaro and Patrick Beltran\u003Cbr>\n1700 Santa Fe Ave, Unit 420\u003Cbr>\nLos Angeles, CA 90021\u003C\u002Fp>\n\n\u003Cp>Puff Bar Wholesale\u003Cbr>\n101 N. Verdugo Rd, #11001\u003Cbr>\nGlendale, CA 91226\u003C\u002Fp>\n\n\u003Cp>PVG2, LLC\u003Cbr>\n777 S Alameda St, 2nd Floor\u003Cbr>\nLos Angeles, CA 90021\u003C\u002Fp>\n\n\u003Cp>PVG2, LLC d\u002Fb\u002Fa Puff Bar LLC\u003Cbr>\nAttn: Nicholas Minas Alfaro and Patrick Beltran\u003Cbr>\n3920 Brilliant Drive\u003Cbr>\nLos Angeles, CA 90065\u003C\u002Fp>\n\n\u003Cp>Puffin Vape Shop\u003Cbr>\n2201 Griffin Road\u003Cbr>\nFort Lauderdale, FL 33312\u003Cbr>\ninfo@puffinvapeshop.com\u003C\u002Fp>\n\n\u003Cp>The Disposable World LLC\u003Cbr>\n5200 W HWY 52\u003Cbr>\nEmmett, ID 83617\u003Cbr>\nsupport@thedisposableworld.com\u003C\u002Fp>\n\n\u003Cp>Thompson Hine LLC\u003Cbr>\nAttn: Eric Heyer\u003Cbr>\n1919 M Street NW, Suite 700\u003Cbr>\nWashington, D.C. 20036-3537\u003Cbr>\neric.heyer@thompsonhine.com\u003C\u002Fp>\n\n\u003Cp>Contact Privacy Inc.\u003Cbr>\npuffbar.com@contactprivacy.com\u003C\u002Fp>\n\n\u003Cp>Tucows Domains, Inc.\u003Cbr>\ndomainabuse@tucows.com\u003C\u002Fp>\n\n\u003Cp>Shopify, Inc.\u003Cbr>\nabuse@shopify.com\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS and Electronic Mail\n\nProduct:\n\nTobacco\n\nRecipient:\n\nRecipient Name\n\nNicholas Minas Alfaro and Patrick Beltran\n\nEVO Brands, LLC and PVG2, LLC d\u002Fb\u002Fa Puff Bar\n\n251 Little Falls Drive\n\nWilmington, DE 19807\n\nUnited States\n\ninfo@puffbar.com\n\nmedia@puffbar.com\n\nnick@puffbar.com\n\nsupport@puffbar.com\n\nIssuing Office:\n\nCenter for Tobacco Products\n\nUnited States\n\nOctober 6, 2022\n\nWARNING LETTER\n\nDear Nicholas Minas Alfaro and Patrick Beltran:\n\nThe Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) recently reviewed the website https:\u002F\u002Fpuffbar.com, and additional information, and determined that electronic nicotine delivery system (ENDS) products listed there are received and delivered in the United States without a marketing authorization order.\n\nUnder section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. § 321(rr)), these products are tobacco products because they are made or derived from tobacco or contain nicotine from any source, and are intended for human consumption. Certain tobacco products, including ENDS products, are subject to FDA jurisdiction under section 901(b) of the FD&C Act (21 U.S.C. § 387a(b)), and are required to be in compliance with the requirements in the FD&C Act.\n\nPlease be aware that, on March 15, 2022, the President signed legislation to amend the FD&C Act to extend FDA’s jurisdiction to products “containing nicotine from any source,” not just nicotine derived from tobacco. See Consolidated Appropriations Act, 2022, Public Law 117-103, Division P, Title I, Subtitle B. Specifically, this legislation expanded the definition of “tobacco product” under section 201(rr) of the FD&C Act (21 U.S.C. § 321(rr)) to include products containing nicotine from any source. Tobacco products, including ENDS products containing nicotine from any source, must be in compliance with the FD&C Act and its implementing regulations. For more information, please see https:\u002F\u002Fwww.fda.gov\u002Ftobacco-products\u002Fctp-newsroom\u002Frequirements-products-made-non-tobacco-nicotine-take-effect-april-14.\n\nGenerally, to be legally marketed in the United States, the FD&C Act requires “new tobacco products” to have a premarket authorization order in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&C Act (21 U.S.C. § 387e(j)(3)).\n\nNew Tobacco Products Without Required Marketing Authorization are Adulterated and Misbranded\n\nOur review of the website https:\u002F\u002Fpuffbar.com, and additional information, revealed that EVO Brands, LLC and PVG2, LLC receive and deliver ENDS products without a marketing authorization order. Specifically, PVG2, LLC receives the products, including those listed below, from a foreign manufacturer and distributes those products in the United States to some or all of the retailers listed on https:\u002F\u002Fpuffbar.com. EVO Brands, LLC and\u002For PVG2, LLC owns and operates the website https:\u002F\u002Fpuffbar.com, which lists the products below for sale, identifies retailers that sell those products, and directs consumers to those retailers. Such retailers, which are found in the “Store Locator” tab of https:\u002F\u002Fpuffbar.com, include Puffin Vape Shop (https:\u002F\u002Fwww.puffinvapeshop.com) and The Disposable World LLC (https:\u002F\u002Fthedisposableworld.com). ENDS products offered for sale or distribution within the United States on https:\u002F\u002Fwww.puffinvapeshop.com include: Puff Max - Clear and Puff Max - Mystery. ENDS products offered for sale or distribution within the United States on https:\u002F\u002Fthedisposableworld.com include: Puff Flow - Lemon Ice.\n\nThe ENDS products listed above are new tobacco products because they were not commercially marketed in the United States as of February 15, 2007. These products do not have an FDA marketing authorization order in effect under section 910(c)(1)(A)(i) of the FD&C Act and are not otherwise exempt from the marketing authorization requirement. Therefore, these products are adulterated under section 902(6)(A) of the FD&C Act (21 U.S.C. § 387b(6)(A)). In addition, these products are misbranded under section 903(a)(6) of the FD&C Act (21 U.S.C. § 387c(a)(6)) because a notice or other information respecting these products were not provided as required by section 905(j) of the FD&C Act.\n\nConclusion and Requested Actions\n\nFDA has determined that your firms receive and deliver new tobacco products lacking premarket authorization in the United States. All new tobacco products on the market without the statutorily required premarket authorization are marketed unlawfully and are subject to enforcement action at FDA’s discretion.\n\nThe violations discussed in this letter do not necessarily constitute an exhaustive list. You should address any violations that are referenced above, as well as violations that are the same as or similar to those stated above, and promptly take any necessary actions to bring your tobacco products into compliance with the FD&C Act. It is your responsibility to ensure that your tobacco products and all related labeling and\u002For advertising on this website, on any other websites (including e-commerce, social networking, or search engine websites), in any other media in which you advertise, and in any retail establishments comply with each applicable provision of the FD&C Act and FDA’s implementing regulations. Failure to address any violations of the FD&C Act, 21 U.S.C. § 301 et seq., and implementing regulations relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, and 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated or misbranded may be detained or refused admission.\n\nPlease submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring your products into compliance, including the dates on which you discontinued the violative labeling, advertising, sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&C Act. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&C Act through links on FDA’s homepage at http:\u002F\u002Fwww.fda.gov.\n\nPlease note your reference number, RW2201866, in your response and direct your response via email at CTPCompliance@fda.hhs.gov and to the following address:\n\nDPAL-WL Response, Office of Compliance and Enforcement\n\nFDA Center for Tobacco Products\n\nc\u002Fo Document Control Center\n\nBuilding 71, Room G335\n\n10903 New Hampshire Avenue\n\nSilver Spring, MD 20993-0002\n\nIf you have any questions about the content of this letter, please contact Bryan Hills at (301) 796-9367 or via email at CTPCompliance@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nAnn Simoneau, J.D.\n\nDirector\n\nOffice of Compliance and Enforcement\n\nCenter for Tobacco Products\n\nVIA UPS and Electronic Mail\n\ncc:\n\nEVO Brands LLC\n\nAttn: Nicholas Minas Alfaro and Patrick Beltran\n\n1700 Santa Fe Ave, Unit 420\n\nLos Angeles, CA 90021\n\nPuff Bar Wholesale\n\n101 N. Verdugo Rd, #11001\n\nGlendale, CA 91226\n\nPVG2, LLC\n\n777 S Alameda St, 2nd Floor\n\nLos Angeles, CA 90021\n\nPVG2, LLC d\u002Fb\u002Fa Puff Bar LLC\n\nAttn: Nicholas Minas Alfaro and Patrick Beltran\n\n3920 Brilliant Drive\n\nLos Angeles, CA 90065\n\nPuffin Vape Shop\n\n2201 Griffin Road\n\nFort Lauderdale, FL 33312\n\ninfo@puffinvapeshop.com\n\nThe Disposable World LLC\n\n5200 W HWY 52\n\nEmmett, ID 83617\n\nsupport@thedisposableworld.com\n\nThompson Hine LLC\n\nAttn: Eric Heyer\n\n1919 M Street NW, Suite 700\n\nWashington, D.C. 20036-3537\n\neric.heyer@thompsonhine.com\n\nContact Privacy Inc.\n\npuffbar.com@contactprivacy.com\n\nTucows Domains, Inc.\n\ndomainabuse@tucows.com\n\nShopify, Inc.\n\nabuse@shopify.com","EVO Brands, LLC and PVG2, LLC d\u002Fb\u002Fa Puff Bar","evo-brands-llc-and-pvg2-llc-dba-puff-bar-643091-10062022","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fevo-brands-llc-and-pvg2-llc-dba-puff-bar-643091-10062022","2026-10-26T08:08:37.69201+00:00","2022-10-06","643091","Nicholas Minas Alfaro and Patrick Beltran","2026-08-20T01:31:19.077+00:00",{"id":341,"raw":342,"subject":58,"body_html":345,"body_text":346,"firm_name":347,"letter_id":348,"created_at":18,"fei_number":19,"letter_url":349,"updated_at":350,"action_type":22,"case_status":23,"posted_date":150,"marcs_cms_no":351,"product_type":68,"closeout_date":19,"issuing_office":57,"recipient_name":19,"body_fetched_at":352,"delivery_method":70,"recipient_title":19,"reference_number":353,"action_taken_date":354,"medical_device_id":19,"response_letter_date":19},622,[140,343,344,57,58,13,13,13],"\u003Ctime datetime=\"2025-09-05T04:00:00Z\">09\u002F05\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fhed-technologies-llc-dba-everything-420-701687-09052025\">HED Technologies, LLC d\u002Fb\u002Fa Everything 420\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS and Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>RW2502332\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Tobacco                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\u003C\u002Fdd>\n                    \n            \u003Cdd>HED Technologies, LLC d\u002Fb\u002Fa Everything 420\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>2025 Royal Lane, Suite 370\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Dallas\u003C\u002Fspan>, \u003Cspan>TX\u003C\u002Fspan> \u003Cspan>75229\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:social@everything420.com\"> social@everything420.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Tobacco Products\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>September 5, 2025\u003C\u002Fp>\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>To Whom It May Concern:\u003C\u002Fp>\u003Cp>The Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) recently reviewed the website https:\u002F\u002Feverythingfor420.com and determined that electronic nicotine delivery system (ENDS) products listed there are offered for sale or distribution to customers in the United States.\u003C\u002Fp>\u003Cp>Under section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) (21 U.S.C. § 321(rr)), these products are tobacco products because they are made or derived from tobacco or contain nicotine from any source and intended for human consumption. Certain tobacco products, including ENDS products, are subject to FDA jurisdiction under section 901(b) of the FD&amp;C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1, and are required to be in compliance with the requirements in the FD&amp;C Act.\u003C\u002Fp>\u003Cp>Please be aware that, on March 15, 2022, the President signed legislation to amend the FD&amp;C Act to extend FDA’s jurisdiction to products “containing nicotine from any source,” not just nicotine derived from tobacco. See Consolidated Appropriations Act, 2022, Public Law 117-103, Division P, Title I, Subtitle B. Specifically, this legislation expanded the definition of “tobacco product” under section 201(rr) of the FD&amp;C Act (21 U.S.C. § 321(rr)) to include products containing nicotine from any source. Tobacco products, including ENDS products, containing nicotine from any source, must be in compliance with the FD&amp;C Act and its implementing regulations. For more information, please see https:\u002F\u002Fwww.fda.gov\u002Ftobacco-products\u002Fctp-newsroom\u002Frequirements-products-made-non-tobacco-nicotine-take-effect-april-14.\u003C\u002Fp>\u003Cp>Generally, to be legally marketed in the United States, the FD&amp;C Act requires “new tobacco products” to have a premarket authorization order in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&amp;C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&amp;C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&amp;C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&amp;C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&amp;C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&amp;C Act (21 U.S.C. § 387e(j)(3)).\u003C\u002Fp>\u003Cp>\u003Cstrong>New Tobacco Products Without Required Marketing Authorization Are Adulterated and Misbranded\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>FDA has determined that you offer for sale or distribution to customers in the United States ENDS products that lack a marketing authorization order: RAZ TN9000 5% 9K PUFFS PICK 3 – Sour Mango Pineapple and RAZ TN9000 5% 9K PUFFS PICK 3 – Tropical Storm.\u003C\u002Fp>\u003Cp>The tobacco products listed above are new tobacco products because they were not commercially marketed in the United States as of February 15, 2007. These products do not have FDA marketing authorization orders in effect under section 910(c)(1)(A)(i) of the FD&amp;C Act and are not otherwise exempt from the marketing authorization requirement. Therefore, these products are adulterated under section 902(6)(A) of the FD&amp;C Act (21 U.S.C. § 387b(6)(A)). In addition, they are misbranded under section 903(a)(6) of the FD&amp;C Act (21 U.S.C. § 387c(a)(6)) because a notice or other information respecting these products was not provided as required by section 905(j) of the FD&amp;C Act (21 U.S.C. § 387e(j)).\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion and Requested Actions\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>FDA has determined that your firm markets new tobacco products in the United States that lack premarket authorization. All new tobacco products on the market without the statutorily required premarket authorization are marketed unlawfully and are subject to enforcement action at FDA’s discretion.\u003C\u002Fp>\u003Cp>For a list of all products that have been authorized by the FDA and certain others that may be legally marketed, please visit the Searchable Tobacco Products Database: https:\u002F\u002Fwww.fda.gov\u002Fsearchtobacco.\u003C\u002Fp>\u003Cp>It is your responsibility to ensure that all tobacco products you sell and\u002For distribute in the United States and all related labeling and\u002For advertising on any websites or other media (such as e-commerce, social networking, or search engine websites), and in any retail establishments in which you advertise, comply with each applicable provision of the FD&amp;C Act and FDA’s implementing regulations. Failure to adequately address any violations of the FD&amp;C Act, 21 U.S.C. § 301 et seq., or its implementing regulations relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, and 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&amp;C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated and\u002For misbranded may be detained or refused admission.\u003C\u002Fp>\u003Cp>The violations discussed in this letter do not necessarily constitute an exhaustive list. You should take prompt action to address any violations that are referenced above and take any necessary actions to bring these tobacco products into compliance with the FD&amp;C Act.\u003C\u002Fp>\u003Cp>Please submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring these products into compliance, including the dates on which you discontinued the violative sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&amp;C Act. If you believe that these products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&amp;C Act through links on FDA’s homepage at https:\u002F\u002Fwww.fda.gov\u002F.\u003C\u002Fp>\u003Cp>Please note your reference number, RW2502332, in your response and direct your response via email at CTPCompliance@fda.hhs.gov and to the following address:\u003C\u002Fp>\u003Cp>DPAL-WL Response, Office of Compliance and Enforcement&nbsp;&nbsp;\u003Cbr>FDA Center for Tobacco Products&nbsp;&nbsp;\u003Cbr>c\u002Fo Document Control Center&nbsp;&nbsp;\u003Cbr>Building 71, Room G335&nbsp;&nbsp;\u003Cbr>10903 New Hampshire Avenue&nbsp;&nbsp;\u003Cbr>Silver Spring, MD 20993-0002\u003C\u002Fp>\u003Cp>If you have any questions about the content of this letter, please contact CTPCompliance@fda.hhs.gov.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>John E. Verbeten\u003Cbr>Director\u003Cbr>Office of Compliance and Enforcement\u003Cbr>Center for Tobacco Products\u003C\u002Fp>\u003Cp>\u003Cstrong>VIA UPS and Electronic Mail\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>cc:\u003Cbr>Everything 420\u003Cbr>2020 Royal Lane Road\u003Cbr>Dallas, TX 75229\u003C\u002Fp>\u003Cp>Hed Technologies, LLC\u003Cbr>1360 S Figueroa St, Ste D, Unit 114\u003Cbr>Los Angeles, CA 90015\u003Cbr>hedtechnologies@gmail.com\u003C\u002Fp>\u003Cp>HED Technologies\u003Cbr>1107 S Boyle Ave\u003Cbr>Los Angeles, CA 90023\u003C\u002Fp>\u003Cp>NameCheap, Inc.\u003Cbr>abuse@namecheap.com\u003C\u002Fp>\u003Cp>Shopify, Inc.\u003Cbr>abuse@shopify.com\u003Cbr>&nbsp;\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS and Electronic Mail\n\nReference #:\n\nRW2502332\n\nProduct:\n\nTobacco\n\nRecipient:\n\nHED Technologies, LLC d\u002Fb\u002Fa Everything 420\n\n2025 Royal Lane, Suite 370\n\nDallas, TX 75229\n\nUnited States\n\nsocial@everything420.com\n\nIssuing Office:\n\nCenter for Tobacco Products\n\nUnited States\n\nSeptember 5, 2025\nWARNING LETTER\nTo Whom It May Concern:\nThe Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) recently reviewed the website https:\u002F\u002Feverythingfor420.com and determined that electronic nicotine delivery system (ENDS) products listed there are offered for sale or distribution to customers in the United States.\nUnder section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. § 321(rr)), these products are tobacco products because they are made or derived from tobacco or contain nicotine from any source and intended for human consumption. Certain tobacco products, including ENDS products, are subject to FDA jurisdiction under section 901(b) of the FD&C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1, and are required to be in compliance with the requirements in the FD&C Act.\nPlease be aware that, on March 15, 2022, the President signed legislation to amend the FD&C Act to extend FDA’s jurisdiction to products “containing nicotine from any source,” not just nicotine derived from tobacco. See Consolidated Appropriations Act, 2022, Public Law 117-103, Division P, Title I, Subtitle B. Specifically, this legislation expanded the definition of “tobacco product” under section 201(rr) of the FD&C Act (21 U.S.C. § 321(rr)) to include products containing nicotine from any source. Tobacco products, including ENDS products, containing nicotine from any source, must be in compliance with the FD&C Act and its implementing regulations. For more information, please see https:\u002F\u002Fwww.fda.gov\u002Ftobacco-products\u002Fctp-newsroom\u002Frequirements-products-made-non-tobacco-nicotine-take-effect-april-14.\nGenerally, to be legally marketed in the United States, the FD&C Act requires “new tobacco products” to have a premarket authorization order in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&C Act (21 U.S.C. § 387e(j)(3)).\nNew Tobacco Products Without Required Marketing Authorization Are Adulterated and Misbranded\nFDA has determined that you offer for sale or distribution to customers in the United States ENDS products that lack a marketing authorization order: RAZ TN9000 5% 9K PUFFS PICK 3 – Sour Mango Pineapple and RAZ TN9000 5% 9K PUFFS PICK 3 – Tropical Storm.\nThe tobacco products listed above are new tobacco products because they were not commercially marketed in the United States as of February 15, 2007. These products do not have FDA marketing authorization orders in effect under section 910(c)(1)(A)(i) of the FD&C Act and are not otherwise exempt from the marketing authorization requirement. Therefore, these products are adulterated under section 902(6)(A) of the FD&C Act (21 U.S.C. § 387b(6)(A)). In addition, they are misbranded under section 903(a)(6) of the FD&C Act (21 U.S.C. § 387c(a)(6)) because a notice or other information respecting these products was not provided as required by section 905(j) of the FD&C Act (21 U.S.C. § 387e(j)).\nConclusion and Requested Actions\nFDA has determined that your firm markets new tobacco products in the United States that lack premarket authorization. All new tobacco products on the market without the statutorily required premarket authorization are marketed unlawfully and are subject to enforcement action at FDA’s discretion.\nFor a list of all products that have been authorized by the FDA and certain others that may be legally marketed, please visit the Searchable Tobacco Products Database: https:\u002F\u002Fwww.fda.gov\u002Fsearchtobacco.\nIt is your responsibility to ensure that all tobacco products you sell and\u002For distribute in the United States and all related labeling and\u002For advertising on any websites or other media (such as e-commerce, social networking, or search engine websites), and in any retail establishments in which you advertise, comply with each applicable provision of the FD&C Act and FDA’s implementing regulations. Failure to adequately address any violations of the FD&C Act, 21 U.S.C. § 301 et seq., or its implementing regulations relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, and 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated and\u002For misbranded may be detained or refused admission.\nThe violations discussed in this letter do not necessarily constitute an exhaustive list. You should take prompt action to address any violations that are referenced above and take any necessary actions to bring these tobacco products into compliance with the FD&C Act.\nPlease submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring these products into compliance, including the dates on which you discontinued the violative sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&C Act. If you believe that these products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&C Act through links on FDA’s homepage at https:\u002F\u002Fwww.fda.gov\u002F.\nPlease note your reference number, RW2502332, in your response and direct your response via email at CTPCompliance@fda.hhs.gov and to the following address:\nDPAL-WL Response, Office of Compliance and Enforcement\nFDA Center for Tobacco Products\nc\u002Fo Document Control Center\nBuilding 71, Room G335\n10903 New Hampshire Avenue\nSilver Spring, MD 20993-0002\nIf you have any questions about the content of this letter, please contact CTPCompliance@fda.hhs.gov.\nSincerely,\n\u002FS\u002F\nJohn E. Verbeten\nDirector\nOffice of Compliance and Enforcement\nCenter for Tobacco Products\nVIA UPS and Electronic Mail\ncc:\nEverything 420\n2020 Royal Lane Road\nDallas, TX 75229\nHed Technologies, LLC\n1360 S Figueroa St, Ste D, Unit 114\nLos Angeles, CA 90015\nhedtechnologies@gmail.com\nHED Technologies\n1107 S Boyle Ave\nLos Angeles, CA 90023\nNameCheap, Inc.\nabuse@namecheap.com\nShopify, Inc.\nabuse@shopify.com","HED Technologies, LLC d\u002Fb\u002Fa Everything 420","hed-technologies-llc-dba-everything-420-701687-09052025","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fhed-technologies-llc-dba-everything-420-701687-09052025","2026-10-26T08:08:54.171238+00:00","701687","2026-08-19T16:22:17.502+00:00","RW2502332","2025-09-05",{"id":356,"raw":357,"subject":362,"body_html":363,"body_text":364,"firm_name":365,"letter_id":366,"created_at":367,"fei_number":19,"letter_url":368,"updated_at":369,"action_type":22,"case_status":23,"posted_date":370,"marcs_cms_no":371,"product_type":26,"closeout_date":19,"issuing_office":361,"recipient_name":372,"body_fetched_at":373,"delivery_method":92,"recipient_title":19,"reference_number":19,"action_taken_date":374,"medical_device_id":19,"response_letter_date":19},3533,[358,359,360,361,362,13,13,13],"\u003Ctime datetime=\"2021-02-16T14:20:00Z\">02\u002F16\u002F2021\u003C\u002Ftime>\n","\u003Ctime datetime=\"2021-02-11T05:00:00Z\">02\u002F11\u002F2021\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fevolved-ayurvedic-discoveries-incbiocbdplus-609772-02112021\">Evolved Ayurvedic Discoveries, Inc.\u002FBioCBDPlus\u003C\u002Fa>","Center for Drug Evaluation and Research | CDER","Finished Pharmaceuticals\u002FUnapproved New Drug\u002FMisbranded\u002FAdulterated","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Email\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>James Sol Radina\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                    \n            \u003Cdd>Evolved Ayurvedic Discoveries, Inc.\u002FBioCBDPlus\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>315 S. Coast Highway 101 Suite U75\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Encinitas\u003C\u002Fspan>, \u003Cspan>CA\u003C\u002Fspan> \u003Cspan>92024\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:support@biocbdplus.com\"> support@biocbdplus.com\u003C\u002Fa>\u003C\u002Fdd>\n    \u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:happy@eadlabs.com\"> happy@eadlabs.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research | CDER\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>February 11, 2021\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>RE: 609772\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Radina:\u003C\u002Fp>\n\n\u003Cp>This letter is to advise you that the Food and Drug Administration (FDA) reviewed your website at the Internet address www.biocbdplus.com from August through October 2020 and has determined that you take orders there for “BioCBD+ Total Body Care,” “BioCBD+ Topical Oil Muscle &amp; Joint Support,” and “BioCBD+ Peace Vape” (hereinafter referred to as your “BioCBD+ products”) that claim to contain cannabidiol (CBD). We have also reviewed your social media websites at https:\u002F\u002Fwww.facebook.com\u002FBioCBDPlus and https:\u002F\u002Fwww.instagram.com\u002Fbio_cbd_plus\u002F; these social media websites direct consumers to your website http:\u002F\u002Fwww.biocbdplus.com to purchase your products. In addition, we observed that your website offers CBD products that are intended to mitigate, prevent, treat, diagnose, or cure COVID-19\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> in people. The claims on your website and social media websites establish that your BioCBD+ products are unapproved new drugs sold in violation of sections 505(a) and 301(d) of the Federal Food, Drug, and Cosmetic Act (the FD&amp;C Act), 21 U.S.C. 355(a) and 331(d). Furthermore, these products are misbranded drugs sold in violation of section 502(f)(1) of the FD&amp;C Act, 21 U.S.C. 352(f)(1). As explained further below, introducing or delivering these products for introduction into interstate commerce violates the FD&amp;C Act. You can find the FD&amp;C Act and FDA regulations through links on FDA’s home page at \u003Ca>www.fda.gov\u003C\u002Fa>. You can find specific information about how FDA regulates CBD at \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fnews-events\u002Fpublic-health-focus\u002Ffda-regulation-cannabis-and-cannabis-derived-products-including-cannabidiol-cbd\">https:\u002F\u002Fwww.fda.gov\u002Fnews-events\u002Fpublic-health-focus\u002Ffda-regulation-cannabis-and-cannabis-derived-products-including-cannabidiol-cbd\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>Furthermore, your “BioCBD+ Peace Vape” product is particularly concerning to the agency because the ingredients and potential impurities in oral inhalation products may trigger laryngospasm and bronchospasm and may be toxic to the tissues in the upper or lower airways. Inhalation products that are intended to act locally in the respiratory system also may be absorbed and exert undesirable systemic effects, such as increased heart rate or elevated blood pressure.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Dietary Supplement Labeling\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your “BioCBD+ Total Body Care” product is labeled as a dietary supplement. However, it cannot be a dietary supplement because it does not meet the definition of a dietary supplement under section 201(ff) of the FD&amp;C Act, 21 U.S.C. 321(ff). FDA has concluded that, based on available evidence, CBD products are excluded from the dietary supplement definition under sections 201(ff)(3)(B)(i) and (ii) of the FD&amp;C Act. Under those provisions, if an article (such as CBD) is an active ingredient in a drug product that has been approved under section 505 of the FD&amp;C Act, 21 U.S.C. 355, or has been authorized for investigation as a new drug for which substantial clinical investigations have been instituted and for which the existence of such investigations has been made public, then products containing that substance are outside the definition of a dietary supplement. There is an exception if the substance was “marketed as” a dietary supplement or as a conventional food before the new drug investigations were authorized; however, based on available evidence, FDA has concluded that this is not the case for CBD.\u003Csup>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> FDA is not aware of any evidence that would call into question its current conclusion that CBD products are excluded from the dietary supplement definition under sections 201(ff)(3)(B)(i) and (ii) of the FD&amp;C Act, but you may present FDA with any evidence that has bearing on this issue.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Unapproved New Drug Products\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Based on our review of your websites, your BioCBD+ products are drugs under section 201(g)(1) of the FD&amp;C Act, 21 U.S.C. 321(g)(1), because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease and\u002For intended to affect the structure or any function of the body.\u003C\u002Fp>\n\n\u003Cp>Some examples of claims observed on your website and social media websites that established the intended use of your products as drugs include, but may not be limited to, the following:\u003C\u002Fp>\n\n\u003Cp>On your website, www.biocbdplus.com:\u003C\u002Fp>\n\n\u003Cp>From the webpage titled “Health Benefits of Vaping CBD”:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>“May Support Depression and Mood Disorders”\u003C\u002Fli>\n\t\u003Cli>“If you suffer from depression or other mood disorders, vaping CBD may be as effective at fighting these issues as pharmaceuticals, but without the drawbacks and side effects, especially those that are all too common with benzodiazepines such as: Addiction . . . Sexual dysfunction [and] Substance Abuse”\u003C\u002Fli>\n\t\u003Cli>“May Prevent Bone Disease”\u003C\u002Fli>\n\t\u003Cli>“Reduces the risk of osteoporosis and osteoarthritis.”\u003C\u002Fli>\n\t\u003Cli>“May Help Improve Cholesterol and Decrease the Risk of Cardiovascular Diseases”\u003C\u002Fli>\n\t\u003Cli>“Decreased cardiovascular inflammation and inflammatory response.”\u003C\u002Fli>\n\t\u003Cli>“Slower atherosclerosis progression.”\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>From the webpage titled “CBD for Children with Autism”:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>“CBD for autism isn’t a traditional treatment, as of now, but could soon be because CBD is both an anti-oxidant and an anti-inflammatory . . ..”\u003C\u002Fli>\n\t\u003Cli>“CBD for autism could help because CBD is a powerful antioxidant with neuroprotective properties that protect the brain against neurodegenerative disorders.”\u003C\u002Fli>\n\t\u003Cli>CBD for autism has the following beneficial effects: Anxiolytic. (Reduce anxiety)[,] Anti-inflammatory. (Reduces brain swelling)[,] Antiemetic. (Prevents vomiting) [and] Antipsychotic.”\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>From the webpage titled “CBD for PTSD: The All-Natural Alternative”:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>“CBD has shown even more promise for veterans due to CBD’s potential to benefit those with PTSD. Consuming CBD for PTSD could become the norm in a relatively short time period as CBD continues to gain notoriety and momentum.”\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>From the webpage titled “CBD Oil for Anxiety . . . A Peaceful Solution”:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>“CBD To The Rescue!! . . . From seizure prevention (most commonly studied with epilepsy), to neuroreceptor protection (support against neurodegenerative disorders, Alzheimer’s, Parkinson’s), the vast range of CBD’s healing potential is just truly beginning to be realized.”\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>From the webpage titled “CBD Oil for Pain Relief: What to Know”:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>“From using CBD oil for anxiety, to exploring CBD’s potential effects on epilepsy or rheumatoid arthritis . . . there are a variety of ways that CBD can be administered for different causes.”\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>From the webpage titled “Can CBD Help Stop the Spread of Viruses?”:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>“[H]aving a strong immune system right now is our best defense, and CBD may help support your immune system’s strength.”\u003C\u002Fli>\n\t\u003Cli>“We also have evidence of great medicinal results of CBD for different diseases and ailments. . .”\u003C\u002Fli>\n\t\u003Cli>“[I]f you do contract the virus, you’ll experience mild symptoms and your body will fight it off quickly. For that, CBD may help.”\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>From May 4, 2020 and June 10, 2020 posts to your Facebook page at www.facebook.com\u002FBioCBDPlus:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>“As COVID-19 spreads around the world, customers are asking us how CBD can help. . . the good news is, a healthy immune system may support you during this pandemic, and CBD is great for immune support.”\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>From September 18, 2020 posts to your Facebook and Instagram pages at www.facebook.com\u002FBioCBDPlus and https:\u002F\u002Fwww.instagram.com\u002Fbio_cbd_plus\u002F, respectively:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>“Have you tried our topical oil?” accompanied by a graphic with the text ‘I love the product and was about to order more bottles. I have rheumatoid arthritis, and use it on my knees, knuckles and fingers. It really helps me sleep better at night.’”\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>From a February 26, 2020 post to your Instagram page at https:\u002F\u002Fwww.instagram.com\u002Fbio_cbd_plus\u002F:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>“‘BioCBD+ has been a huge relief to my quality of life with Crohns, anxiety . . . #cbdoil’ accompanied by a graphic displaying “BioCBD+ Total Body Care” and “BioCBD+ Topical Oil Muscle &amp; Joint Support.”\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>Your BioCBD+ products are not generally recognized as safe and effective for their above referenced uses and, therefore, these products are “new drugs” under section 201(p) of the FD&amp;C Act, 21 U.S.C. 321(p). With certain exceptions not applicable here, new drugs may not be legally introduced or delivered for introduction into interstate commerce without prior approval from the FDA, as described in sections 301(d) and 505(a) of the FD&amp;C Act, 21 U.S.C. 331(d) and 355(a). FDA approves a new drug on the basis of scientific data and information demonstrating that the drug is safe and effective. There are no FDA-approved applications in effect for your BioCBD+ products.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Misbranded Drug Products\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your BioCBD+ products are also misbranded within the meaning of section 502(f)(1) of the FD&amp;C Act, 21 U.S.C. 352(f)(1), in that their labeling fails to bear adequate directions for use. “Adequate directions for use” means directions under which a layperson can use a drug safely and for the purposes for which it is intended. (See 21 CFR 201.5.) The aforementioned products are offered for conditions that are not amenable to self-diagnosis and treatment by individuals who are not medical practitioners. Therefore, adequate directions for use cannot be written so that a layperson can use these drugs safely for their intended purposes. Under 21 CFR 201.100(c)(2) and 201.115, FDA-approved prescription drugs that bear their FDA-approved labeling are exempt from the requirements that they bear adequate directions for use by a layperson. However, your products are not exempt from the requirement that their labeling bear adequate directions for use, because no FDA-approved applications are in effect for your products. The introduction or delivery for introduction into interstate commerce of these misbranded drugs is a prohibited act under section 301(a) of the FD&amp;C Act, 21 U.S.C. 331(a).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The violations cited in this letter are not intended to be an all-inclusive statement of violations that exist in connection with your marketed products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\n\n\u003Cp>You should take prompt action to address the violations cited in this letter. Failure to promptly address these violations may result in legal action without further notice, including, without limitation, seizure and\u002For injunction.\u003C\u002Fp>\n\n\u003Cp>Please notify FDA in writing, within fifteen working days of receipt of this letter, of the specific steps you have taken to address these violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. If you cannot complete addressing these violations within fifteen working days, state the reason for the delay and the time within which you will do so.\u003C\u002Fp>\n\n\u003Cp>Your response should be sent to U.S. Food and Drug Administration, Center for Drug Evaluation and Research\u002FOffice of Compliance\u002FOffice of Unapproved Drugs and Labeling Compliance by e-mail to FDAADVISORY@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Donald D. Ashley\u003Cbr>\nDirector\u003Cbr>\nOffice of Compliance\u003Cbr>\nCenter for Drug Evaluation and Research\u003Cbr>\nFood and Drug Administration\u003C\u002Fp>\n\n\u003Cp>_________________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> There is currently a global outbreak of respiratory disease caused by a novel coronavirus that has been named “severe acute respiratory syndrome coronavirus 2” (SARS-CoV-2). The disease caused by the virus has been named “Coronavirus Disease 2019” (COVID-19). On January 31, 2020, the Department of Health and Human Services (HHS) issued a declaration of a public health emergency related to COVID-19 and mobilized the Operating Divisions of HHS. In addition, on March 13, 2020, there was a Presidential declaration of a national emergency in response to COVID-19. Therefore, FDA is taking urgent measures to protect consumers from certain products that, without approval or authorization by FDA, claim to mitigate, prevent, treat, diagnose, or cure COVID-19 in people.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> CBD is the active ingredient in the approved drug product Epidiolex. Furthermore, the existence of substantial clinical investigations regarding CBD has been made public. For example, two such substantial clinical investigations include GW Pharmaceuticals’ investigations regarding Sativex and Epidiolex. (See \u003Cem>GW Pharmaceuticals Receives Investigational New Drug (IND) from FDA for Phase 2\u002F3 Clinical Trial of Epidiolex in the Treatment of Dravet Syndrome\u003C\u002Fem>). FDA considers a substance to be “authorized for investigation as a new drug” if it is the subject of an Investigational New Drug application (IND) that has gone into effect. Under 21 CFR 312.2, unless a clinical investigation meets the limited criteria in that regulation, an IND is required for all clinical investigations of products that are subject to section 505 of the FD&amp;C Act.\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Email\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nJames Sol Radina\n\nEvolved Ayurvedic Discoveries, Inc.\u002FBioCBDPlus\n\n315 S. Coast Highway 101 Suite U75\n\nEncinitas, CA 92024\n\nUnited States\n\nsupport@biocbdplus.com\n\nhappy@eadlabs.com\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research | CDER\n\nUnited States\n\nWARNING LETTER\n\nFebruary 11, 2021\n\nRE: 609772\n\nDear Mr. Radina:\n\nThis letter is to advise you that the Food and Drug Administration (FDA) reviewed your website at the Internet address www.biocbdplus.com from August through October 2020 and has determined that you take orders there for “BioCBD+ Total Body Care,” “BioCBD+ Topical Oil Muscle & Joint Support,” and “BioCBD+ Peace Vape” (hereinafter referred to as your “BioCBD+ products”) that claim to contain cannabidiol (CBD). We have also reviewed your social media websites at https:\u002F\u002Fwww.facebook.com\u002FBioCBDPlus and https:\u002F\u002Fwww.instagram.com\u002Fbio_cbd_plus\u002F; these social media websites direct consumers to your website http:\u002F\u002Fwww.biocbdplus.com to purchase your products. In addition, we observed that your website offers CBD products that are intended to mitigate, prevent, treat, diagnose, or cure COVID-191 in people. The claims on your website and social media websites establish that your BioCBD+ products are unapproved new drugs sold in violation of sections 505(a) and 301(d) of the Federal Food, Drug, and Cosmetic Act (the FD&C Act), 21 U.S.C. 355(a) and 331(d). Furthermore, these products are misbranded drugs sold in violation of section 502(f)(1) of the FD&C Act, 21 U.S.C. 352(f)(1). As explained further below, introducing or delivering these products for introduction into interstate commerce violates the FD&C Act. You can find the FD&C Act and FDA regulations through links on FDA’s home page at www.fda.gov. You can find specific information about how FDA regulates CBD at https:\u002F\u002Fwww.fda.gov\u002Fnews-events\u002Fpublic-health-focus\u002Ffda-regulation-cannabis-and-cannabis-derived-products-including-cannabidiol-cbd.\n\nFurthermore, your “BioCBD+ Peace Vape” product is particularly concerning to the agency because the ingredients and potential impurities in oral inhalation products may trigger laryngospasm and bronchospasm and may be toxic to the tissues in the upper or lower airways. Inhalation products that are intended to act locally in the respiratory system also may be absorbed and exert undesirable systemic effects, such as increased heart rate or elevated blood pressure.\n\nDietary Supplement Labeling\n\nYour “BioCBD+ Total Body Care” product is labeled as a dietary supplement. However, it cannot be a dietary supplement because it does not meet the definition of a dietary supplement under section 201(ff) of the FD&C Act, 21 U.S.C. 321(ff). FDA has concluded that, based on available evidence, CBD products are excluded from the dietary supplement definition under sections 201(ff)(3)(B)(i) and (ii) of the FD&C Act. Under those provisions, if an article (such as CBD) is an active ingredient in a drug product that has been approved under section 505 of the FD&C Act, 21 U.S.C. 355, or has been authorized for investigation as a new drug for which substantial clinical investigations have been instituted and for which the existence of such investigations has been made public, then products containing that substance are outside the definition of a dietary supplement. There is an exception if the substance was “marketed as” a dietary supplement or as a conventional food before the new drug investigations were authorized; however, based on available evidence, FDA has concluded that this is not the case for CBD.2 FDA is not aware of any evidence that would call into question its current conclusion that CBD products are excluded from the dietary supplement definition under sections 201(ff)(3)(B)(i) and (ii) of the FD&C Act, but you may present FDA with any evidence that has bearing on this issue.\n\nUnapproved New Drug Products\n\nBased on our review of your websites, your BioCBD+ products are drugs under section 201(g)(1) of the FD&C Act, 21 U.S.C. 321(g)(1), because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease and\u002For intended to affect the structure or any function of the body.\n\nSome examples of claims observed on your website and social media websites that established the intended use of your products as drugs include, but may not be limited to, the following:\n\nOn your website, www.biocbdplus.com:\n\nFrom the webpage titled “Health Benefits of Vaping CBD”:\n\n“May Support Depression and Mood Disorders”\n\n“If you suffer from depression or other mood disorders, vaping CBD may be as effective at fighting these issues as pharmaceuticals, but without the drawbacks and side effects, especially those that are all too common with benzodiazepines such as: Addiction . . . Sexual dysfunction [and] Substance Abuse”\n\n“May Prevent Bone Disease”\n\n“Reduces the risk of osteoporosis and osteoarthritis.”\n\n“May Help Improve Cholesterol and Decrease the Risk of Cardiovascular Diseases”\n\n“Decreased cardiovascular inflammation and inflammatory response.”\n\n“Slower atherosclerosis progression.”\n\nFrom the webpage titled “CBD for Children with Autism”:\n\n“CBD for autism isn’t a traditional treatment, as of now, but could soon be because CBD is both an anti-oxidant and an anti-inflammatory . . ..”\n\n“CBD for autism could help because CBD is a powerful antioxidant with neuroprotective properties that protect the brain against neurodegenerative disorders.”\n\nCBD for autism has the following beneficial effects: Anxiolytic. (Reduce anxiety)[,] Anti-inflammatory. (Reduces brain swelling)[,] Antiemetic. (Prevents vomiting) [and] Antipsychotic.”\n\nFrom the webpage titled “CBD for PTSD: The All-Natural Alternative”:\n\n“CBD has shown even more promise for veterans due to CBD’s potential to benefit those with PTSD. Consuming CBD for PTSD could become the norm in a relatively short time period as CBD continues to gain notoriety and momentum.”\n\nFrom the webpage titled “CBD Oil for Anxiety . . . A Peaceful Solution”:\n\n“CBD To The Rescue!! . . . From seizure prevention (most commonly studied with epilepsy), to neuroreceptor protection (support against neurodegenerative disorders, Alzheimer’s, Parkinson’s), the vast range of CBD’s healing potential is just truly beginning to be realized.”\n\nFrom the webpage titled “CBD Oil for Pain Relief: What to Know”:\n\n“From using CBD oil for anxiety, to exploring CBD’s potential effects on epilepsy or rheumatoid arthritis . . . there are a variety of ways that CBD can be administered for different causes.”\n\nFrom the webpage titled “Can CBD Help Stop the Spread of Viruses?”:\n\n“[H]aving a strong immune system right now is our best defense, and CBD may help support your immune system’s strength.”\n\n“We also have evidence of great medicinal results of CBD for different diseases and ailments. . .”\n\n“[I]f you do contract the virus, you’ll experience mild symptoms and your body will fight it off quickly. For that, CBD may help.”\n\nFrom May 4, 2020 and June 10, 2020 posts to your Facebook page at www.facebook.com\u002FBioCBDPlus:\n\n“As COVID-19 spreads around the world, customers are asking us how CBD can help. . . the good news is, a healthy immune system may support you during this pandemic, and CBD is great for immune support.”\n\nFrom September 18, 2020 posts to your Facebook and Instagram pages at www.facebook.com\u002FBioCBDPlus and https:\u002F\u002Fwww.instagram.com\u002Fbio_cbd_plus\u002F, respectively:\n\n“Have you tried our topical oil?” accompanied by a graphic with the text ‘I love the product and was about to order more bottles. I have rheumatoid arthritis, and use it on my knees, knuckles and fingers. It really helps me sleep better at night.’”\n\nFrom a February 26, 2020 post to your Instagram page at https:\u002F\u002Fwww.instagram.com\u002Fbio_cbd_plus\u002F:\n\n“‘BioCBD+ has been a huge relief to my quality of life with Crohns, anxiety . . . #cbdoil’ accompanied by a graphic displaying “BioCBD+ Total Body Care” and “BioCBD+ Topical Oil Muscle & Joint Support.”\n\nYour BioCBD+ products are not generally recognized as safe and effective for their above referenced uses and, therefore, these products are “new drugs” under section 201(p) of the FD&C Act, 21 U.S.C. 321(p). With certain exceptions not applicable here, new drugs may not be legally introduced or delivered for introduction into interstate commerce without prior approval from the FDA, as described in sections 301(d) and 505(a) of the FD&C Act, 21 U.S.C. 331(d) and 355(a). FDA approves a new drug on the basis of scientific data and information demonstrating that the drug is safe and effective. There are no FDA-approved applications in effect for your BioCBD+ products.\n\nMisbranded Drug Products\n\nYour BioCBD+ products are also misbranded within the meaning of section 502(f)(1) of the FD&C Act, 21 U.S.C. 352(f)(1), in that their labeling fails to bear adequate directions for use. “Adequate directions for use” means directions under which a layperson can use a drug safely and for the purposes for which it is intended. (See 21 CFR 201.5.) The aforementioned products are offered for conditions that are not amenable to self-diagnosis and treatment by individuals who are not medical practitioners. Therefore, adequate directions for use cannot be written so that a layperson can use these drugs safely for their intended purposes. Under 21 CFR 201.100(c)(2) and 201.115, FDA-approved prescription drugs that bear their FDA-approved labeling are exempt from the requirements that they bear adequate directions for use by a layperson. However, your products are not exempt from the requirement that their labeling bear adequate directions for use, because no FDA-approved applications are in effect for your products. The introduction or delivery for introduction into interstate commerce of these misbranded drugs is a prohibited act under section 301(a) of the FD&C Act, 21 U.S.C. 331(a).\n\nConclusion\n\nThe violations cited in this letter are not intended to be an all-inclusive statement of violations that exist in connection with your marketed products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\n\nYou should take prompt action to address the violations cited in this letter. Failure to promptly address these violations may result in legal action without further notice, including, without limitation, seizure and\u002For injunction.\n\nPlease notify FDA in writing, within fifteen working days of receipt of this letter, of the specific steps you have taken to address these violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. If you cannot complete addressing these violations within fifteen working days, state the reason for the delay and the time within which you will do so.\n\nYour response should be sent to U.S. Food and Drug Administration, Center for Drug Evaluation and Research\u002FOffice of Compliance\u002FOffice of Unapproved Drugs and Labeling Compliance by e-mail to FDAADVISORY@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nDonald D. Ashley\n\nDirector\n\nOffice of Compliance\n\nCenter for Drug Evaluation and Research\n\nFood and Drug Administration\n\n_________________________\n\n1 There is currently a global outbreak of respiratory disease caused by a novel coronavirus that has been named “severe acute respiratory syndrome coronavirus 2” (SARS-CoV-2). The disease caused by the virus has been named “Coronavirus Disease 2019” (COVID-19). On January 31, 2020, the Department of Health and Human Services (HHS) issued a declaration of a public health emergency related to COVID-19 and mobilized the Operating Divisions of HHS. In addition, on March 13, 2020, there was a Presidential declaration of a national emergency in response to COVID-19. Therefore, FDA is taking urgent measures to protect consumers from certain products that, without approval or authorization by FDA, claim to mitigate, prevent, treat, diagnose, or cure COVID-19 in people.\n\n2 CBD is the active ingredient in the approved drug product Epidiolex. Furthermore, the existence of substantial clinical investigations regarding CBD has been made public. For example, two such substantial clinical investigations include GW Pharmaceuticals’ investigations regarding Sativex and Epidiolex. (See GW Pharmaceuticals Receives Investigational New Drug (IND) from FDA for Phase 2\u002F3 Clinical Trial of Epidiolex in the Treatment of Dravet Syndrome). FDA considers a substance to be “authorized for investigation as a new drug” if it is the subject of an Investigational New Drug application (IND) that has gone into effect. Under 21 CFR 312.2, unless a clinical investigation meets the limited criteria in that regulation, an IND is required for all clinical investigations of products that are subject to section 505 of the FD&C Act.","Evolved Ayurvedic Discoveries, Inc.\u002FBioCBDPlus","evolved-ayurvedic-discoveries-incbiocbdplus-609772-02112021","2026-08-18T06:42:29.460824+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fevolved-ayurvedic-discoveries-incbiocbdplus-609772-02112021","2026-10-26T08:08:37.915322+00:00","2021-02-16","609772","James Sol Radina","2026-08-20T03:22:48.593+00:00","2021-02-11",{"id":376,"raw":377,"subject":38,"body_html":383,"body_text":384,"firm_name":385,"letter_id":386,"created_at":387,"fei_number":19,"letter_url":388,"updated_at":389,"action_type":22,"case_status":23,"posted_date":390,"marcs_cms_no":391,"product_type":392,"closeout_date":19,"issuing_office":381,"recipient_name":393,"body_fetched_at":394,"delivery_method":70,"recipient_title":19,"reference_number":19,"action_taken_date":395,"medical_device_id":19,"response_letter_date":19},1824,[378,379,380,381,382,13,13,13],"\u003Ctime datetime=\"2023-09-29T19:00:00Z\">09\u002F29\u002F2023\u003C\u002Ftime>\n","\u003Ctime datetime=\"2023-09-28T04:00:00Z\">09\u002F28\u002F2023\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Finfinant-health-inc-formerly-evolve-biosystems-inc-667715-09282023\">Infinant Health, Inc formerly Evolve Biosystems Inc.\u003C\u002Fa>","Center for Biologics Evaluation and Research (CBER)","Unapproved New Drugs\u002FMisbranded ","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS and Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Biologics\u003Cbr>Food &amp; Beverages                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Michael D. Johnson\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>CEO\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Infinant Health, Inc formerly Evolve Biosystems Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>2121 2nd Street, Suite C108\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Davis\u003C\u002Fspan>, \u003Cspan>CA\u003C\u002Fspan> \u003Cspan>95618-6567\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:lhannan@infinanthealth.com\"> lhannan@infinanthealth.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Biologics Evaluation and Research (CBER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Date: September 28, 2023\u003C\u002Fp>\n\n\u003Cp>\u003Cbr>\nLisa Hannan, General Counsel, Corporate Secretary, Chief Compliance &amp; Regulatory Officer\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>RE: 667715\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Johnson and Ms. Hannan:\u003C\u002Fp>\n\n\u003Cp>This is to advise you that the United States Food and Drug Administration (FDA) has reviewed your company’s website at www.evivo.com in September 2023 and your marketing materials, including your Evivo with MCT Oil Product Information sheet, which contains directions for purchasing your product, Evivo with MCT Oil (hereinafter, Evivo with MCT Oil or your product). You refer to your product as a probiotic and offer it for sale in the United States. Your product contains \u003Cem>B. longum\u003C\u002Fem> subsp. \u003Cem>infantis\u003C\u002Fem> EVC001 bacteria, and you market it for use in infants aged 0 to 36 months.\u003C\u002Fp>\n\n\u003Cp>Based on the statements on your website and your Evivo with MCT Oil Product Information sheet, your product is an unapproved new drug and unlicensed biological product, which was introduced or delivered for introduction into interstate commerce in violation of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) [21 U.S.C. § 331(d)] and the Public Health Service Act (PHS Act) [42 U.S.C. § 262(a)(1)]. These violations are described in more detail below.\u003C\u002Fp>\n\n\u003Cp>Further, your Evivo with MCT Oil product is intended to be added to food for infants, including preterm infants. As described in your Evivo with MCT Oil Product Information sheet, this product is designed specifically for infants in the Neonatal Intensive Care Unit (NICU). Preterm infants are often hospitalized in a NICU. Furthermore, statements on the product page of your website indicate your product is “[e]xclusively for Healthcare Settings” and “made specifically for use in healthcare settings.” The care of infants in a healthcare setting includes care of preterm infants; therefore, this use is further evidence of the intended use of this product for consumption by preterm infants.\u003C\u002Fp>\n\n\u003Cp>Therefore, in addition to your product being an unapproved new drug and unlicensed biological product, your Evivo with MCT Oil product is an adulterated food under section 402(a)(2)(C)(i) of the FD&amp;C Act [21 U.S.C. § 342(a)(2)(C)(i)], because when intended for consumption by preterm infants, this use of \u003Cem>B. longum\u003C\u002Fem> subsp. \u003Cem>infantis\u003C\u002Fem> “EVC001” is an unsafe food additive within the meaning of sections 201(s) and 409(a) of the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>As explained further below, introducing or delivering your product for introduction into interstate commerce violates the FD&amp;C Act and the PHS Act. You can find the FD&amp;C Act, PHS Act, and FDA regulations through links on FDA’s home page at www.fda.gov.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Unapproved New Drug and Unlicensed Biological Product\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your website at www.evivo.com (last visited on September 28, 2023), through which providers can contact you to purchase your product, includes references to articles that discuss uses for your product in the mitigation, treatment, or prevention of disease, specifically:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>“Bifidobacterium longum subsp. infantis EVC001 Administration Is Associated with a Significant Reduction in the Incidence of Necrotizing Enterocolitis in Very Low Birth Weight Infants” (article title);\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> and\u003C\u002Fli>\n\t\u003Cli>“Probiotics containing B. infantis decrease the risk of necrotizing enterocolitis in premature infants” (from opening summary of article titled, “Bifidobacterium longum subspecies infantis: champion colonizer of the infant gut”).\u003Csup>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>As noted above, your website further states that your product is “made specifically for use in healthcare settings,” and your Evivo with MCT Oil Product Information sheet describes the product as “[d]esigned specifically for infants in the NICU[.]”\u003C\u002Fp>\n\n\u003Cp>Because these statements indicate that your product is intended for use in the mitigation, treatment, or prevention of disease, your product is a drug under section 201(g)(1)(B) of the FD&amp;C Act [21 U.S.C. § 321(g)(1)(B)]. Additionally, your product is a biological product as defined in section 351(i) of the PHS Act [42 U.S.C. § 262(i)], because it is applicable to the prevention, treatment, or cure of a disease or condition of human beings.\u003C\u002Fp>\n\n\u003Cp>Please be advised that to lawfully market a drug that is also a biological product, a valid biologics license application (BLA) must be in effect [42 U.S.C. § 262(a)]. Such licenses are issued only after a demonstration that the product is safe, pure, and potent. While in the development stage, such products may be distributed for clinical use in humans only if the sponsor has an investigational new drug application (IND) in effect as specified by FDA regulations (21 U.S.C. § 355(i); 42 U.S.C. § 262(a)(3); 21 CFR Part 312). Your product is not the subject of an approved BLA nor is there an IND in effect for its use. Based on this information, your actions have violated the FD&amp;C Act and the PHS Act.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Adulterated Food: Unsafe Food Additive\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>In addition to your product Evivo with MCT Oil being an unapproved new drug and unlicensed biological product, your product is adulterated within the meaning of section 402(a)(2)(C)(i) of the FD&amp;C Act [21 U.S.C. § 342(a)(2)(C)(i)] because under its intended use in food for preterm infants, \u003Cem>B. longum\u003C\u002Fem> subsp. \u003Cem>infantis\u003C\u002Fem> “EVC001” is an unsafe food additive within the meaning of sections 201(s) of the Act and 409(a) of the FD&amp;C Act [21 U.S.C. §§ 321(s) and 348(a)].\u003C\u002Fp>\n\n\u003Cp>The label of your Evivo with MCT Oil product declares the ingredient “\u003Cem>Bifidobacterium longum\u003C\u002Fem> subsp. \u003Cem>infantis\u003C\u002Fem> EV C001 (milk, soy)* CFU Count: 8 Billion CFU per 0.5 milliliters.”\u003C\u002Fp>\n\n\u003Cp>Any substance added or intended for addition to food must have premarket approval by FDA for that use unless the use is generally recognized as safe (GRAS) by qualified experts or meets one of the listed exceptions at Section 201(s)(1)-(6) of the FD&amp;C Act [21 U.S.C. § 321(s)(1)-(6)]. Otherwise, the substance is deemed an unsafe food additive, and food that is or contains an unsafe food additive is adulterated under the FD&amp;C Act. There is no food additive regulation that authorizes the use of \u003Cem>B. longum\u003C\u002Fem> subsp. \u003Cem>infantis\u003C\u002Fem> “EVC001.” We are not aware of an applicable exception under section 201(s) of the FD&amp;C Act [21 U.S.C. § 321(s)] for the use of \u003Cem>B. longum\u003C\u002Fem> subsp. \u003Cem>Infantis\u003C\u002Fem> “EVC001” in conventional foods, including infant formula. We are also not aware of a basis to conclude that any use of \u003Cem>B. longum\u003C\u002Fem> subsp. \u003Cem>Infantis\u003C\u002Fem> “EVC001” in food for preterm infants, including infant formula, is GRAS.\u003C\u002Fp>\n\n\u003Cp>GRAS status requires publicly available evidence that the intended use is safe and a consensus among qualified experts that the intended use is safe (21 CFR 170.30). The information on the use of living microorganisms (also referred to as “probiotics”) by preterm infants in the scientific literature raises serious safety concerns. Preterm infants are a highly susceptible, heterogenous subpopulation of varying ages (&lt;37 weeks of gestation) and weight, who are physiologically, developmentally, and metabolically immature compared to healthy term infants, resulting in their having a high risk for morbidity and mortality and requiring specialized care; thus, we have greater safety concerns for this population than we have for a healthy term infant population. Because their gastrointestinal system is not fully matured, preterm infants have more permeable intestinal linings, often referred to as “leaky guts,” and motility problems, which can lead to opportunistic infections and sepsis when ingesting living microorganisms. The current published literature does not show consensus among qualified experts that the use of living microorganisms in preterm infants is safe. For example, the American Academy of Pediatrics does not endorse the routine use of living microorganisms in preterm infants, finding conflicting data on its safety and efficacy in this vulnerable population, particularly those with birth weight &lt;1000 grams.” FDA communicated these safety concerns related to use in food for preterm infants during a meeting between the FDA’s Center for Food Safety and Applied Nutrition (CFSAN), Office of Food Additive Safety’s Division of Food Ingredients and Infinant Health on July 7, 2023. In particular, FDA questioned whether the clinical studies Infinant cited in its presentation to FDA were robust enough to support safety, as the studies were short-term, poorly designed, and difficult to interpret without appropriate controls. FDA also noted that short-term clinical studies, in general, are only supportive evidence of safety for the use of living microorganisms and have not served as the primary basis for safety in any GRAS conclusions to date for the use of living microorganisms that have come through the GRAS Notification program.\u003C\u002Fp>\n\n\u003Cp>Therefore, based on our review, FDA has determined that the intended use in food for preterm infants of \u003Cem>B. longum\u003C\u002Fem> subsp. \u003Cem>infantis\u003C\u002Fem> is not GRAS. As such, your EVIVO with MCT oil product is adulterated within the meaning of section 402(a)(2)(C)(i) of the FD&amp;C Act [21 U.S.C. § 342(a)(2)(C)(i)] because this use in food for preterm infants of \u003Cem>B. longum\u003C\u002Fem> subsp. \u003Cem>infantis\u003C\u002Fem> “EVC001” is an unsafe food additive within the meaning of sections 201(s) of the Act and 409 of the FD&amp;C Act [21 U.S.C. §§ 321(s) and 348]. The introduction or delivery for introduction into interstate commerce of any food that is adulterated is a prohibited act under section 301(a) of the FD&amp;C Act [21 U.S.C. § 331(a)].\u003C\u002Fp>\n\n\u003Cp>The violations cited in this letter are not meant to be an all-inclusive list of violations that may exist in connection with your products. You are responsible for promptly investigating and determining the causes of any violations, correcting them, and preventing their recurrence, and ensuring full compliance with the law.\u003C\u002Fp>\n\n\u003Cp>During a meeting with FDA on September 21, 2023, your firm emphasized to Agency representatives the benefits of \u003Cem>B. longum\u003C\u002Fem> subsp. \u003Cem>infantis\u003C\u002Fem> in Evivo with MCT Oil for preterm infants in neonatal intensive care units, including by reducing the incidence of necrotizing enterocolitis. These statements suggest that similar claims may exist in other labeling or promotional materials that may be inaccessible to FDA.\u003C\u002Fp>\n\n\u003Cp>We advise you to comprehensively review your website, product labels, and other labeling and marketing materials to ensure that you are lawfully marketing your products in full compliance with the FD&amp;C Act, the PHS Act, and their implementing regulations. Failure to adequately address this matter may result in enforcement action without further notice, including, without limitation, seizure and\u002For injunction.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. If you believe that your product is not in violation of the FD&amp;C Act and the PHS Act, include your reasoning and any supporting information for our consideration in your response to this letter.\u003C\u002Fp>\n\n\u003Cp>Within fifteen working days of receipt of this letter, please notify FDA in writing of the specific steps that you have taken to correct any violations. Your response should include an explanation of each step being taken to prevent the recurrence of violations as well as related documentation. If you cannot complete all corrective actions within fifteen working days, state the reason for the delay and the date by which you will complete the correction.\u003C\u002Fp>\n\n\u003Cp>Your written response should be sent to the following address: U.S. Food and Drug Administration, Center for Biologics Evaluation and Research, Document Control Center, 10903 New Hampshire Avenue, WO71-G112, Silver Spring, MD 20993-0002. Please also email your response to CBERDCMRecommendations@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Melissa J. Mendoza\u003Cbr>\nDirector, Office of Compliance and Biologics Quality\u003Cbr>\nCenter for Biologics Evaluation and Research\u003C\u002Fp>\n\n\u003Cp>\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Ann M. Oxenham\u003Cbr>\nDirector, Office of Compliance\u003Cbr>\nCenter for Food Safety and Applied Nutrition\u003C\u002Fp>\n\n\u003Cp>Cc: \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>____________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> https:\u002F\u002Fwww.evivo.com\u002Fwp-content\u002Fuploads\u002F2023\u002F04\u002FTobias-OHSU-NEC-Publication.pdf.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> https:\u002F\u002Fwww.evivo.com\u002Fwp-content\u002Fuploads\u002F2023\u002F04\u002FUnderwood_2015_pr2014156.pdf.\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS and Electronic Mail\n\nProduct:\n\nBiologics\nFood & Beverages\n\nRecipient:\n\nRecipient Name\n\nMichael D. Johnson\n\nRecipient Title\n\nCEO\n\nInfinant Health, Inc formerly Evolve Biosystems Inc.\n\n2121 2nd Street, Suite C108\n\nDavis, CA 95618-6567\n\nUnited States\n\nlhannan@infinanthealth.com\n\nIssuing Office:\n\nCenter for Biologics Evaluation and Research (CBER)\n\nUnited States\n\nWARNING LETTER\n\nDate: September 28, 2023\n\nLisa Hannan, General Counsel, Corporate Secretary, Chief Compliance & Regulatory Officer\n\nRE: 667715\n\nDear Mr. Johnson and Ms. Hannan:\n\nThis is to advise you that the United States Food and Drug Administration (FDA) has reviewed your company’s website at www.evivo.com in September 2023 and your marketing materials, including your Evivo with MCT Oil Product Information sheet, which contains directions for purchasing your product, Evivo with MCT Oil (hereinafter, Evivo with MCT Oil or your product). You refer to your product as a probiotic and offer it for sale in the United States. Your product contains B. longum subsp. infantis EVC001 bacteria, and you market it for use in infants aged 0 to 36 months.\n\nBased on the statements on your website and your Evivo with MCT Oil Product Information sheet, your product is an unapproved new drug and unlicensed biological product, which was introduced or delivered for introduction into interstate commerce in violation of the Federal Food, Drug, and Cosmetic Act (FD&C Act) [21 U.S.C. § 331(d)] and the Public Health Service Act (PHS Act) [42 U.S.C. § 262(a)(1)]. These violations are described in more detail below.\n\nFurther, your Evivo with MCT Oil product is intended to be added to food for infants, including preterm infants. As described in your Evivo with MCT Oil Product Information sheet, this product is designed specifically for infants in the Neonatal Intensive Care Unit (NICU). Preterm infants are often hospitalized in a NICU. Furthermore, statements on the product page of your website indicate your product is “[e]xclusively for Healthcare Settings” and “made specifically for use in healthcare settings.” The care of infants in a healthcare setting includes care of preterm infants; therefore, this use is further evidence of the intended use of this product for consumption by preterm infants.\n\nTherefore, in addition to your product being an unapproved new drug and unlicensed biological product, your Evivo with MCT Oil product is an adulterated food under section 402(a)(2)(C)(i) of the FD&C Act [21 U.S.C. § 342(a)(2)(C)(i)], because when intended for consumption by preterm infants, this use of B. longum subsp. infantis “EVC001” is an unsafe food additive within the meaning of sections 201(s) and 409(a) of the FD&C Act.\n\nAs explained further below, introducing or delivering your product for introduction into interstate commerce violates the FD&C Act and the PHS Act. You can find the FD&C Act, PHS Act, and FDA regulations through links on FDA’s home page at www.fda.gov.\n\nUnapproved New Drug and Unlicensed Biological Product\n\nYour website at www.evivo.com (last visited on September 28, 2023), through which providers can contact you to purchase your product, includes references to articles that discuss uses for your product in the mitigation, treatment, or prevention of disease, specifically:\n\n“Bifidobacterium longum subsp. infantis EVC001 Administration Is Associated with a Significant Reduction in the Incidence of Necrotizing Enterocolitis in Very Low Birth Weight Infants” (article title);1 and\n\n“Probiotics containing B. infantis decrease the risk of necrotizing enterocolitis in premature infants” (from opening summary of article titled, “Bifidobacterium longum subspecies infantis: champion colonizer of the infant gut”).2\n\nAs noted above, your website further states that your product is “made specifically for use in healthcare settings,” and your Evivo with MCT Oil Product Information sheet describes the product as “[d]esigned specifically for infants in the NICU[.]”\n\nBecause these statements indicate that your product is intended for use in the mitigation, treatment, or prevention of disease, your product is a drug under section 201(g)(1)(B) of the FD&C Act [21 U.S.C. § 321(g)(1)(B)]. Additionally, your product is a biological product as defined in section 351(i) of the PHS Act [42 U.S.C. § 262(i)], because it is applicable to the prevention, treatment, or cure of a disease or condition of human beings.\n\nPlease be advised that to lawfully market a drug that is also a biological product, a valid biologics license application (BLA) must be in effect [42 U.S.C. § 262(a)]. Such licenses are issued only after a demonstration that the product is safe, pure, and potent. While in the development stage, such products may be distributed for clinical use in humans only if the sponsor has an investigational new drug application (IND) in effect as specified by FDA regulations (21 U.S.C. § 355(i); 42 U.S.C. § 262(a)(3); 21 CFR Part 312). Your product is not the subject of an approved BLA nor is there an IND in effect for its use. Based on this information, your actions have violated the FD&C Act and the PHS Act.\n\nAdulterated Food: Unsafe Food Additive\n\nIn addition to your product Evivo with MCT Oil being an unapproved new drug and unlicensed biological product, your product is adulterated within the meaning of section 402(a)(2)(C)(i) of the FD&C Act [21 U.S.C. § 342(a)(2)(C)(i)] because under its intended use in food for preterm infants, B. longum subsp. infantis “EVC001” is an unsafe food additive within the meaning of sections 201(s) of the Act and 409(a) of the FD&C Act [21 U.S.C. §§ 321(s) and 348(a)].\n\nThe label of your Evivo with MCT Oil product declares the ingredient “Bifidobacterium longum subsp. infantis EV C001 (milk, soy)* CFU Count: 8 Billion CFU per 0.5 milliliters.”\n\nAny substance added or intended for addition to food must have premarket approval by FDA for that use unless the use is generally recognized as safe (GRAS) by qualified experts or meets one of the listed exceptions at Section 201(s)(1)-(6) of the FD&C Act [21 U.S.C. § 321(s)(1)-(6)]. Otherwise, the substance is deemed an unsafe food additive, and food that is or contains an unsafe food additive is adulterated under the FD&C Act. There is no food additive regulation that authorizes the use of B. longum subsp. infantis “EVC001.” We are not aware of an applicable exception under section 201(s) of the FD&C Act [21 U.S.C. § 321(s)] for the use of B. longum subsp. Infantis “EVC001” in conventional foods, including infant formula. We are also not aware of a basis to conclude that any use of B. longum subsp. Infantis “EVC001” in food for preterm infants, including infant formula, is GRAS.\n\nGRAS status requires publicly available evidence that the intended use is safe and a consensus among qualified experts that the intended use is safe (21 CFR 170.30). The information on the use of living microorganisms (also referred to as “probiotics”) by preterm infants in the scientific literature raises serious safety concerns. Preterm infants are a highly susceptible, heterogenous subpopulation of varying ages (\u003C37 weeks of gestation) and weight, who are physiologically, developmentally, and metabolically immature compared to healthy term infants, resulting in their having a high risk for morbidity and mortality and requiring specialized care; thus, we have greater safety concerns for this population than we have for a healthy term infant population. Because their gastrointestinal system is not fully matured, preterm infants have more permeable intestinal linings, often referred to as “leaky guts,” and motility problems, which can lead to opportunistic infections and sepsis when ingesting living microorganisms. The current published literature does not show consensus among qualified experts that the use of living microorganisms in preterm infants is safe. For example, the American Academy of Pediatrics does not endorse the routine use of living microorganisms in preterm infants, finding conflicting data on its safety and efficacy in this vulnerable population, particularly those with birth weight \u003C1000 grams.” FDA communicated these safety concerns related to use in food for preterm infants during a meeting between the FDA’s Center for Food Safety and Applied Nutrition (CFSAN), Office of Food Additive Safety’s Division of Food Ingredients and Infinant Health on July 7, 2023. In particular, FDA questioned whether the clinical studies Infinant cited in its presentation to FDA were robust enough to support safety, as the studies were short-term, poorly designed, and difficult to interpret without appropriate controls. FDA also noted that short-term clinical studies, in general, are only supportive evidence of safety for the use of living microorganisms and have not served as the primary basis for safety in any GRAS conclusions to date for the use of living microorganisms that have come through the GRAS Notification program.\n\nTherefore, based on our review, FDA has determined that the intended use in food for preterm infants of B. longum subsp. infantis is not GRAS. As such, your EVIVO with MCT oil product is adulterated within the meaning of section 402(a)(2)(C)(i) of the FD&C Act [21 U.S.C. § 342(a)(2)(C)(i)] because this use in food for preterm infants of B. longum subsp. infantis “EVC001” is an unsafe food additive within the meaning of sections 201(s) of the Act and 409 of the FD&C Act [21 U.S.C. §§ 321(s) and 348]. The introduction or delivery for introduction into interstate commerce of any food that is adulterated is a prohibited act under section 301(a) of the FD&C Act [21 U.S.C. § 331(a)].\n\nThe violations cited in this letter are not meant to be an all-inclusive list of violations that may exist in connection with your products. You are responsible for promptly investigating and determining the causes of any violations, correcting them, and preventing their recurrence, and ensuring full compliance with the law.\n\nDuring a meeting with FDA on September 21, 2023, your firm emphasized to Agency representatives the benefits of B. longum subsp. infantis in Evivo with MCT Oil for preterm infants in neonatal intensive care units, including by reducing the incidence of necrotizing enterocolitis. These statements suggest that similar claims may exist in other labeling or promotional materials that may be inaccessible to FDA.\n\nWe advise you to comprehensively review your website, product labels, and other labeling and marketing materials to ensure that you are lawfully marketing your products in full compliance with the FD&C Act, the PHS Act, and their implementing regulations. Failure to adequately address this matter may result in enforcement action without further notice, including, without limitation, seizure and\u002For injunction.\n\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. If you believe that your product is not in violation of the FD&C Act and the PHS Act, include your reasoning and any supporting information for our consideration in your response to this letter.\n\nWithin fifteen working days of receipt of this letter, please notify FDA in writing of the specific steps that you have taken to correct any violations. Your response should include an explanation of each step being taken to prevent the recurrence of violations as well as related documentation. If you cannot complete all corrective actions within fifteen working days, state the reason for the delay and the date by which you will complete the correction.\n\nYour written response should be sent to the following address: U.S. Food and Drug Administration, Center for Biologics Evaluation and Research, Document Control Center, 10903 New Hampshire Avenue, WO71-G112, Silver Spring, MD 20993-0002. Please also email your response to CBERDCMRecommendations@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nMelissa J. Mendoza\n\nDirector, Office of Compliance and Biologics Quality\n\nCenter for Biologics Evaluation and Research\n\n\u002FS\u002F\n\nAnn M. Oxenham\n\nDirector, Office of Compliance\n\nCenter for Food Safety and Applied Nutrition\n\nCc: (b)(4)\n\n____________________\n\n1 https:\u002F\u002Fwww.evivo.com\u002Fwp-content\u002Fuploads\u002F2023\u002F04\u002FTobias-OHSU-NEC-Publication.pdf.\n\n2 https:\u002F\u002Fwww.evivo.com\u002Fwp-content\u002Fuploads\u002F2023\u002F04\u002FUnderwood_2015_pr2014156.pdf.","Infinant Health, Inc formerly Evolve Biosystems Inc.","infinant-health-inc-formerly-evolve-biosystems-inc-667715-09282023","2026-08-18T06:42:28.994808+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Finfinant-health-inc-formerly-evolve-biosystems-inc-667715-09282023","2026-10-26T08:08:58.729306+00:00","2023-09-29","667715","BiologicsFood & Beverages","Michael D. Johnson","2026-08-20T00:37:59.96+00:00","2023-09-28",20,{"510k":398,"classification":399,"enforcement":400,"event":401,"event_backfill":402,"pma":403,"warning_letter":404},"2026-11-16T02:00:55.89+00:00","2026-11-16T02:00:41.999+00:00","2026-11-16T02:00:49.415+00:00","2026-11-18T04:00:44.748+00:00","2026-09-07T05:17:28.839+00:00","2026-11-16T02:01:03.155+00:00","2026-11-17T01:02:55.859+00:00"]